FedInvent Patent Applications

Patent Application Details for Thursday, June 03, 2021 

This page was updated on Saturday, July 17, 2021 at 01:39 AM GMT

Department of Health and Human Services (HHS) 

US 20210161126 Uygun et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
APPLICANT(S) The General Hospital Corporation (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Musfata Korkut Uygun (Boston, Massachusetts);  Bote G. Bruinsma (Boston, Massachusetts);  Maria-Louisa Izamis (Boston, Massachusetts)
ABSTRACT The present invention relates to organ perfusion systems that can be used at room temperature. The organ perfusion systems do not comprise a temperature controller. In some embodiments, the organ perfusion systems do not comprise a cleaning device for cleaning the perfusion fluid. The perfusion fluid can comprise Williams' medium E. The organ perfusion systems can be portable and can be used to preserving an organ, preventing ischemic damage in an organ, or recovering an ischemically damaged organ.
FILED Friday, February 12, 2021
APPL NO 17/175160
CURRENT CPC
Preservation of Bodies of Humans or Animals or Plants or Parts Thereof; Biocides, e.g as Disinfectants, as Pesticides or as Herbicides; Pest Repellants or Attractants; Plant Growth Regulators
A01N 1/0226 (20130101)
A01N 1/0247 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161150 GAROFOLO et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) Locus Biosciences, Inc. (Morrisville, North Carolina);  North Carolina State University (Raleigh, North Carolina)
ASSIGNEE(S)
INVENTOR(S) Paul M. GAROFOLO (Cary, North Carolina);  David G. OUSTEROUT (Raleigh, North Carolina);  Kurt SELLE (Raleigh, North Carolina);  Sandi WONG (South San Francisco, California);  Chase Lawrence BEISEL (Würzburg, Germany);  Atul Kumar SINGH (Raleigh, North Carolina)
ABSTRACT Provided herein are methods and compositions for killing a target bacterium with a CRISPR-Cpf1 system. Also disclosed are engineered bacteriophages.
FILED Friday, May 24, 2019
APPL NO 17/057601
CURRENT CPC
Preservation of Bodies of Humans or Animals or Plants or Parts Thereof; Biocides, e.g as Disinfectants, as Pesticides or as Herbicides; Pest Repellants or Attractants; Plant Growth Regulators
A01N 63/40 (20200101) Original (OR) Class

Preparations for Medical, Dental, or Toilet Purposes
A61K 35/76 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 7/00 (20130101)
C12N 15/70 (20130101)
C12N 15/74 (20130101)
C12N 2310/20 (20170501)
C12N 2795/14022 (20130101)
C12N 2795/14033 (20130101)
C12N 2800/80 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161383 MACKNIK et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Eye Institute (NEI)
National Science Foundation (NSF)
APPLICANT(S) THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (Albany, New York);  CORNELL UNIVERSITY (Ithaca, New York)
ASSIGNEE(S) THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (Albany, New York);  CORNELL UNIVERSITY (Ithaca, New York)
INVENTOR(S) Stephen MACKNIK (Albany, New York);  Susana MARTINEZ-CONDE (Albany, New York);  Nozomi NISHIMURA (Ithaca, New York);  Christopher SCHAFFER (Ithaca, New York);  Mitch PENDER (Freeville, New York)
ABSTRACT Provided is a method of detecting neural activity, including inducing neurons of a subject to express two or more polypeptides each comprising an amino acid sequence represented by one of SEQ ID NOs:13-24, wherein inducing comprises stimulating interneuronally different relative levels of expression of the two or more polypeptides; applying coelenterazine to the subject; applying a first stimulation of neural activity to the subject; detecting a first spatiotemporal and spectral pattern of electromagnetic radiation emitted by neurons of the subject in response to the first stimulation; recording the first spatiotemporal and spectral pattern of electromagnetic radiation in a computer memory; applying a second stimulation of neural activity to the subject; detecting a second spatiotemporal and spectral pattern of electromagnetic radiation emitted by neurons of the subject in response to the second stimulation; comparing the second spatiotemporal and spectral pattern of electromagnetic radiation to the first spatiotemporal and spectral pattern of electromagnetic radiation, wherein differences between the second spatiotemporal and spectral pattern of electromagnetic radiation and the first spatiotemporal and spectral pattern of electromagnetic radiation indicate differences in neural activity caused by the first stimulation and the second stimulation.
FILED Wednesday, June 12, 2019
APPL NO 17/251499
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/0036 (20180801) Original (OR) Class
A61B 5/0042 (20130101)
A61B 5/0071 (20130101)
A61B 5/4848 (20130101)
A61B 5/4884 (20130101)
A61B 5/7246 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/65 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161385 BEN-YAKAR et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Aging (NIA)
APPLICANT(S) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas)
ASSIGNEE(S)
INVENTOR(S) Adela BEN-YAKAR (Austin, Texas);  Tianqi LI (Poway, California);  Chris MARTIN (Austin, Texas);  Peisen ZHAO (Austin, Texas)
ABSTRACT Disclosed herein are systems and methods for line excitation array detection (LEAD) microscopy. The systems and methods include an excitation beam from an optical beam source and a subject of interest. Light is scanned across the subject of interest and optical signals are detected using a parallel optical detection means. A number of mechanical, acoustic and or optical components such as scanning mirrors, DMDs, OADs, electric motors may be used in separately or in conjunction to aid in the scanning of the excitation beam across the subject of interest
FILED Friday, May 10, 2019
APPL NO 17/054266
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/0071 (20130101) Original (OR) Class
A61B 5/0082 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 21/6458 (20130101)

Optical Elements, Systems, or Apparatus
G02B 21/006 (20130101)
G02B 21/0036 (20130101)
G02B 21/0048 (20130101)
G02B 21/0072 (20130101)
G02B 21/0076 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161467 Linnes et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
APPLICANT(S) Purdue Research Foundation (West Lafayette, Indiana)
ASSIGNEE(S) Purdue Research Foundation (West Lafayette, Indiana)
INVENTOR(S) Jacqueline C. Linnes (West Lafayette, Indiana);  Benjamin David Walters (Castle Rock, Colorado);  Orlando S. Hoilett (West Lafayette, Indiana)
ABSTRACT This invention generally relates to methods useful for measuring heart rate, respiration conditions, and oxygen saturation and a wearable device that incorporate those methods with a computerized system supporting data collection, analysis, readout and sharing. Particularly this present invention relates to a wearable device, such as a wristwatch or ring, for real time measuring heart rate, respiration conditions, and oxygen saturation.
FILED Friday, October 16, 2020
APPL NO 17/073223
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/0022 (20130101)
A61B 5/0205 (20130101)
A61B 5/681 (20130101) Original (OR) Class
A61B 5/743 (20130101)
A61B 5/1112 (20130101)
A61B 5/02433 (20130101)
A61B 5/4833 (20130101)
A61B 5/7207 (20130101)
A61B 5/7257 (20130101)
A61B 5/14552 (20130101)
A61B 2560/0214 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161507 XU et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
U.S. Public Health Service (USPHS)
APPLICANT(S) KONINKLIJKE PHILIPS N.V. (Eindhoven, Netherlands);  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (Bethesda, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) SHENG XU (ROCKVILLE, Maryland);  JOCHEN KRUECKER (WASHINGTON DC, District of Columbia);  BRADFORD JOHNS WOOD (POTOMAC, Maryland)
ABSTRACT A system and method for integrating diagnosis and treatment for internal tissues includes imaging at least a portion of an internal organ of a subject using a first technology capable of differentiating tissue types, and targeting and accessing biopsy sites using images of the first technology fused with images of a second technology capable of real-time image updates. Treatment of a biopsy site is planned using the images of the first technology. Instruments for treating the biopsy site are guided by fusing the images of the first technology with the images of the second technology.
FILED Tuesday, February 16, 2021
APPL NO 17/176218
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 6/12 (20130101)
A61B 6/5247 (20130101)
A61B 8/12 (20130101)
A61B 8/0833 (20130101) Original (OR) Class
A61B 8/0841 (20130101)
A61B 8/5238 (20130101)
A61B 10/0233 (20130101)
A61B 18/02 (20130101)
A61B 18/14 (20130101)
A61B 34/20 (20160201)
A61B 2090/374 (20160201)
A61B 2090/378 (20160201)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161825 Oupicky et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (Lincoln, Nebraska)
ASSIGNEE(S)
INVENTOR(S) David Oupicky (La Vista, Nebraska);  Fei Yu (Omaha, Nebraska)
ABSTRACT Provided herein are copolymers comprising a plurality of a first monomer and a plurality of a second monomer, wherein chloroquine, hydroxychloroquine, or a chloroquine analog is appended to at least a portion of the plurality of the first monomer. Also provided are nanoparticles comprising copolymers as described herein, and methods of using the copolymers and nanoparticles for treating diseases or disorders, e.g., Inflammatory Bowel Disease (IBD) or cancer (e.g., colon cancer).
FILED Friday, April 12, 2019
APPL NO 17/047132
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0053 (20130101)
A61K 9/5031 (20130101) Original (OR) Class
A61K 9/5153 (20130101)
A61K 31/713 (20130101)
A61K 31/4706 (20130101)
A61K 39/3955 (20130101)
A61K 45/06 (20130101)
A61K 47/58 (20170801)
A61K 47/6927 (20170801)
A61K 47/6929 (20170801)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 1/00 (20180101)

Macromolecular Compounds Obtained by Reactions Only Involving Carbon-to-carbon Unsaturated Bonds
C08F 220/281 (20200201)
C08F 293/005 (20130101)
C08F 2438/03 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161836 WAY et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) The University of Chicago (Chicago, Illinois)
ASSIGNEE(S) The University of Chicago (Chicago, Illinois)
INVENTOR(S) Sharon WAY (Chicago, Illinois);  Benjamin CLAYTON (Chicago, Illinois);  Brian POPKO (Chicago, Illinois)
ABSTRACT This invention discloses methods and compositions for the treatment of demyelinating disorders. Specifically, the invention relates to the use guanabenz or guanabenz derivative for treating demyelinating disorders.
FILED Monday, January 25, 2021
APPL NO 17/248432
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0019 (20130101)
A61K 31/136 (20130101)
A61K 31/137 (20130101)
A61K 31/155 (20130101) Original (OR) Class
A61K 31/225 (20130101)
A61K 31/277 (20130101)
A61K 31/4409 (20130101)
A61K 38/03 (20130101)
A61K 38/215 (20130101)
A61K 39/3955 (20130101)
A61K 45/06 (20130101)
A61K 2039/505 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161837 Chen et al.
FUNDED BY
Department of Veterans Affairs (DVA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S) The Regents of the University of California (Oakland, California);  Guangzhou Institutes of Biomedicine and Health (Guangzhou, China PRC);  U.S. Government represented by the Department of Veterans Affairs (Washington, District of Columbia)
INVENTOR(S) Hongwu Chen (Davis, California);  June X. Zou (Davis, California);  Junjian Wang (Davis, California);  Demin Cai (Davis, California);  Yong Xu (Guangzhou, China PRC);  Xiaoqian Xue (Guangzhou, China PRC);  Yan Zhang (Guangzhou, China PRC)
ABSTRACT The present invention provides compositions, methods, and kits comprising one or more compounds of Formula I, such as XY018, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, gastric cancer, lymphoma, and glioma.
FILED Tuesday, June 30, 2020
APPL NO 16/917818
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/58 (20130101)
A61K 31/138 (20130101)
A61K 31/167 (20130101) Original (OR) Class
A61K 31/222 (20130101)
A61K 31/277 (20130101)
A61K 31/337 (20130101)
A61K 31/4166 (20130101)
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Acyclic or Carbocyclic Compounds
C07C 205/11 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161845 LI et al.
FUNDED BY
Department of Health and Human Services (HHS)
APPLICANT(S) The USA, as reprsented by the Secretary, Dept. of Health and Human Services (Bethesda, Maryland)
ASSIGNEE(S)
INVENTOR(S) Wei LI (Bethesda, Maryland);  Tantai ZHAO (Hunan, China PRC);  Jingxing OU (Guangdong, China PRC)
ABSTRACT Methods are disclosed for treating and/or preventing a neurological condition, such as neural injury or neurological disorder, in a subject through metabolic regulation of mitochondria using compounds that are natural metabolites, metabolite analogs, or derivatives of natural metabolites to modulate biochemical pathways comprising succinate and/or succinate dehydrogenase, thereby reducing microglial cell and/or astrocyte activation. Compounds and related formulations are also provided to modulate the biochemical pathways comprising succinate and/or succinate dehydrogenase for reducing or inhibiting microglial cell and/or astrocyte activation.
FILED Wednesday, August 21, 2019
APPL NO 17/268203
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/23 (20130101)
A61K 31/194 (20130101) Original (OR) Class

Enzymes
C12Y 103/05001 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161848 Goodyear et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
APPLICANT(S) Joslin Diabetes Center, Inc. (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Laurie J. Goodyear (Southborough, Massachusetts);  Kristin Stanford (Columbus, Ohio)
ABSTRACT The invention includes methods and compositions for treating a metabolic disorder, such as metabolic syndrome, hyperlipidemia and associated disorders, such as obesity and diabetes. The invention includes a method of treating a human subject comprising administering 12,13-dihydroxy-9Z-octadecenoic acid (12,13-diHOME) to the subject. The invention also includes methods and compositions for treating disorders and conditions that would benefit from skeletal muscle fatty acid uptake and oxidation, increased mitochondrial respiration in skeletal muscle and/or enhanced exercise capacity.
FILED Monday, October 26, 2020
APPL NO 17/080528
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/201 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 3/04 (20180101)
A61P 21/06 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161861 Kellar et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of Child Health and Human Development (NICHD)
National Institute on Drug Abuse (NIDA)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) Georgetown University (Washington, District of Columbia)
ASSIGNEE(S)
INVENTOR(S) Kenneth J. Kellar (Bethesda, Maryland);  Yingxian Xiao (Potomac, Maryland);  Patrick A. Forcelli (Washington, District of Columbia)
ABSTRACT Previous studies (Xiao et al., 2001) have identified two metabolites of methadone, EMDP (2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline) and EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine), which are considered to be inactive at opiate receptors, as relatively potent noncompetitive channel blockers of α3β4 nAChRs. We have now evaluated these compounds in rats and mice in preclinical behavioral models predictive of potential anxiolytic and antidepressant efficacy. We found that EMDP, but not EDDP, displayed robust effects predictive of anxiolytic and antidepressant efficacy without significant effects on locomotor activity. Moreover, EMDP at behaviorally active doses, unlike mecamylamine, did not produce eyelid ptosis, suggesting it may produce fewer autonomic side effects than mecamylamine. Thus, the methadone metabolite EMDP may represent a novel therapeutic avenue for the treatment of some affective disorders.
FILED Monday, July 13, 2020
APPL NO 16/927544
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0053 (20130101)
A61K 31/40 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/22 (20180101)
A61P 25/24 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161868 Saffitz
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) Beth Israel Deaconess Medical Center, Inc. (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Jeffrey E. Saffitz (Waban, Massachusetts)
ABSTRACT Described herein are, inter alia, methods for treating arrhythmogenic cardiomyopathy (ACM) using anti-inflammatory agents that target nuclear factor-kappa-B (NFkB).
FILED Thursday, April 25, 2019
APPL NO 17/050259
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/277 (20130101)
A61K 31/436 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 9/06 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161881 HAMMOCK et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Environmental Health Sciences (NIEHS)
APPLICANT(S) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, California);  CHIBA UNIVERSITY (CHIBA, Japan)
ASSIGNEE(S)
INVENTOR(S) Bruce D. HAMMOCK (Davis, California);  Sung Hee HWANG (Woodland, California);  Kenji HASHIMOTO (Chiba, Japan);  Qian REN (Chiba, Japan)
ABSTRACT Provided are methods of preventing, delaying, mitigating, reducing and/or inhibiting alpha-synuclein aggregates in the brains of a subject at risk of developing or suffering a cognitive disease associated with, caused and/or mediated at least in part by alpha-synuclein aggregates, for example, Parkinson's Disease or Dementia with Lewy Bodies (DLB).
FILED Tuesday, February 05, 2019
APPL NO 16/967115
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/198 (20130101)
A61K 31/415 (20130101)
A61K 31/453 (20130101) Original (OR) Class
A61K 31/454 (20130101)
A61K 31/4525 (20130101)
A61K 31/4545 (20130101)
A61K 31/5377 (20130101)
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/28 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/1137 (20130101)
C12N 2310/14 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161891 Gradilone et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
APPLICANT(S) MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (Rochester, Minnesota)
ASSIGNEE(S)
INVENTOR(S) Sergio A. Gradilone (Rochester, Minnesota);  Nicholas F. LaRusso (Rochester, Minnesota)
ABSTRACT An HDAC6-specific inhibitor (i.e., a compound of Formula I or II) is shown to reduce the pathogenesis associated with polycystic disease. Administration of an HDAC6-specific inhibitor attenuated many of the symptoms characteristic of polycystic liver disease including cyst formation, cyst growth and cholangiocyte proliferation. Treatment with a HDAC6-specific inhibitor also increased the amount of bile duct acetylated tubulin and β-catenin phosphorylation and/or acetylation while reducing bile duct β-catenin synthesis. These results demonstrate that HDAC6 is overexpressed in cystic cholangiocytes and that its pharmacological inhibition reduces cholangiocyte proliferation and cyst growth.
FILED Thursday, May 14, 2020
APPL NO 16/874251
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/505 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161900 Wang et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Duke University (Durham, North Carolina)
ASSIGNEE(S)
INVENTOR(S) Xiao-Fan Wang (Durham, North Carolina);  Christopher Pan (Durham, North Carolina);  Lifeng Yuan (Durham, North Carolina)
ABSTRACT The present disclosure comprises compositions and methods for the treatment of senescent tumor cells. In particular, compositions and methods for countering negative effects of cancer therapy-induced senescence in tumor cells are provided.
FILED Monday, April 29, 2019
APPL NO 17/047258
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/443 (20130101)
A61K 31/506 (20130101)
A61K 31/519 (20130101) Original (OR) Class
A61K 31/4439 (20130101)
A61K 31/5377 (20130101)
A61K 38/10 (20130101)
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/04 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161910 Yan et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Aging (NIA)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) University of Connecticut (Farmington, Connecticut)
ASSIGNEE(S)
INVENTOR(S) Riqiang Yan (Farmington, Connecticut);  Brati Das (Farmington, Connecticut)
ABSTRACT Disclosed pharmaceutical compositions including a Beta site APP Cleaving Enzyme (BACE1) inhibitor and an metabotropic glutamate receptor (mGluR) agonist, and methods for use of such compositions to treat Alzheimer's disease (AD), Down's syndrome, Parkinson's disease, vascular dementia, Dementia with Lewy Bodies, dementia, and/or frontal temporal dementia.
FILED Tuesday, December 01, 2020
APPL NO 17/108227
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/506 (20130101)
A61K 31/541 (20130101)
A61K 31/549 (20130101) Original (OR) Class
A61K 31/4439 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/28 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161928 Baylin et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Stephen B. Baylin (Baltimore, Maryland);  Drew M. Pardoll (Brookeville, Maryland);  Suzanne L. Topalian (Brookeville, Maryland)
ASSIGNEE(S) The Johns Hopkins University (Baltimore, Maryland)
INVENTOR(S) Stephen B. Baylin (Baltimore, Maryland);  Drew M. Pardoll (Brookeville, Maryland);  Suzanne L. Topalian (Brookeville, Maryland)
ABSTRACT Cancer therapies that combine epigenetic modulating agent(s) with immune modulating agent(s), which were remarkably identified to provide an improved treatment regimen over single agent therapy, are disclosed. In particular embodiments, the invention provides for improved treatment of NSCLC in patients via administration of exemplary immune modulating agents anti-PD-1 antibody or anti-PD-L1 antibody, which were observed to show enhanced activity in combination with the exemplary epigenetic modulating agent 5-deoxyazacytidine. Further, expression markers of responsive neoplastic cells are also disclosed.
FILED Thursday, February 04, 2021
APPL NO 17/167819
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/167 (20130101)
A61K 31/706 (20130101) Original (OR) Class
A61K 38/15 (20130101)
A61K 39/395 (20130101)
A61K 39/3955 (20130101)
A61K 45/06 (20130101)
A61K 2039/505 (20130101)

Peptides
C07K 16/2818 (20130101)
C07K 16/2827 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6886 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161937 Shirasu-Hiza et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute on Aging (NIA)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) The Trustees of Columbia University in the City of New York (New York, New York)
ASSIGNEE(S)
INVENTOR(S) Mimi Shirasu-Hiza (New York, New York);  Julie Canman (New York, New York);  Matt Ulgherait (New York, New York)
ABSTRACT The present invention relates to activating mitochondrial uncoupling as a therapeutic intervention which has many beneficial effects to both healthy and sick subjects. The beneficial effects of activating mitochondrial uncoupling include extended lifespan, decreasing or suppressing harmful or unwanted cellular proliferation, increasing or restoring intestinal homeostasis and slowing or inhibiting tumor growth. The invention includes the administration of activators of mitochondrial uncoupling to subjects in order to extend lifespan, decrease or suppress harmful or unwanted cellular proliferation, increase or restore intestinal homeostasis, prevent and treat cancer, and slow or inhibit tumor growth.
FILED Wednesday, January 23, 2019
APPL NO 16/961767
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/05 (20130101)
A61K 31/06 (20130101)
A61K 31/20 (20130101)
A61K 31/167 (20130101)
A61K 31/426 (20130101)
A61K 31/567 (20130101)
A61K 31/4985 (20130101)
A61K 31/7088 (20130101) Original (OR) Class
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161943 RIBAS et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) Antoni RIBAS (Los Angeles, California);  Gabriel Abril RODRIGUEZ (Los Angeles, California);  Catherine Grasso (Santa Monica, California);  Davis Y. TORREJON (Los Angeles, California)
ABSTRACT Disclosed herein are methods of treating cancer in a subject, comprising: administering at least one PAK4 inhibitor to the subject; and in certain embodiments administering at least one immunostimulatory agent to the subject. In some aspects, the immunostimulatory agent can be a checkpoint inhibitor. In certain aspects the checkpoint inhibitor can be an anti-PD1 antibody.
FILED Tuesday, April 16, 2019
APPL NO 17/048473
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/7105 (20130101) Original (OR) Class
A61K 45/06 (20130101)
A61K 2039/507 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Peptides
C07K 16/2818 (20130101)
C07K 16/2827 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161958 Ridky et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
APPLICANT(S) THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, Pennsylvania)
ASSIGNEE(S)
INVENTOR(S) Todd Ridky (Bryn Mawr, Pennsylvania);  Christopher Natale (Philadelphia, Pennsylvania);  Aimee S. Payne (Merion Station, Pennsylvania);  Christoph T. Ellebrecht (Philadelphia, Pennsylvania)
ABSTRACT The present invention includes compositions and methods for using a chimeric antigen receptor that specifically binds to melanocortin receptor (MCR). The present invention relates generally to the treatment of a patient having cancer that expresses one or more melanocortin receptors (MCR), such as melanoma. The invention also includes methods of making a genetically modified T cell expressing a chimeric antigen receptors (CAR) that binds to MCR.
FILED Wednesday, April 17, 2019
APPL NO 17/047993
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/17 (20130101) Original (OR) Class
A61K 38/00 (20130101)

Peptides
C07K 14/72 (20130101)
C07K 14/7051 (20130101)
C07K 14/70517 (20130101)
C07K 16/2818 (20130101)
C07K 16/2869 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161965 Hsu
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) MEMORIAL SLOAN KETTERING CANCER CENTER (New York, New York)
ASSIGNEE(S) MEMORIAL SLOAN KETTERING CANCER CENTER (New York, New York)
INVENTOR(S) Katharine Hsu (New York, New York)
ABSTRACT The present disclosure relates generally to methods for treating leukemia in a subject in need thereof comprising administering to the subject an effective amount of hematopoietic cells obtained from a candidate donor having a specific combination of KIR3DL1 and HLA-B alleles. Also disclosed herein are methods for protecting a leukemia patient recipient from leukemic relapse following allogeneic hematopoietic cell transplantation (HCT).
FILED Friday, March 09, 2018
APPL NO 16/493264
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/02 (20130101)
A61K 35/28 (20130101) Original (OR) Class

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6881 (20130101)
C12Q 2600/118 (20130101)
C12Q 2600/156 (20130101)
C12Q 2600/158 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161966 Cherqui et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) Stephanie Cherqui (La Jolla, California);  Eric Adler (La Jolla, California);  Sylvia Evans (La Jolla, California)
ABSTRACT Provided herein are methods for treating a lysosomal transmembrane protein disease or disorder through ex vivo introduction of a nucleic acid molecule into hematopoietic stem and progenitor cells (HSPCs) followed by transplantation of the HSPCs into a subject in need of treatment. Also provided are vectors containing the nucleic acid molecule.
FILED Thursday, March 15, 2018
APPL NO 16/493573
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/14 (20130101)
A61K 35/28 (20130101) Original (OR) Class
A61K 38/00 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 3/00 (20180101)

Peptides
C07K 14/705 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/86 (20130101)
C12N 2740/15043 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161974 LEY et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Office of the Director (NIHOD)
APPLICANT(S) CORNELL UNIVERSITY (Ithaca, New York)
ASSIGNEE(S)
INVENTOR(S) Ruth E. LEY (Ithaca, New York);  Julia GOODRICH (Ithaca, New York);  Jillian WATERS (Ithaca, New York)
ABSTRACT Disclosed herein are compositions that have substantially purified Christensenellaceae bacteria, and uses of these compositions to alter the microbiome of an individual. The addition of Christensenellaceae bacteria, such as Christensenella, to the microbiome of an individual can treat or prevent weight gain, reduce body weight, inhibit fat accumulation, reduce excess adiposity, and reduce a high body mass index (BMI), and can also treat or prevent conditions correlating with excess weight and fat and a high RMT, such as insulin sensitivity, metabolic syndrome, excess adiposity, and diabetes.
FILED Monday, February 08, 2021
APPL NO 17/170294
CURRENT CPC
Foods, Foodstuffs, or Non-alcoholic Beverages, Not Covered by Subclasses A23B - A23J; Their Preparation or Treatment, e.g Cooking, Modification of Nutritive Qualities, Physical Treatment; Preservation of Foods or Foodstuffs, in General
A23L 33/30 (20160801)
A23L 33/135 (20160801)

Indexing Scheme Relating to Foods, Foodstuffs or Non-alcoholic Beverages
A23V 2002/00 (20130101)

Preparations for Medical, Dental, or Toilet Purposes
A61K 9/19 (20130101)
A61K 9/0056 (20130101)
A61K 35/74 (20130101)
A61K 35/741 (20130101) Original (OR) Class
A61K 2035/115 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161979 van den Pol et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Yale University (New Haven, Connecticut)
ASSIGNEE(S)
INVENTOR(S) Anthony N. van den Pol (Branford, Connecticut);  Guido Wollmann (Innsbruck, Austria)
ABSTRACT Methods of treating cancer including administering to a subject with cancer a pharmaceutical composition including an effective amount of a chimeric VSV virus are disclosed. The chimeric viruses are based on a VSV background where the VSV G protein is replaced with one or more heterologous viral glycoproteins. In the most preferred embodiment, the VSV G protein is replaced with the glycoprotein from Lassa virus or a functional fragment thereof. The resulting chimeric virus is an oncolytic virus that is attenuated and safe in the brain, yet still retains sufficient oncolytic activity to infect and destroy cancer cells such glioblastoma, and to generate an immune response against infected cancer cells. Methods of using chimeric viruses as a platform for immunization against other pathogenic microbes are also provided.
FILED Friday, October 30, 2020
APPL NO 17/084841
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/007 (20130101)
A61K 9/0019 (20130101)
A61K 9/0043 (20130101)
A61K 35/12 (20130101)
A61K 35/766 (20130101) Original (OR) Class
A61K 39/205 (20130101)
A61K 45/06 (20130101)
A61K 2039/5152 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 7/00 (20130101)
C12N 7/04 (20130101)
C12N 2760/20133 (20130101)
C12N 2760/20223 (20130101)
C12N 2760/20232 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161980 Luesch et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) University of Florida Research Foundation, Incorporated (Gainesville, Florida)
ASSIGNEE(S)
INVENTOR(S) Hendrik Luesch (Gainesville, Florida);  Michelle S. Bousquet (Gainesville, Florida)
ABSTRACT The instant invention relates to seaweed extract compositions, processes for isolation, isolated active agents, and methods of treating disease, disorders and conditions in a subject, including, reactive oxygen species (ROS)-mediated diseases and diseases mediated through the activation of the Nrf2-ARE (antioxidant response element) pathway, including proliferative diseases and disorders, Alzheimer's disease, stroke, and certain diseases and disorders of aging and associated with aging and exposure, by use of the extracts, compounds, and compositions thereof.
FILED Thursday, December 06, 2018
APPL NO 16/770558
CURRENT CPC
Foods, Foodstuffs, or Non-alcoholic Beverages, Not Covered by Subclasses A23B - A23J; Their Preparation or Treatment, e.g Cooking, Modification of Nutritive Qualities, Physical Treatment; Preservation of Foods or Foodstuffs, in General
A23L 33/105 (20160801)

Preparations for Medical, Dental, or Toilet Purposes
A61K 8/347 (20130101)
A61K 8/498 (20130101)
A61K 31/055 (20130101)
A61K 31/085 (20130101)
A61K 31/352 (20130101)
A61K 36/05 (20130101) Original (OR) Class
A61K 2236/33 (20130101)
A61K 2236/53 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 29/00 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161999 SEGAL et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Health Research, Inc. (Buffalo, New York)
ASSIGNEE(S)
INVENTOR(S) Brahm SEGAL (Williamsville, New York);  Kelly SINGEL (Bethesda, Maryland)
ABSTRACT Provided are methods for identifying and treating individuals who have cancer, and also have immunosuppressive neutrophils. The method of treating includes administering one or more drugs that inhibit formation of immunosuppressive neutrophils. Cancer patients can be identified, and selected for treatment, based on a positive result obtained by exposing a biological sample from the patient to normal neutrophils, and subsequently exposing the neutrophils to T cells, and measuring activation of T the cells. Reduced activation of the T cells relative to a control provides an indication that the individual has the immunosuppressive neutrophils, and is a candidate to receive the drug. The drug administered to the cancer patient functions to inhibit SNARE-dependent exocytosis, or inhibits NADPH oxidase, or inhibits complement signaling. The method further includes administering to the individual an immune checkpoint inhibitor, which may increase the efficacy of the checkpoint inhibitor.
FILED Friday, August 09, 2019
APPL NO 17/266993
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/12 (20130101) Original (OR) Class
A61K 39/3955 (20130101)
A61K 2039/505 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/505 (20130101)
G01N 33/5011 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162007 Zhang et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
APPLICANT(S) President and Fellows of Harvard College (Cambridge, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Yanbo Zhang (Malden, Massachusetts);  Christophe Benoist (Brookline, Massachusetts);  Diane Mathis (Brookline, Massachusetts)
ABSTRACT The invention provides compositions and methods of modulating and regulating the activity of, expression of, or level of Nr2c2, to thereby modulate T regulatory cell (Treg) differentiation, function, activity, or maturation, or combinations of these biological activities. Such modulation may be useful in methods of treating and preventing cancer, inflammation, and inflammatory diseases, among other diseases, conditions, and illnesses.
FILED Monday, April 08, 2019
APPL NO 17/046447
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/201 (20130101)
A61K 31/203 (20130101)
A61K 38/1783 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162009 DWINELL et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) THE MEDICAL COLLEGE OF WISCONSIN, INC. (Milwaukee, Wisconsin)
ASSIGNEE(S) THE MEDICAL COLLEGE OF WISCONSIN, INC. (Milwaukee, Wisconsin)
INVENTOR(S) Michael DWINELL (Milwaukee, Wisconsin);  Bryon JOHNSON (Milwaukee, Wisconsin);  Brian VOLKMAN (Muskego, Wisconsin);  Francis PETERSON (Racine, Wisconsin)
ABSTRACT The present disclosure provides methods of using the CXCL12-α2 locked dimer polypeptide to mobilize cancer cells and hematopoietic stem cells into the bloodstream of a subject.
FILED Friday, December 07, 2018
APPL NO 16/770544
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/195 (20130101) Original (OR) Class
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162011 Wang et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
APPLICANT(S) University of Massachusetts (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Yong-Xu Wang (Southborough, Massachusetts);  Lei Huang (Shrewsbury, Massachusetts);  Yong Du (Houston, Texas)
ABSTRACT Methods for altering leptin resistance and the hormonal control of energy balance, and methods for treating obesity and diabetes, as well as promoting weight gain, using batotin and batotin inhibitors.
FILED Thursday, May 09, 2019
APPL NO 17/054334
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0019 (20130101)
A61K 9/0029 (20130101)
A61K 38/24 (20130101)
A61K 38/40 (20130101)
A61K 38/385 (20130101)
A61K 38/2264 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 3/04 (20180101)
A61P 3/10 (20180101)

Peptides
C07K 14/59 (20130101)
C07K 14/79 (20130101)
C07K 14/765 (20130101)
C07K 14/5759 (20130101)
C07K 16/26 (20130101)
C07K 2319/00 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 7/00 (20130101)
C12N 15/86 (20130101)
C12N 15/1136 (20130101)
C12N 2310/11 (20130101)
C12N 2310/14 (20130101)
C12N 2310/31 (20130101)
C12N 2310/33 (20130101)
C12N 2310/122 (20130101)
C12N 2310/341 (20130101)
C12N 2310/531 (20130101)
C12N 2310/3231 (20130101)
C12N 2320/32 (20130101)
C12N 2750/14143 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162014 WEISS et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Materials Research (DMR)
APPLICANT(S) CASE WESTERN RESERVE UNIVERSITY (Cleveland, Ohio)
ASSIGNEE(S)
INVENTOR(S) Michael WEISS (Moreland Hills, Ohio);  Jon POKORSKI (Cleveland, Ohio)
ABSTRACT An insulin composition comprises an insulin analogue and polymer blend. The insulin analogue contains cysteine substitutions at positions B4 and A10 (to form cystine B4-A10), and one or more additional substitutions selected from the group consisting of: a connecting domain of 5-11 amino acids between insulin A- and B domains; a non-beta-branched amino-acid substitution at position A8; a non-beta-branched acidic or polar side chain at position A14; a halogenic modification of PheB24 at the ortho position; and substitution of lysine at position B29 by Glu, Ala, Val, Ile, Leu, amino-propionic acid, amino-butryic acid, or Norleucine. The insulin analogue is compatible with a process of manufacture that includes one or more steps within the temperature range 90-120 oC. The encapsulated insulin analogue may optionally contain free PEG or be PEGylated. The insulin analogue-encapsulated polymer blend may be cast as a microneedle patch for topical administration or as micropellets for subcutaneous injection.
FILED Friday, December 23, 2016
APPL NO 16/065596
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0021 (20130101)
A61K 38/28 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162020 Childers et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) Wake Forest University Health Sciences (Winston-Salem, North Carolina);  Genethon (Evry, France);  Children's Medical Center Corporation (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Martin K. Childers (Seattle, Washington);  Alan H. Beggs (Needham, Massachusetts);  Ana Maria Buj Bello (Paris, France)
ABSTRACT The present invention provides compositions and methods for treating a myopathy. In certain embodiments, the invention provides compositions and methods for treating, improving muscle function, and prolonging survival in a subject with X-linked myotubular myopathy (XLMTM). The present invention provides a method comprising systemic administration of a composition that induces the increased expression of myotubularin in the muscle of a subject. The invention provides sustained regional and global increases in muscle function.
FILED Wednesday, July 22, 2020
APPL NO 16/935437
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/465 (20130101) Original (OR) Class
A61K 48/005 (20130101)
A61K 48/0058 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 7/00 (20130101)
C12N 9/16 (20130101)
C12N 2750/14143 (20130101)

Enzymes
C12Y 301/03 (20130101)
C12Y 301/03064 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162038 KLEMKE et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) The Regents of the University of California (La Jolla, California)
ASSIGNEE(S)
INVENTOR(S) Richard KLEMKE (La Jolla, California);  Huawei WANG (San Diego, California)
ABSTRACT Provided herein are cytoplasts, compositions comprising cytoplasts, methods of using cytoplasts, and methods of treating a subject, such as providing benefits to a healthy or unhealthy subject, or treating or diagnosing a disease or condition in a subject. In some embodiments, methods of treating a subject include: administering to the subject a therapeutically effective amount of a composition comprising a cytoplast. Also, provided herein are compositions (e.g., pharmaceutical compositions) that include a cytoplast. Also, provided herein are kits comprising instructions for using the compositions or methods.
FILED Wednesday, January 27, 2021
APPL NO 17/159595
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/12 (20130101)
A61K 39/215 (20130101) Original (OR) Class
A61K 39/001102 (20180801)
A61K 2039/515 (20130101)
A61K 2039/545 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162048 Mazitschek et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute on Drug Abuse (NIDA)
APPLICANT(S) The General Hospital Corporation (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Ralph Mazitschek (Belmont, Massachusetts);  Balaram Ghosh (Boston, Massachusetts);  James Adam Hendricks (Watertown, Massachusetts);  Surya Reis (Boston, Massachusetts);  Stephen John Haggarty (Dorchester, Massachusetts)
ABSTRACT This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same.
FILED Friday, November 06, 2020
APPL NO 17/091863
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 41/0028 (20130101) Original (OR) Class

Acyclic or Carbocyclic Compounds
C07C 245/08 (20130101)
C07C 259/06 (20130101)
C07C 259/10 (20130101)

Heterocyclic Compounds
C07D 333/20 (20130101)
C07D 409/14 (20130101)
C07D 491/16 (20130101)

Acyclic, Carbocyclic or Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium or Tellurium
C07F 5/022 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162050 Zakrewsky et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) Michael Zakrewsky (San Diego, California);  Samir Mitragotri (Lexington, Massachusetts)
ABSTRACT Compositions containing a complex that contains a cation with alkyl chains and a macromolecule anion, and methods of making and using are disclosed. The compositions are typically charge neutral and a liquid at room temperature and standard pressure. The macromolecule anions may be nucleic acids, peptides, proteins, and/or carbohydrates. The compositions have enhanced penetration across the skin barrier (stratum corneum) and into the skin cells, delivering the macromolecules to the skin cells. The compositions are topically applied to the skin and are particularly useful for treatment of skin conditions.
FILED Friday, February 05, 2021
APPL NO 17/168709
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 8/416 (20130101)
A61K 8/735 (20130101)
A61K 9/0014 (20130101)
A61K 31/713 (20130101)
A61K 38/385 (20130101)
A61K 47/36 (20130101)
A61K 47/42 (20130101)
A61K 47/186 (20130101) Original (OR) Class

Specific Use of Cosmetics or Similar Toilet Preparations
A61Q 19/08 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162053 Manoharan et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) ARBUTUS BIOPHARMA CORPORATION (Burnaby, Canada)
ASSIGNEE(S) ARBUTUS BIOPHARMA CORPORATION (Burnaby, Canada)
INVENTOR(S) Muthiah Manoharan (Cambridge, Massachusetts);  Kallanthottathil G. Rajeev (Cambridge, Massachusetts);  Muthusamy Jayaraman (Cambridge, Massachusetts);  David Butler (Medford, Massachusetts);  Jayaprakash K. Nair (Cambridge, Massachusetts);  Martin Maier (Cambridge, Massachusetts);  Laxman Eltepu (Cambridge, Massachusetts)
ABSTRACT The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure (I) wherein R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylheterocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ω-aminoalkyls, ω-(substituted)aminoalkyls, ω-phosphoalkyls, ω-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; E is O, S, N(Q), C(O), N(Q)C(O), C(O)N(Q), (Q)N(CO)O, O(CO)N(Q), S(O), NS(O)2N(Q), S(O)2, N(Q)S(O)2, SS, O═N, aryl, heteroaryl, cyclic or heterocycle; and, Q is H, alkyl, ω-aminoalkyl, ω-(substituted)aminoalkyl, ω-phosphoalkyl or ω-thiophosphoalkyl.
FILED Wednesday, October 07, 2020
APPL NO 17/065208
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/1272 (20130101)
A61K 31/713 (20130101)
A61K 31/7088 (20130101)
A61K 39/00 (20130101)
A61K 39/39 (20130101)
A61K 47/10 (20130101)
A61K 47/18 (20130101)
A61K 47/20 (20130101)
A61K 47/28 (20130101)
A61K 47/44 (20130101) Original (OR) Class
A61K 2039/55555 (20130101)
A61K 2039/55561 (20130101)

Acyclic or Carbocyclic Compounds
C07C 229/08 (20130101)
C07C 229/30 (20130101)
C07C 237/16 (20130101)
C07C 251/38 (20130101)
C07C 251/78 (20130101)
C07C 271/12 (20130101)
C07C 271/20 (20130101)
C07C 323/25 (20130101)

Heterocyclic Compounds
C07D 203/10 (20130101)
C07D 317/28 (20130101)
C07D 317/44 (20130101)
C07D 317/46 (20130101)
C07D 317/72 (20130101)
C07D 319/06 (20130101)
C07D 405/12 (20130101)
C07D 491/056 (20130101)
C07D 491/113 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/111 (20130101)
C12N 15/113 (20130101)
C12N 2310/14 (20130101)
C12N 2310/3515 (20130101)
C12N 2320/32 (20130101)

Technologies for Adaptation to Climate Change
Y02A 50/30 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162056 Peti-Peterdi
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
APPLICANT(S) MACULA DENSA CELL LLC (PALOS VERDES ESTATES, California)
ASSIGNEE(S)
INVENTOR(S) Janos Peti-Peterdi (Palos Verdes Estates, California)
ABSTRACT There is no specific cure for chronic kidney disease (CKD), which affects one in every ten adults. The unmet medical need has created significant interest in regenerative therapeutic approaches. Described herein is a radically new and innovative therapeutic approach identified by characterizing a novel mechanism of renal tissue repair and its role in glomerular injury. By targeting this mechanism in CKD, significant therapeutic benefit supported by rapid cellular remodeling of kidney tissues, coincident with structural and functional nephron regeneration. Methods and compositions for achieving the described therapeutic approach are fundamentally different from existing strategies.
FILED Thursday, October 01, 2020
APPL NO 17/061115
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 47/64 (20170801) Original (OR) Class
A61K 47/6455 (20170801)
A61K 49/0008 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 13/12 (20180101)

Peptides
C07K 14/47 (20130101)
C07K 14/475 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/113 (20130101)
C12N 2310/141 (20130101)
C12N 2310/3513 (20130101)
C12N 2320/32 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162065 Castro et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Ohio State Innovation Foundation (Columbus, Ohio)
ASSIGNEE(S)
INVENTOR(S) Carlos Castro (Columbus, Ohio);  Christopher Lucas (Columbus, Ohio);  Patrick Halley (Columbus, Ohio);  John Byrd (Columbus, Ohio)
ABSTRACT Disclosed herein are DNA origami nanostmcture that can be functionalized for personalized and targeted drug delivery. The disclosed nanostructures enter cells through the endolysosomal pathway and circumvent drug resistance mechanisms in target cells. The disclosed nanostructures can be loaded small molecule drugs (e.g. anthracyclines, anti-metabolites) and nucleic acids (e.g. antisense oligonucleotides, siRNA, miRNA) with targeting and/or therapeutic antibodies against tumor-specific antigens (e.g. anti-CD33, anti-CD20) that can be modified to treat to a wide range of cancers and ultimately tailored to specific patients' needs for precision medicine.
FILED Tuesday, April 09, 2019
APPL NO 17/046521
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/704 (20130101)
A61K 39/39558 (20130101)
A61K 47/10 (20130101)
A61K 47/26 (20130101)
A61K 47/6803 (20170801)
A61K 47/6921 (20170801) Original (OR) Class
A61K 2039/51 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/113 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162066 Shapiro et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) The United States of America, as represented by the Secretary, Department of Health and Human Servic (Bethesda, Maryland)
ASSIGNEE(S) The United States of America,as represented by the Secretary,Department of Health and Human Services (Bethesda, Maryland)
INVENTOR(S) Bruce Allen Shapiro (Gaithersburg, Maryland);  Kirill Andreevich Afonin (Charlotte, North Carolina);  Mathias D. Viard (Frederick, Maryland);  Eckart H.U. Bindewald (Frederick, Maryland);  Lorena Parlea (Frederick, Maryland)
ABSTRACT The invention discloses the use of single-stranded RNA toeholds of different lengths to promote the re-association of various RNA-DNA hybrids, which results in activation of multiple split functionalities inside human cells. Previously designed RNA/DNA nanoparticles employed single-stranded DNA toeholds to initiate re-association. The use of RNA toeholds is advantageous because of the simpler design rules, the shorter toeholds, and the smaller size of the resulting nanoparticles compared to the same hybrid nanoparticles with single-stranded DNA toeholds. Moreover, the co-transcriptional assemblies result in higher yields for hybrid nanoparticles with ssRNA toeholds.
FILED Tuesday, November 24, 2020
APPL NO 17/102786
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 47/555 (20170801)
A61K 47/6925 (20170801)
A61K 47/6929 (20170801) Original (OR) Class

Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures
B82Y 5/00 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/87 (20130101)
C12N 15/111 (20130101)
C12N 15/113 (20130101)
C12N 2310/14 (20130101)
C12N 2320/50 (20130101)
C12N 2330/50 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162127 DASSAU et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
APPLICANT(S) PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, Massachusetts)
ASSIGNEE(S) PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, Massachusetts)
INVENTOR(S) Eyal DASSAU (Cambridge, Massachusetts);  Francis J. DOYLE (Cambridge, Massachusetts);  Dawei SHI (Cambridge, Massachusetts)
ABSTRACT A system for the delivery of insulin to a patient is provided. The systems and methods disclose include an insulin delivery device configured to deliver insulin to a patient in response to control signals. The system also includes a controller programmed to receive the sensor glucose measurement signal from the glucose sensor. The sensor glucose measurement signal received indicates a concentration of the real time glucose concentration in a bloodstream. The controller is further configured to enact an impeding glycemia protocol based on a zone model predictive control (MPC) algorithm in response to the real time glucose concentration. The impeding glycemia protocol includes in determining a relationship between predicted glucose concentrations, a rate of change of the predicted glucose concentrations, and a set of control parameters that determine insulin doses above and below a patient-specific basal rate.
FILED Wednesday, June 19, 2019
APPL NO 16/973628
CURRENT CPC
Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor
A61M 5/1723 (20130101) Original (OR) Class
A61M 2005/14208 (20130101)
A61M 2230/201 (20130101)

Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data
G16H 10/60 (20180101)
G16H 20/17 (20180101)
G16H 40/40 (20180101)
G16H 40/67 (20180101)
G16H 50/20 (20180101)
G16H 50/30 (20180101)
G16H 70/40 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162408 Sabaawy et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Rutgers, The State University of New Jersey (New Brunswick, New Jersey)
ASSIGNEE(S)
INVENTOR(S) Hatem E. Sabaawy (New Brunswick, New Jersey);  Howon Lee (Piscataway, New Jersey);  Chen Yang (New Brunswick, New Jersey);  Daehoon Han (New Brunswick, New Jersey)
ABSTRACT An expandable array and methods of maintaining a biological sample within an expandable array are provided. The expandable array includes a plurality of receptacles configured to receive a biological sample and a plurality of beams comprising a programmable material. Each beam of the plurality of beams is located between and connects at least two receptacles. The programmable material can be a shape-memory polymer or a magnetoactive material that transitions the plurality of beams from an extended state to a contracted state upon application of a stimulus.
FILED Friday, October 30, 2020
APPL NO 17/085985
CURRENT CPC
Chemical or Physical Laboratory Apparatus for General Use
B01L 3/50855 (20130101) Original (OR) Class
B01L 2300/18 (20130101)
B01L 2300/0636 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163384 Petitjean et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
National Science Foundation (NSF)
APPLICANT(S) YALE UNIVERSITY (New Haven, Connecticut)
ASSIGNEE(S)
INVENTOR(S) Laurene Petitjean (New Haven, Connecticut);  Paul Thomas Anastas (Guilford, Connecticut);  Tamara Marie DeWinter (San Francisco, California);  Philip Coish (North Haven, Connecticut);  Hanno Christian Erythropel (New Haven, Connecticut);  Predrag Petrovic (New Haven, Connecticut)
ABSTRACT The invention relates to novel, scalable synthetic routes that allow for direct reduction of enones to the corresponding saturated alcohols. The invention relates, in certain aspects, to synthetic routes that allow for the reduction of enones to the corresponding ketones. Such reactions take place under mild conditions, are compatible with a wide range of functional groups, and expand the repertoire of existing green chemistry methodology. In certain embodiments, the reactions are run in aqueous solvent.
FILED Wednesday, December 02, 2020
APPL NO 17/109719
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 21/04 (20130101)
B01J 21/10 (20130101)
B01J 23/72 (20130101)

Acyclic or Carbocyclic Compounds
C07C 29/145 (20130101) Original (OR) Class
C07C 45/62 (20130101)
C07C 49/04 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163393 Burke et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) The Board of Trustees of the University of Illinois (Urbana, Illinois)
ASSIGNEE(S)
INVENTOR(S) Martin D. Burke (Champaign, Illinois);  Anthony S. Grillo (Champaign, Illinois);  Alexander G. Cioffi (Urbana, Illinois);  Anna SantaMaria (Rockville, Maryland);  Daniel Blair (Hull, United Kingdom);  Andrew Blake (Urbana, Illinois)
ABSTRACT Disclosed are analogues of hinokitiol, methods for preparing them, and pharmaceutical compositions thereof. Also disclosed are methods for their use in treating iron-related diseases.
FILED Friday, April 12, 2019
APPL NO 17/046608
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 45/06 (20130101)

Acyclic or Carbocyclic Compounds
C07C 45/68 (20130101) Original (OR) Class
C07C 61/22 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163403 FREEMAN et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
APPLICANT(S) Cedars-Sinai Medical Center (Los Angeles, California)
ASSIGNEE(S) Cedars-Sinai Medical Center (Los Angeles, California)
INVENTOR(S) Michael FREEMAN (West Hollywood, California);  Mirja ROTINEN (Beverly Hills, California);  Ramachandran MURALI (Beverly Hills, California);  Sungyong YOU (Los Angeles, California)
ABSTRACT Provided herein are compositions and methods for treating, inhibiting and/or reducing the severity of cancer in subjects in need thereof. The methods include providing an agent that inhibits expression or activity of ONECUT2 and administering a therapeutically effective amount of the agent so as to treat, inhibit and/or reduce the severity of cancer in the subject.
FILED Friday, January 08, 2021
APPL NO 17/145152
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/40 (20130101)
A61K 31/45 (20130101)
A61K 31/165 (20130101)
A61K 31/397 (20130101)
A61K 31/416 (20130101)
A61K 31/417 (20130101)
A61K 31/445 (20130101)
A61K 31/4164 (20130101)
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

General Methods of Organic Chemistry; Apparatus Therefor
C07B 2200/07 (20130101)

Acyclic or Carbocyclic Compounds
C07C 233/31 (20130101)
C07C 237/08 (20130101) Original (OR) Class
C07C 237/22 (20130101)
C07C 259/06 (20130101)

Heterocyclic Compounds
C07D 205/04 (20130101)
C07D 207/09 (20130101)
C07D 207/16 (20130101)
C07D 211/60 (20130101)
C07D 211/76 (20130101)
C07D 211/78 (20130101)
C07D 231/56 (20130101)
C07D 233/64 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/68 (20130101)
C12Q 1/6886 (20130101)
C12Q 2600/106 (20130101)
C12Q 2600/158 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163406 Erker et al.
FUNDED BY
Department of Veterans Affairs (DVA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
APPLICANT(S) University of Pittsburgh - Of the Commonwealth System of Higher Education (Pittsburgh, Pennsylvania);  The United States Government as represented by the Department of Veterans Affairs (Washington, District of Columbia);  Universität Wien (Wien, Austria)
ASSIGNEE(S)
INVENTOR(S) Thomas Erker (Vienna, Austria);  Philipp Schreppel (Vienna, Austria);  Dandan Sun (Pittsburgh, Pennsylvania)
ABSTRACT The present invention relates to bumetanide derivatives of formula (I) as well as pharmaceutical compositions comprising these compounds for use in the treatment or prevention of neurological diseases/disorders involving Na+-K+-20Γ-cotransporters (NKCCs), such as stroke, traumatic brain injury (TBI), spinal cord injury (SCI), peripheral nerve injury (PNI), brain edema, or glioma, and particularly for use in the treatment or prevention of stroke. The invention likewise relates to a method of treating or preventing a neurological disease or disorder involving an NKCC, such as stroke, TBI, SCI, PNI, brain edema, or glioma, the method comprising administering a compound of formula (I) to a subject in need thereof.
FILED Friday, April 05, 2019
APPL NO 17/045395
CURRENT CPC
Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 9/10 (20180101)
A61P 35/00 (20180101)

Acyclic or Carbocyclic Compounds
C07C 311/39 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163453 DENKO et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Ohio State Innovation Foundation (Columbus, Ohio)
ASSIGNEE(S)
INVENTOR(S) Nicholas DENKO (Dublin, Ohio);  Ioanna PAPANDREOU (Columbus, Ohio);  Martin BENEJ (Upper Arlington, Ohio);  Ching-Shih CHEN (Taichung, Taiwan);  Sandip VIBHUTE (Columbus, Ohio)
ABSTRACT Disclosed herein are compounds, compositions, and methods for inhibiting mitochondrial oxygen consumption in a cancerous tissue. The compounds, compositions, and methods can be used to treat a subject with hypoxic cancerous tissue.
FILED Tuesday, July 23, 2019
APPL NO 17/262989
CURRENT CPC
Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Heterocyclic Compounds
C07D 217/24 (20130101)
C07D 239/72 (20130101)
C07D 401/06 (20130101)
C07D 405/06 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163454 Cunningham et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) President and Fellows of Harvard College (Cambridge, Massachusetts);  THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) James Cunningham (Wellesley, Massachusetts);  Hu Liu (Chestnut Hill, Massachusetts);  Ye Tian (Jinan, China PRC);  Kyungae Lee (Allston, Massachusetts)
ABSTRACT Disclosed herein are compounds having a structure of formula (I), compositions and methods useful for the treatment of a disease or infection, such as a viral infection (e.g., Ebola), cancer and obesity: wherein
    • A is N or CR8;
    • Z is
    • E is selected from optionally substituted alkyl, cycloalkyl, arylalkyl, cycloalkylalkyl, amino, alkoxy, cycloalkyloxy, and cycloalkylamino;
    • R1 is selected from optionally substituted aryl and heteroaryl,
    • R2 and R3 are independently selected from H, deutero, optionally substituted alkyl, haloalkyl, or R2 and R3, together with the carbon to which they are bound, combine to form a carbonyl; and
    • R8 is selected from H, deutero, halo, hydroxyl, cyano, amino, alkyl, alkoxy, carboxy, alkoxycarbonyl, and aminocarbonyl, provided that E is not
FILED Monday, September 10, 2018
APPL NO 16/645341
CURRENT CPC
Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/12 (20180101)

General Methods of Organic Chemistry; Apparatus Therefor
C07B 2200/05 (20130101)

Heterocyclic Compounds
C07D 209/14 (20130101)
C07D 211/16 (20130101)
C07D 211/62 (20130101)
C07D 213/68 (20130101)
C07D 213/75 (20130101)
C07D 213/647 (20130101)
C07D 215/12 (20130101)
C07D 231/56 (20130101)
C07D 295/185 (20130101)
C07D 405/12 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163506 AMANN et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
APPLICANT(S) VENATORX PHARMACEUTICALS, INC. (Malvern, Pennsylvania)
ASSIGNEE(S)
INVENTOR(S) Franz AMANN (Hunzenschwil, Switzerland);  Matthew M. BIO (Cambridge, Massachusetts);  Jonas BÜRGLER (Hunzenschwil, Switzerland);  Yuanqing FANG (Cambridge, Massachusetts);  David FORD (Cambridge, Massachusetts);  Daniel McGARRY (Malvern, Pennsylvania)
ABSTRACT Described herein are boron-containing compounds, compositions, and methods for their preparation.
FILED Tuesday, December 08, 2020
APPL NO 17/115514
CURRENT CPC
Acyclic, Carbocyclic or Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium or Tellurium
C07F 5/025 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163508 Stansbury et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Dental and Craniofacial Research (NIDCR)
APPLICANT(S) THE REGENTS OF THE UNIVERSITY OF COLORADO (Boulder, Colorado)
ASSIGNEE(S)
INVENTOR(S) Jeffrey W. Stansbury (Boulder, Colorado);  Kangmin Kim (Boulder, Colorado);  Charles B. Musgrave (Boulder, Colorado);  Jasmine Sinha (Boulder, Colorado)
ABSTRACT A quaternary ammonium salt comprising a chromophore constituent, a tertiary amine cation constituent connected to the para-position of the chromophore constituent via a methylene linkage, and a borate anion constituent, wherein chromophore constituent is a 3-ketocoumarin constituent or a benzophenone constituent. Also, a photobase-redox initiating system comprising the quaternary ammonium salt and a peroxide.
FILED Monday, December 10, 2018
APPL NO 16/770725
CURRENT CPC
Heterocyclic Compounds
C07D 311/16 (20130101)
C07D 311/56 (20130101)
C07D 311/92 (20130101)

Acyclic, Carbocyclic or Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium or Tellurium
C07F 5/027 (20130101) Original (OR) Class

Photomechanical Production of Textured or Patterned Surfaces, e.g for Printing, for Processing of Semiconductor Devices; Materials Therefor; Originals Therefor; Apparatus Specially Adapted Therefor;
G03F 7/029 (20130101)
G03F 7/0045 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163532 Aldrich et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
APPLICANT(S) University of Florida Research Foundation, Incorporated (Gainesville, Florida)
ASSIGNEE(S) University of Florida Research Foundation, Incorporated (Gainesville, Florida)
INVENTOR(S) Jane V. Aldrich (Gainesville, Florida);  Michael J. Ferracane (Irvine, California)
ABSTRACT The invention relates to macrocyclic peptides and pharmaceutical compositions thereof. The invention further provides macrocyclic tetrapeptides comprising sarcosine. The invention further relates to pharmaceutical compositions for modulating opioid receptor activity. The macrocyclic tetrapeptides provided herein are useful in treating diseases or disorders relating to the activity of one or more opioid receptors, such as neurological disorders.
FILED Wednesday, April 17, 2019
APPL NO 17/047977
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/00 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/04 (20180101)

Peptides
C07K 5/126 (20130101) Original (OR) Class
C07K 7/64 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163533 Endo et al.
FUNDED BY
Department of Health and Human Services (HHS)
Centers for Disease Control and Prevention (CDC)
Center for Global Health (CGH)
APPLICANT(S) Astellas Pharma Inc. (Chuo-ku, Tokyo, Japan);  National Center for Global Health and Medicine (Shinjuku-ku, Tokyo, Japan);  Hiroshima University (Higashihiroshima-shi, Hiroshima, Japan)
ASSIGNEE(S) Astellas Pharma Inc. (Chuo-ku, Tokyo, Japan);  National Center for Global Health and Medicine (Shinjuku-ku, Tokyo, Japan);  Hiroshima University (Higashihiroshima-shi, Hiroshima, Japan)
INVENTOR(S) Hideki Endo (Tokyo, Japan);  Yukihito ISHIZAKA (Tokyo, Japan);  Akira ISHIGURO (Tokyo, Japan);  Tomoki TAKASHINA (Tokyo, Japan);  Takashi YAMAMOTO (Hiroshima, Japan);  Tetsushi SAKUMA (Hiroshima, Japan)
ABSTRACT An object of the present invention is to provide a cell penetrating peptide having a penetrating ability into cells. The present inventors provided a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.
FILED Monday, December 10, 2018
APPL NO 16/771009
CURRENT CPC
Peptides
C07K 7/06 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163551 GREENE et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) The Trustees of Columbia University in the City of New York (New York, New York);  The Regents of the University of California (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) LLOYD A. GREENE (LARCHMONT, New York);  XIAOTIAN SUN (FORT LEE, New Jersey);  JAMES M. ANGELASTRO (DAVID, California)
ABSTRACT Dominant negative forms of CEBPB and CEBPD, and cell-penetrating forms thereof are described. Methods for using the dominant negative forms of CEBPB and CEBPD proteins, and cell-penetrating forms thereof, for decreasing viability of neoplastic cells and treating cancer in a subject are also described.
FILED Monday, February 08, 2021
APPL NO 17/170151
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/337 (20130101)
A61K 31/704 (20130101)
A61K 31/4706 (20130101)
A61K 38/1709 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Peptides
C07K 14/47 (20130101) Original (OR) Class
C07K 2319/10 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163555 BI et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) WESTERN UNIVERSITY OF HEALTH SCIENCES (Pomona, California)
ASSIGNEE(S)
INVENTOR(S) Xiaoning BI (Corona, California);  Michel BAUDRY (Corona, California);  Jiandong SUN (Chino Hills, California)
ABSTRACT Accumulating evidence indicates that the lysosomal Ragulator complex is essential for full activation of the mechanistic target of rapamycin complex 1 (mTORC1). Abnormal mTORC1 activation has been implicated in several developmental neurological disorders, including Angelman syndrome (AS), which is caused by maternal deficiency of the ubiquitin E3 ligase UBE3A. Here, it is reported that Ube3a regulates mTORC1 signaling by targeting p18, a subunit of the Ragulator. Ube3a ubiquinates p18, resulting in its proteasomal degradation, and Ube3a deficiency in the hippocampus of AS mice induces increased lysosomal localization of p18 and other members of the Ragulator-Rag complex, and increased mTORC1 activity. p18 knockdown in hippocampal CA1 neurons of AS mice reduces elevated mTORC1 activity and improves dendritic spine maturation, long-term potentiation (LTP), as well as learning performance. The results described herein indicate that Ube3a-mediated regulation of p18 and subsequent mTORC1 signaling is critical for typical synaptic plasticity, dendritic spine development, and learning and memory.
FILED Friday, May 31, 2019
APPL NO 17/059882
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/00 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/00 (20180101)

Peptides
C07K 14/4703 (20130101) Original (OR) Class
C07K 2319/10 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/113 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163556 Stupp et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) Northwestern University (Evanston, Illinois)
ASSIGNEE(S)
INVENTOR(S) Samuel I. Stupp (Chicago, Illinois);  Alexandra N. Kolberg (Chicago, Illinois);  Zaida Alvarez (Chicago, Illinois)
ABSTRACT Provided herein are peptide amphiphiles (PAs) and supramolecular PA nanostructures that mimic brain derived neurotrophic factor (BDNF), a growth factor that induces neuronal survival, maturation, and increased electrical activity. In particular, injectable biomaterials comprising BDNF mimetic PAs are provided, as well as methods of using BDNF mimetic PAs for the treatment or prevention of neurological injuries, diseases, and disorders.
FILED Friday, April 05, 2019
APPL NO 17/045728
CURRENT CPC
Peptides
C07K 7/64 (20130101)
C07K 14/475 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163557 Dewji et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Aging (NIA)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S) The Regents of the University of California (Oakland, California)
INVENTOR(S) Nazneen Dewji (San Diego, California);  S. Jonathan Singer (La Jolla, California)
ABSTRACT The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease.
FILED Friday, September 11, 2020
APPL NO 17/018450
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/00 (20130101)
A61K 38/08 (20130101)
A61K 38/10 (20130101)
A61K 38/1709 (20130101)

Peptides
C07K 7/06 (20130101)
C07K 7/08 (20130101)
C07K 14/4711 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163570 Marasco et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Dana-Farber Cancer Institute, Inc. (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Wayne A. Marasco (Wellsley, Massachusetts);  Quan Karen Zhu (Southborough, Massachusetts);  Emily Kuiper (Boston, Massachusetts)
ABSTRACT This invention is directed to engineered cells and methods for using the same. In embodiments, the engineered cell comprises a nucleic acid encoding a chimeric antigen receptor and a polypeptide, wherein the chimeric antigen receptor is specific for two or more antigens on the surface of a cancer cell, and wherein the polypeptide comprises an antibody or fragment thereof that can be secreted from the engineered cell.
FILED Thursday, March 14, 2019
APPL NO 16/980742
CURRENT CPC
Peptides
C07K 14/705 (20130101) Original (OR) Class
C07K 16/2818 (20130101)
C07K 16/2827 (20130101)
C07K 16/2866 (20130101)
C07K 2317/565 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0636 (20130101)
C12N 2510/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163578 Achkar et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) Albert Einstein College of Medicine (Bronx, New York)
ASSIGNEE(S)
INVENTOR(S) Jacqueline M. Achkar (Brooklyn, New York);  Jonathan Lai (Dobbs Ferry, New York);  Elise Ishida (Aiea, Hawaii);  Daniel Hofmann (Moembris, Germany);  Tingting Chen (Bronx, New York)
ABSTRACT Provided are high affinity Mycobacterium tuberculosis capsule-specific antibodies and fragments thereof, as well as methods of use and devices employing such antibodies and/or fragments.
FILED Friday, April 12, 2019
APPL NO 17/047256
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 2039/505 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/06 (20180101)

Peptides
C07K 16/1289 (20130101) Original (OR) Class
C07K 2317/21 (20130101)
C07K 2317/52 (20130101)
C07K 2317/76 (20130101)
C07K 2317/92 (20130101)
C07K 2317/565 (20130101)
C07K 2317/567 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/5695 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163602 BRADLEY et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) Sanford Burnham Prebys Medical Discovery Institute (La Jolla, California)
ASSIGNEE(S)
INVENTOR(S) Linda M. BRADLEY (San Diego, California);  Roberto TINOCO (San Diego, California)
ABSTRACT The present invention relates to the seminal discovery that P-selectin glycoprotein ligand-1 (PSGL-1) modulates the immune system and immune responses. Specifically, the present invention provides PSGL-1 agonists and antagonists which increase the survival of multifunctional T cells and viral clearance. The present invention further provides methods of treating infectious diseases, cancer and immune and inflammatory diseases and disorders using a PSGL-1 modulator.
FILED Monday, November 02, 2020
APPL NO 17/086922
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 2039/505 (20130101)

Peptides
C07K 14/70596 (20130101)
C07K 16/2854 (20130101) Original (OR) Class
C07K 16/2896 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163609 REMOLD-O'DONNELL et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) THE CHILDREN'S MEDICAL CENTER CORPORATION (Boston, Massachusetts)
ASSIGNEE(S) THE CHILDREN'S MEDICAL CENTER CORPORATION (Boston, Massachusetts)
INVENTOR(S) Eileen REMOLD-O'DONNELL (Brookline, Massachusetts);  Lifei HOU (Dover, Massachusetts)
ABSTRACT Described herein are methods and compositions for treating an autoimmune disease. Aspects of the methods described herein relate, in part, to administering to a subject an agent that targets CXCR6. Another aspect of the methods described herein relate, in part, to administering to a subject an agent that inhibits SerpinB1.
FILED Tuesday, April 09, 2019
APPL NO 17/046341
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 37/00 (20180101)

Peptides
C07K 16/2866 (20130101) Original (OR) Class

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/68 (20130101)
G01N 2800/24 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163624 SCHEINBERG et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
APPLICANT(S) Memorial Sloan Kettering Cancer Center (New York, New York);  Eureka Therapeutics, Inc. (Emeryville, California)
ASSIGNEE(S) Memorial Sloan Kettering Cancer Center (New York, New York);  Eureka Therapeutics, Inc. (Emeryville, California)
INVENTOR(S) David SCHEINBERG (New York, New York);  Tao DAO (New York, New York);  Cheng LIU (Emeryville, California);  Su YAN (Emeryville, California)
ABSTRACT The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.
FILED Friday, October 30, 2020
APPL NO 17/085234
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 47/6849 (20170801)
A61K 47/6851 (20170801)
A61K 2039/505 (20130101)

Peptides
C07K 16/18 (20130101)
C07K 16/32 (20130101) Original (OR) Class
C07K 16/2809 (20130101)
C07K 16/2833 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/5748 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163869 SWEET et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
APPLICANT(S) EnTox Sciences, Inc. (Mercer Island, Washington);  University of Washington (Seattle, Washington)
ASSIGNEE(S)
INVENTOR(S) Ian SWEET (Mercer Island, Washington);  Gamal KHALIL (Redmond, Washington);  Daniel COOK (Seattle, Washington)
ABSTRACT A microperifusion system includes at least one perifusate reservoir module having N receptacles and at least one port to communicate a pressurizing gas into or out from the respective perifusate reservoir module. A corresponding perifusion chamber module having M microperifusion channels is mechanically coupleable to at least one perifusate reservoir module to thereby form, when coupled, a sealed fluid communication between a selected first number of the N receptacles and a selected second number of the M microperifusion channels. A control system module is coupleable to each perifusate reservoir and each perifusion chamber to control a flow of pressuring gas communicated into or out from the perifusate reservoir sense an effect of a microperifusion test operation occurring in each microperifusion channel.
FILED Tuesday, December 04, 2018
APPL NO 16/769569
CURRENT CPC
Apparatus for Enzymology or Microbiology;
C12M 23/16 (20130101)
C12M 23/42 (20130101)
C12M 23/44 (20130101)
C12M 29/10 (20130101) Original (OR) Class
C12M 29/14 (20130101)
C12M 41/32 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163872 Parekkadan et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) Rutgers, The State University of New Jersey (New Brunswick, New Jersey);  The General Hospital Corporation (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Biju Parekkadan (Piscataway, New Jersey);  Matthew Li (Somerville, Massachusetts)
ABSTRACT Systems and methods for the dynamic co-culturing of two cell populations are provided. The system includes a barrier configured to physically separate a stimulator cell population from a responder cell population disposed within a container. The barrier is permeable to the secreted factors of at least one of the cell populations. The responder cell population can thereby be altered by exposure to the secreted factors to produce a population of reprogrammed cells that includes biomolecules (e.g., nucleic acids) originating from the stimulator cell population and/or that exhibits one or more additional or modified functional activities than a parental population of the reprogrammed cells.
FILED Friday, January 11, 2019
APPL NO 16/961098
CURRENT CPC
Apparatus for Enzymology or Microbiology;
C12M 25/02 (20130101)
C12M 25/10 (20130101)
C12M 29/10 (20130101)
C12M 29/14 (20130101)
C12M 35/08 (20130101) Original (OR) Class

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0636 (20130101)
C12N 5/0645 (20130101)
C12N 15/86 (20130101)
C12N 2502/1114 (20130101)
C12N 2502/1323 (20130101)
C12N 2502/1358 (20130101)
C12N 2502/1394 (20130101)
C12N 2510/00 (20130101)
C12N 2521/00 (20130101)
C12N 2740/15043 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163888 Tesar et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of Child Health and Human Development (NICHD)
National Institute of General Medical Sciences (NIGMS)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) Case Western Reserve University (Cleveland, Ohio)
ASSIGNEE(S)
INVENTOR(S) Paul Tesar (Wickliffe, Ohio);  Mayur Madhavan (Beachwood, Ohio);  Zachary Nevin (Cleveland Heights, Ohio)
ABSTRACT The invention described herein provides a method for generating oligocortical spheroids from (human) pluripotent stem cells. The cortical spheroids so generated produces maturing oligodendrocytes that can, for example, myelinate axons, and model myelin disease and drug effects.
FILED Tuesday, April 16, 2019
APPL NO 17/048289
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0622 (20130101) Original (OR) Class
C12N 2501/105 (20130101)
C12N 2501/135 (20130101)
C12N 2501/395 (20130101)
C12N 2501/999 (20130101)
C12N 2503/02 (20130101)
C12N 2506/45 (20130101)
C12N 2513/00 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/5058 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163892 BOLLARD et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) CHILDREN'S NATIONAL MEDICAL CENTER (Washington, District of Columbia)
ASSIGNEE(S) CHILDREN'S NATIONAL MEDICAL CENTER (Washington, District of Columbia)
INVENTOR(S) Catherine M. BOLLARD (Washington, District of Columbia);  Conrad Russell CRUZ (Washington, District of Columbia);  Patrick J. HANLEY (Washington, District of Columbia)
ABSTRACT Safe, rapid and efficient methods for producing antigen-specific T cells recognizing human papilloma virus or HPV antigens.
FILED Tuesday, January 19, 2021
APPL NO 17/152149
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/17 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 15/00 (20180101)
A61P 31/00 (20180101)
A61P 37/04 (20180101)

Peptides
C07K 14/55 (20130101)
C07K 14/5412 (20130101)
C07K 14/5418 (20130101)
C07K 14/5434 (20130101)
C07K 14/5443 (20130101)
C07K 14/70514 (20130101)
C07K 14/70517 (20130101)
C07K 14/70521 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0636 (20130101) Original (OR) Class
C12N 2501/59 (20130101)
C12N 2501/2302 (20130101)
C12N 2501/2307 (20130101)
C12N 2501/2315 (20130101)
C12N 2502/1121 (20130101)
C12N 2502/1157 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163900 Landweber et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (New York, New York)
ASSIGNEE(S)
INVENTOR(S) Laura Landweber (Princeton, New Jersey);  Yee Ming Leslie Beh (Singapore, Singapore)
ABSTRACT The present disclosure provides, inter alia, methods for treating a disease characterized by an abnormal level of m6dA in a subject, such as cancer, methods of modifying a nucleic acid from a cell, methods for identifying protein binding sites on DNA, methods of mediating DNA N6-adenine methylation, methods of modulating nucleosome organization and/or transcription in a cell, using MTA1c or any components thereof. The present disclosure also provides methods of generating a synthetic chromosome and synthetic chromosomes made by such methods. Pharmaceutical compositions comprising MTA1c or any components thereof and kits containing such compositions or for carrying out such processes are further provided. Eukaryotic cells, vectors and transgenic organisms comprising MTA1c or any components thereof are also provided. Synthetic chromosomes and methods of making same are also provided.
FILED Wednesday, January 20, 2021
APPL NO 17/153761
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/45 (20130101)
A61K 45/06 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/1007 (20130101) Original (OR) Class

Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture
C12P 19/34 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6869 (20130101)

Enzymes
C12Y 201/01072 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163924 Packer et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, Massachusetts);  IPSEN BIOINNOVATION LTD (Oxon, United Kingdom);  IPSEN BIOPHARM LTD (Wrexham, United Kingdom)
ASSIGNEE(S) President and Fellows of Harvard College (Cambridge, Massachusetts);  Ipsen Biopharm Ltd (Wrexham, United Kingdom)
INVENTOR(S) Michael S. Packer (Arlington, Massachusetts);  Travis R. Blum (Cambridge, Massachusetts);  David R. Liu (Lexington, Massachusetts);  Keith A. Foster (Salisbury, Wiltshire, United Kingdom);  Matthew Brian Beard (Leighton Buzzard, Bedfordshire, United Kingdom)
ABSTRACT The disclosure provides amino acid sequence variants of Botulinum neurotoxin (BoNT) proteases that cleave (VAMP1, VAMP2, VAMP7, VAMP8, SNAP25, SNAP23, PTEN, etc.) and methods of evolving the same. In some embodiments, proteases described by the disclosure are useful for cleaving proteins found in a cell, that is in an intracellular environment. In some embodiments, proteases described by the disclosure are useful for treating diseases associated with increased or aberrant VAMP7, VAMP8, SNAP23 or PTEN expression or activity, for example, cancer and neurological disorders. Some aspects of this disclosure provide methods for generating BoNT protease variants by continuous directed evolution.
FILED Monday, August 27, 2018
APPL NO 16/641630
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/00 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/52 (20130101)
C12N 15/1058 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163940 FU et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
National Science Foundation (NSF)
APPLICANT(S) The Board of Trustees of the Leland Stanford Junior University (Stanford, California)
ASSIGNEE(S) The Board of Trustees of the Leland Stanford Junior University (Stanford, California)
INVENTOR(S) Xu Hua FU (Stanford, California);  Andrew FIRE (Stanford, California);  Justin D. SMITH (Stanford, California)
ABSTRACT The disclosure describes that both Cas9 and Cpf1 enzymes can exhibit potent nickase activities on an extensive class of mismatched dsDNA targets. These properties allow the production of efficient nickases for a chosen dsDNA target sequence, without modification of the nuclease protein, using guide RNAs with a variety of patterns of mismatch to the intended DNA target. In parallel to the nicking activities observed with purified Cas9 in vitro, sequence-dependent nicking for both perfectly matched and partially mismatched target sequences in a Saccharomyces cerevisae in vivo system was observed.
FILED Thursday, October 29, 2020
APPL NO 17/083918
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/22 (20130101)
C12N 15/113 (20130101) Original (OR) Class
C12N 2310/20 (20170501)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163944 Zhang et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) THE BROAD INSTITUTE, INC. (Cambridge, Massachusetts);  MASSACHUSETTS INSTITUTE OF TECHNOLOGY (Cambridge, Massachusetts)
ASSIGNEE(S) THE BROAD INSTITUTE, INC. (Cambridge, Massachusetts);  MASSACHUSETTS INSTITUTE OF TECHNOLOGY (Cambridge, Massachusetts)
INVENTOR(S) Feng Zhang (Cambridge, Massachusetts);  Jonathan Strecker (Cambridge, Massachusetts);  Ian Slaymaker (Cambridge, Massachusetts);  Sara Jones (Cambridge, Massachusetts)
ABSTRACT The disclosure provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting Cas12b effector protein and at least one targeting nucleic acid component like a guide RNA or crRNA.
FILED Wednesday, August 07, 2019
APPL NO 17/265910
CURRENT CPC
Peptides
C07K 14/32 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/22 (20130101)
C12N 15/113 (20130101) Original (OR) Class
C12N 2310/3519 (20130101)

Enzymes
C12Y 301/00 (20130101)
C12Y 304/22 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163948 Mali et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Human Genome Research Institute (NHGRI)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S) The Regents of the University of California (, None)
INVENTOR(S) Prashant Mali (La Jolla, California);  Dhruva Katrekar (La Jolla, California)
ABSTRACT Aspects of the disclosure relate to a gene therapy approach for diseases, disorders, or conditions caused by mutation in the stop codon utilizing modified tRNA. At least 10-15% of all genetic diseases, including muscular dystrophy (e.g. Duchene muscular dystrophy), some cancers, beta thalassemia, Hurler syndrome, and cystic fibrosis, fall into this category. Not to be bound by theory, it is believed that this approach is safer than CRISPR approaches due to minimal off-target effects and the lack of genome level changes.
FILED Monday, February 08, 2021
APPL NO 17/170693
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/00 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 21/00 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/78 (20130101)
C12N 15/115 (20130101) Original (OR) Class

Enzymes
C12Y 305/04 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163949 CHANDLER et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) The Research Institute at Nationwide Children's Hospital (Columbus, Ohio)
ASSIGNEE(S)
INVENTOR(S) DAWN SUZAN CHANDLER (Bexley, Ohio);  DANIEL FORREST COMISKEY (Columbus, Ohio)
ABSTRACT Compositions and methods for treating cancer in a subject in need thereof are described that includes administering a therapeutically effective amount of an oligonucleotide that inhibits the binding of splicing regulator SRSF1 or SRSF2 to MDM2 exon 4 or 11.
FILED Tuesday, July 23, 2019
APPL NO 16/519211
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/713 (20130101)
A61K 31/7088 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/113 (20130101)
C12N 15/1135 (20130101) Original (OR) Class
C12N 2310/11 (20130101)
C12N 2310/14 (20130101)
C12N 2310/315 (20130101)
C12N 2310/321 (20130101)
C12N 2320/33 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163954 Goel et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) University of Massachusetts (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Hira Lal Goel (Shrewsbury, Massachusetts);  Arthur M. Mercurio (Boston, Massachusetts)
ABSTRACT Methods and compositions for treating cancer, e.g., prostate cancer, using a combination of P-Rex1 or Rac1 inhibitors and VEGF/VEGFR-targeted therapy.
FILED Thursday, February 04, 2021
APPL NO 17/167317
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/404 (20130101)
A61K 31/506 (20130101)
A61K 31/7088 (20130101)
A61K 39/3955 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Peptides
C07K 14/00 (20130101)
C07K 14/4702 (20130101)
C07K 16/22 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/1137 (20130101) Original (OR) Class
C12N 2310/11 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163964 Luesch et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) University of Florida Research Foundation, Incorporated (Gainesville, Florida)
ASSIGNEE(S) University of Florida Research Foundation, Incorporated (Gainesville, Florida)
INVENTOR(S) Hendrik Luesch (Gainesville, Florida);  Dimitrios Kallifidas (Cambridge, Massachusetts)
ABSTRACT In some aspects, the disclosure relates to production of bacterial secondary metabolites. In some embodiments, the disclosure relates to a genetically engineered Streptomyces J1074 bacterium, wherein the bacterium comprises a nucleic acid having a modification to at least one global regulator gene.
FILED Friday, April 05, 2019
APPL NO 17/045240
CURRENT CPC
Peptides
C07K 14/36 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/76 (20130101) Original (OR) Class

Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture
C12P 1/04 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163984 Babu
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
APPLICANT(S) Rutgers, The State University of New Jersey (New Brunswick, New Jersey)
ASSIGNEE(S)
INVENTOR(S) Gopal J. Babu (Randolph, New Jersey)
ABSTRACT Compositions, recombinant viruses, and recombinant viral vectors for inhibiting sarcolipin (SLN) expression or activity in a cell and for preventing or treating Duchenne Muscular Dystrophy (DMD) in a subject (e.g., a human patient having or predisposed to having DMD) and in some embodiments additionally cardiomyopathy, include a therapeutically effective amount of an inhibitor of SLN. Methods of using these compositions, recombinant viruses, and recombinant viral vectors are also described herein. These compositions, recombinant viruses, and recombinant viral vectors and methods of use provide novel therapies for DMD and associated cardiomyopathy based on the reduction of SLN expression and/or activity.
FILED Monday, January 22, 2018
APPL NO 16/479838
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/86 (20130101) Original (OR) Class
C12N 15/113 (20130101)
C12N 2310/531 (20130101)
C12N 2320/32 (20130101)
C12N 2750/14141 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163988 Chatterjee et al.
FUNDED BY
Department of Health and Human Services (HHS)
APPLICANT(S) THE USA as represented by the Secretary, Department of Health and Human Services (Bethesda, Maryland)
ASSIGNEE(S)
INVENTOR(S) Deb K. Chatterjee (Potomac, Maryland);  Stanislaw J. Kaczmarczyk (Frederick, Maryland)
ABSTRACT Described herein is a method of preventing or treating a disease in a mammalian subject, comprising administering to the subject who is in need thereof an effective dosage of a pharmaceutical composition comprising a virus like particle (VLP) comprising: an alphavirus replicon comprising a recombinant polynucleotide, wherein the polynucleotide comprises a sequence encoding both subunits of a human class II major histocompatibility antigen, a retroviral gag protein, and a fusogenic envelope protein, wherein the VLP does not contain an alphavirus structural protein gene.
FILED Monday, December 14, 2020
APPL NO 17/120497
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 39/0011 (20130101)
A61K 39/12 (20130101)
A61K 39/001117 (20180801)
A61K 39/001124 (20180801)
A61K 39/001129 (20180801)
A61K 39/001144 (20180801)
A61K 39/001152 (20180801)
A61K 39/001163 (20180801)
A61K 39/001181 (20180801)
A61K 39/001182 (20180801)
A61K 39/001191 (20180801)
A61K 39/001194 (20180801)
A61K 45/06 (20130101)
A61K 2039/53 (20130101)
A61K 2039/585 (20130101)
A61K 2039/5258 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 7/00 (20130101)
C12N 15/86 (20130101) Original (OR) Class
C12N 2740/11023 (20130101)
C12N 2740/11042 (20130101)
C12N 2770/36123 (20130101)
C12N 2770/36134 (20130101)
C12N 2770/36143 (20130101)
C12N 2770/36145 (20130101)
C12N 2770/36152 (20130101)
C12N 2770/36171 (20130101)
C12N 2800/24 (20130101)
C12N 2810/6081 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163993 Freddolino et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) The Regents of the University of Michigan (Ann Arbor, Michigan)
ASSIGNEE(S)
INVENTOR(S) Peter Louis Freddolino (Ann Arbor, Michigan);  Scott Allen Scholz (Ann Arbor, Michigan);  Xiaoxia Nina Lin (Ann Arbor, Michigan)
ABSTRACT Provided herein are compositions and methods for production of proteins in microbial systems. In particular, provided herein are compositions and methods for expressing exogenous genes from specific chromosomal locations of E. coli. Specifically, the disclosure provides an E. coli bacterium comprising a recombination target site and/or heterologous gene at one or more genomic positions comprising at least one expression enhancement sequence. Further disclosed is a method for expressing a gene of interest, comprising contacting a nucleic acid encoding said gene of interest with the bacterium.
FILED Thursday, May 02, 2019
APPL NO 17/052308
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/74 (20130101)
C12N 15/90 (20130101) Original (OR) Class

Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture
C12P 19/30 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164005 FOX et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Chemistry (CHE)
APPLICANT(S) Joseph M. FOX (Landenberg, Pennsylvania);  Colin THORPE (Newark, Delaware);  Amanda M. TALLON (Claymont, Delaware);  Yixin XIE (Newark, Delaware);  William TROUT (Wilmington, Delaware);  Ashlyn S. CANTREL (Catasauqua, Pennsylvania);  Julia E. ROSENBERGER (Wilmington, Delaware)
ASSIGNEE(S) University of Delaware (Newark, Delaware)
INVENTOR(S) Joseph M. FOX (Landenberg, Pennsylvania);  Colin THORPE (Newark, Delaware);  Amanda M. TALLON (Claymont, Delaware);  Yixin XIE (Newark, Delaware);  William TROUT (Wilmington, Delaware);  Ashlyn S. CANTREL (Catasauqua, Pennsylvania);  Julia E. ROSENBERGER (Wilmington, Delaware)
ABSTRACT A method for catalytically converting a dihydrotetrazine 1 into a tetrazine 2, wherein the dihydrotetrazine 1 comprises a first R group and a second R group, wherein the first R group is a substituted or unsubstituted aryl, heteroaryl, alkyl, alkenyl, alkynyl, carbonyl, or heteroatom-containing group, and the second R group is selected from the group consisting of H and substituted or unsubstituted aryl, heteroaryl, alkyl, alkenyl, alkynyl, carbonyl, and heteroatom-containing groups; wherein the method comprises (a) providing the dihydrotetrazine 1 in a reaction medium, and (b) adding an enzyme as a catalyst and an oxidant to the reaction medium, whereby the dihydrotetrazine 1 is converted to the tetrazine 2.
FILED Wednesday, December 23, 2020
APPL NO 17/132532
CURRENT CPC
Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture
C12P 17/12 (20130101)
C12P 17/165 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164011 Schellenberger et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) Amunix Pharmaceuticals, Inc. (South San Francisco, California)
ASSIGNEE(S)
INVENTOR(S) Volker Schellenberger (Palo Alto, California);  Joshua Silverman (Los Altos Hills, California);  Chia-wei Wang (Santa Clara, California);  Benjamin Spink (San Carlos, California);  Willem P.C. Stemmer (Los Gatos, California);  Nathan C. Geething (Santa Clara, California)
ABSTRACT The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.
FILED Tuesday, September 29, 2020
APPL NO 17/036396
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/00 (20130101)

Peptides
C07K 14/00 (20130101)
C07K 14/7155 (20130101)
C07K 14/8125 (20130101)
C07K 14/70521 (20130101)
C07K 16/18 (20130101)
C07K 16/32 (20130101)
C07K 16/40 (20130101)
C07K 16/241 (20130101)
C07K 16/244 (20130101)
C07K 16/2809 (20130101)
C07K 16/2863 (20130101)
C07K 16/2878 (20130101)
C07K 2317/31 (20130101)
C07K 2317/92 (20130101)
C07K 2317/94 (20130101)
C07K 2317/569 (20130101)
C07K 2317/622 (20130101)
C07K 2319/31 (20130101)
C07K 2319/70 (20130101)
C07K 2319/74 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/625 (20130101)

Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture
C12P 21/02 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164026 ZHANG et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) William Marsh Rice University (Houston, Texas)
ASSIGNEE(S) William Marsh Rice University (Houston, Texas)
INVENTOR(S) David Yu ZHANG (Houston, Texas);  Ruojia WU (Houston, Texas);  Juexiao WANG (Houston, Texas)
ABSTRACT This invention describes a method of controlling the hybridization yield of nucleic acid probes by adjusting the relative concentrations of auxiliary oligonucleotides to the probes and the targets. The auxiliary oligonucleotide is partially or fully complementary to either the probe or the target, and is released upon hybridization of the probe to the target.
FILED Friday, February 05, 2021
APPL NO 17/168508
CURRENT CPC
Sugars; Derivatives Thereof; Nucleosides; Nucleotides; Nucleic Acids
C07H 1/06 (20130101)
C07H 21/02 (20130101)
C07H 21/04 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6811 (20130101)
C12Q 1/6832 (20130101) Original (OR) Class
C12Q 1/6876 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164054 BILD et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) City of Hope (Duarte, California)
ASSIGNEE(S)
INVENTOR(S) Andrea BILD (South Pasadena, California);  Jason I. GRIFFITHS (St. Helens, United Kingdom)
ABSTRACT Provided herein, inter alia, are improved methods and systems of determining immunotherapy response in subjects prior and during treatment. Provided herein are methods of detecting gene expression in T cells and in monocytes as well as measuring relative abundance of particular immune cell populations and determining responsiveness to anticancer immunotherapy.
FILED Wednesday, December 02, 2020
APPL NO 17/110067
CURRENT CPC
Peptides
C07K 16/2818 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6886 (20130101) Original (OR) Class
C12Q 2600/106 (20130101)
C12Q 2600/158 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/574 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164056 SPIOTTO
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Dental and Craniofacial Research (NIDCR)
APPLICANT(S) THE UNIVERSITY OF CHICAGO (Chicago, Illinois)
ASSIGNEE(S)
INVENTOR(S) Michael SPIOTTO (Chicago, Illinois)
ABSTRACT The invention provides methods for treating cancer in a subject and/or predicting outcome of a lymph node metastasis (LNM) in a subject, the methods comprising obtaining a sample comprising LNM cells from the subject; measuring gene expression levels in the sample of at least ten genes; determining a LNM-specific molecular subtype comprising the gene expression levels of the at least ten genes; providing an indication as to the outcome when the LNM-specific molecular subtype indicates that the expression levels of the at least ten genes are altered in a predictive manner; and administering an aggressive cancer treatment regimen to the subject when a determination is made that the subject has LNM cells with decreased outcome.
FILED Wednesday, July 24, 2019
APPL NO 17/262471
CURRENT CPC
Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/686 (20130101)
C12Q 1/6886 (20130101) Original (OR) Class

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 2800/52 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164059 Jewett et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Materiel Command (AFMC)
Air Force Research Laboratory (AFRL)
Defense Advanced Research Projects Agency (DARPA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) NORTHWESTERN UNIVERSITY (Evanston, Illinois)
ASSIGNEE(S)
INVENTOR(S) Michael Christopher Jewett (Evanston, Illinois);  Julius B. Lucks (Evanston, Illinois);  Adam D. Silverman (Chicago, Illinois);  Khalid K. Alam (Evanston, Illinois)
ABSTRACT Disclosed are methods, devices, kits, components, and compositions for detecting a target molecule in a test sample using a cell-free protein synthesis (CFPS) reaction. The methods, devices, kits, components, and compositions may be utilized for detecting target molecules which may include small molecules and/or metabolites of small molecules. The components and compositions used in the disclosed methods, devices, and kits may be dried or lyophilized and may be present or immobilized on a paper substrate, for example, as a paper test article.
FILED Monday, August 05, 2019
APPL NO 17/265785
CURRENT CPC
Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/485 (20130101)
C12Q 1/6897 (20130101) Original (OR) Class

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/521 (20130101)
G01N 33/1826 (20130101)
G01N 2033/184 (20130101)
G01N 2430/20 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164992 MOHR
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) New York University (New York, New York)
ASSIGNEE(S)
INVENTOR(S) Ian MOHR (New York, New York)
ABSTRACT Provided are methods of modulating the type I interferon (IFN) pathway in an individual. The methods involve administering to an individual one or more agents that inhibit expression or function of METTL3, or METTL14, or ALKBH5, thereby modulating the type I IFN pathway. The agent that inhibits the expression and/or function ALKBH5 results in decreased interferon β cytokine production and/or decreased IFNB1 mRNA, and is useful for treating autoimmune and inflammatory conditions. The agent that inhibits expression or function of METTL3 and/or METTL14 result in increased IPNβ cytokine production and/or increased IFNB 1 mRNA, and is useful for treating infections and cancer. Methods for screening and identifying enzyme inhibitors are also provided.
FILED Monday, July 22, 2019
APPL NO 17/262692
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/192 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/6866 (20130101) Original (OR) Class
G01N 2333/565 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164998 Soto Jara et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Aging (NIA)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) Board of Regents of the University of Texas System (Austin, Texas);  Amprion, Inc. (San Francisco, California)
ASSIGNEE(S) Board of Regents of the University of Texas System (Austin, Texas);  Amprion, Inc. (San Francisco, California)
INVENTOR(S) Claudio Soto Jara (Friendswood, Texas);  Mohammad Shahnawaz (Houston, Texas);  Luis Concha (San Diego, California)
ABSTRACT A method is provided for distinguishing between and/or diagnosing Parkinson's disease (PD) or multiple system atrophy (MSA) in a subject who is exhibiting symptoms associated with both PD and MSA. The method comprises: (A) contacting a biological sample obtained from the subject and comprising soluble, misfolded alpha-synuclein (αS) protein with a pre-incubation mixture comprising a monomeric αS substrate and an indicator to form an incubation mixture; (B) conducting an incubation cycle two or more times on the incubation mixture to form misfolded αS aggregates; (C) subjecting the incubation mixture to excitation and detecting via indicator fluorescence emission the misfolded αS aggregates; and (D) diagnosing the subject has having PD or MSA depending on the fluorescence emission intensity. In some aspects, the incubation cycles are conducted in the presence of a bead.
FILED Thursday, January 21, 2021
APPL NO 17/154966
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 8/13 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/582 (20130101)
G01N 33/6893 (20130101) Original (OR) Class
G01N 2800/2835 (20130101)
G01N 2800/2878 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210165065 Trzasko et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) Mayo Foundation For Medical Education and Research (Rochester, Minnesota)
ASSIGNEE(S)
INVENTOR(S) Joshua D. Trzasko (Rochester, Minnesota);  Philip A. Araoz (Rochester, Minnesota);  Matthew A. Bernstein (Rochester, Minnesota);  Richard L. Ehman (Rochester, Minnesota);  Arvin Forghanian-Arani (Rochester, Minnesota);  John Huston, III (Rochester, Minnesota);  Yunhong Shu (Rochester, Minnesota)
ABSTRACT Described here are systems and methods for correcting motion-encoding gradient nonlinearities in magnetic resonance elastography (“MRE”). In general, the systems and methods RF described in the present disclosure compute gradient nonlinearity corrected displacement data based on information about the motion-encoding gradients used when acquiring magnetic resonance data.
FILED Monday, June 03, 2019
APPL NO 17/059931
CURRENT CPC
Measuring Electric Variables; Measuring Magnetic Variables
G01R 33/56358 (20130101)
G01R 33/56572 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210166433 Lee et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) DRVision Technologies LLC (Bellevue, Washington)
ASSIGNEE(S)
INVENTOR(S) Shih-Jong James Lee (Bellevue, Washington);  Hideki Sasaki (Bellevue, Washington)
ABSTRACT A computerized domain matching image conversion method for transportable imaging applications first performs a target domain A to source domain B matching converter training by computing means using domain B training images and at least one domain A image to generate an A to B domain matching converter. The method then applies the A to B domain matching converter to a domain A application image to generate its domain B matched application image. The method further applies a domain B imaging application analytics to the domain B matched application image to generate an imaging application output for the domain A application image.
FILED Tuesday, December 03, 2019
APPL NO 16/702294
CURRENT CPC
Computer Systems Based on Specific Computational Models
G06N 3/084 (20130101)
G06N 20/00 (20190101)

Image Data Processing or Generation, in General
G06T 3/4046 (20130101)
G06T 9/002 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210166782 Van Allen et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Dana-Farber Cancer Institute, Inc. (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Eliezer Van Allen (Brookline, Massachusetts);  Brendan Reardon (Brookline, Massachusetts);  Nathaniel Moore (Scottsdale, Arizona)
ABSTRACT Feature-based clinical interpretation of whole exome and transcriptome data for precision cancer medicine is provided. In various embodiments, genomic data of a subject is received. The genomic data comprises somatic mutations. A plurality of features is determined from the genomic data of the subject. A similarity metric is determined between the plurality of features and each of a plurality of reference genomes. One or more potentially actionable feature is determined from the similarity.
FILED Friday, April 12, 2019
APPL NO 17/047325
CURRENT CPC
Bioinformatics, i.e Information and Communication Technology [ICT] Specially Adapted for Genetic or Protein-related Data Processing in Computational Molecular Biology
G16B 20/00 (20190201)
G16B 20/10 (20190201) Original (OR) Class

Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data
G16H 10/40 (20180101)
G16H 10/60 (20180101)
G16H 20/10 (20180101)
G16H 50/30 (20180101)
G16H 50/70 (20180101)
G16H 70/60 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210166783 SHMAKOV et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Mental Health (NIMH)
APPLICANT(S) THE BROAD INSTITUTE, INC. (Cambridge, Massachusetts);  MASSACHUSETTS INSTITUTE OF TECHNOLOGY (Cambridge, Massachusetts);  RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (New Brunswick, New Jersey);  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (Bethesda, Maryland)
ASSIGNEE(S) THE BROAD INSTITUTE, INC. (Cambridge, Massachusetts);  MASSACHUSETTS INSTITUTE OF TECHNOLOGY (Cambridge, Massachusetts);  RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (New Brunswick, New Jersey);  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (Bethesda, Maryland)
INVENTOR(S) Sergey SHMAKOV (Moscow, Russian Federation);  Kira S. MAKAROVA (Bethesda, Maryland);  Yuri I. WOLF (Bethesda, Maryland);  Aaron SMARGON (Cambridge, Massachusetts);  Neena PYZOCHA (Cambridge, Massachusetts);  David COX (Cambridge, Massachusetts);  Winston YAN (Brookline, Massachusetts);  David SCOTT (Cambridge, Massachusetts);  Konstantin SEVERINOV (Piscataway, New Jersey);  Feng ZHANG (Cambridge, Massachusetts);  Eugene V. KOONIN (Bethesda, Maryland)
ABSTRACT Disclosed here is a method of identifying novel CRISPR effectors, comprising: identifying sequences in a genomic or metagenomic database encoding a CRISPR array; identifying one or more Open Reading Frames (ORFs) in said selected sequences within 10 kb of the CRISPR array; discarding all loci encoding proteins which are assigned to known CRISPR-Cas subtypes and, optionally, all loci encoding a protein of less than 700 amino acids; and identifying putative novel CRISPR effectors, and optionally classifying them based on structure analysis.
FILED Wednesday, August 16, 2017
APPL NO 16/326132
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/22 (20130101)
C12N 15/11 (20130101)
C12N 2310/20 (20170501)
C12N 2800/80 (20130101)

Bioinformatics, i.e Information and Communication Technology [ICT] Specially Adapted for Genetic or Protein-related Data Processing in Computational Molecular Biology
G16B 20/20 (20190201) Original (OR) Class
G16B 30/10 (20190201)
G16B 40/30 (20190201)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210166927 Ouyang et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) Purdue Research Foundation (West Lafayette, Indiana)
ASSIGNEE(S)
INVENTOR(S) Zheng Ouyang (West Lafayette, Indiana);  Linfan Li (West Lafayette, Indiana);  Xiaoyu Zhou (West Lafayette, Indiana)
ABSTRACT The invention generally relates to sample analysis with a miniature mass spectrometer. In certain embodiments, the invention provides methods that involve generating ions of a first analyte and ions of a second analyte. Those ions are transferred through a discontinuous sample introduction interface into a first ion trap of a mass spectrometer in a manner in which the discontinuous sample introduction interface remains open during the transferring. The discontinuous sample introduction interface is closed and the ions are sequentially transferred to a second ion trap of the mass spectrometer where they are sequentially analyzed.
FILED Wednesday, January 20, 2021
APPL NO 17/153156
CURRENT CPC
Electric Discharge Tubes or Discharge Lamps
H01J 49/004 (20130101)
H01J 49/0013 (20130101)
H01J 49/0031 (20130101) Original (OR) Class
H01J 49/0422 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 

National Science Foundation (NSF) 

US 20210161084 ZHANG et al.
FUNDED BY
National Science Foundation (NSF)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) ZYNNOVATION LLC (Ashland, Virginia)
ASSIGNEE(S) ZYNNOVATION LLC (Ashland, Virginia)
INVENTOR(S) Wei ZHANG (Midlothian, Virginia);  Hailing YANG (Midlothian, Virginia)
ABSTRACT One embodiment provides a modular green roof tray, house plant growth media and horticulture growth media, and a tree protection mat for weed and moisture control made from recycled disposable diapers. The growth medium and tree protection mat contain superabsorbent materials from diaper that can absorb waters and greatly reduce irrigation so to provide a drought resistant feature. One embodiment also provides a manufacturing process to perform 100% recycling of disposed diapers.
FILED Monday, March 16, 2020
APPL NO 16/819726
CURRENT CPC
Horticulture; Cultivation of Vegetables, Flowers, Rice, Fruit, Vines, Hops or Seaweed; Forestry; Watering
A01G 9/033 (20180201)
A01G 13/0268 (20130101)
A01G 13/0281 (20130101) Original (OR) Class
A01G 24/00 (20180201)

Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 11/00 (20130101)

Preparation or Pretreatment of the Material to be Shaped; Making Granules or Preforms; Recovery of Plastics or Other Constituents of Waste Material Containing Plastics
B29B 17/02 (20130101)
B29B 2017/0203 (20130101)
B29B 2017/0244 (20130101)

Indexing Scheme Associated With Subclass B29C, Relating to Particular Articles
B29L 2031/4878 (20130101)

Inorganic Fertilisers Not Covered by Subclasses C05B, C05C; Fertilisers Producing Carbon Dioxide
C05D 1/005 (20130101)

Organic Fertilisers Not Covered by Subclasses C05B, C05C, e.g Fertilisers From Waste or Refuse
C05F 3/04 (20130101)

Mixtures of Fertilisers Covered Individually by Different Subclasses of Class C05; Mixtures of One or More Fertilisers With Materials Not Having a Specific Fertilising Activity, e.g Pesticides, Soil-conditioners, Wetting Agents; Fertilisers Characterised by Their Form
C05G 3/00 (20130101)
C05G 5/45 (20200201)

Working-up; General Processes of Compounding; After-treatment Not Covered by Subclasses C08B, C08C, C08F, C08G or C08H
C08J 11/04 (20130101)
C08J 2300/14 (20130101)

Roof Coverings; Sky-lights; Gutters; Roof-working Tools
E04D 11/002 (20130101)

Technologies for Adaptation to Climate Change
Y02A 30/254 (20180101)
Y02A 40/20 (20180101)

Climate Change Mitigation Technologies Related to Buildings, e.g Housing, House Appliances or Related End-user Applications
Y02B 80/32 (20130101)

Climate Change Mitigation Technologies in the Production or Processing of Goods
Y02P 20/143 (20151101)
Y02P 20/145 (20151101)

Climate Change Mitigation Technologies Related to Wastewater Treatment or Waste Management
Y02W 30/52 (20150501)
Y02W 30/62 (20150501)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161383 MACKNIK et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Eye Institute (NEI)
National Science Foundation (NSF)
APPLICANT(S) THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (Albany, New York);  CORNELL UNIVERSITY (Ithaca, New York)
ASSIGNEE(S) THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (Albany, New York);  CORNELL UNIVERSITY (Ithaca, New York)
INVENTOR(S) Stephen MACKNIK (Albany, New York);  Susana MARTINEZ-CONDE (Albany, New York);  Nozomi NISHIMURA (Ithaca, New York);  Christopher SCHAFFER (Ithaca, New York);  Mitch PENDER (Freeville, New York)
ABSTRACT Provided is a method of detecting neural activity, including inducing neurons of a subject to express two or more polypeptides each comprising an amino acid sequence represented by one of SEQ ID NOs:13-24, wherein inducing comprises stimulating interneuronally different relative levels of expression of the two or more polypeptides; applying coelenterazine to the subject; applying a first stimulation of neural activity to the subject; detecting a first spatiotemporal and spectral pattern of electromagnetic radiation emitted by neurons of the subject in response to the first stimulation; recording the first spatiotemporal and spectral pattern of electromagnetic radiation in a computer memory; applying a second stimulation of neural activity to the subject; detecting a second spatiotemporal and spectral pattern of electromagnetic radiation emitted by neurons of the subject in response to the second stimulation; comparing the second spatiotemporal and spectral pattern of electromagnetic radiation to the first spatiotemporal and spectral pattern of electromagnetic radiation, wherein differences between the second spatiotemporal and spectral pattern of electromagnetic radiation and the first spatiotemporal and spectral pattern of electromagnetic radiation indicate differences in neural activity caused by the first stimulation and the second stimulation.
FILED Wednesday, June 12, 2019
APPL NO 17/251499
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/0036 (20180801) Original (OR) Class
A61B 5/0042 (20130101)
A61B 5/0071 (20130101)
A61B 5/4848 (20130101)
A61B 5/4884 (20130101)
A61B 5/7246 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/65 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161388 O'BRIEN et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) VANDERBILT UNIVERSITY (Nashville, Tennessee)
ASSIGNEE(S)
INVENTOR(S) Christine O'BRIEN (Nashville, Tennessee);  Katherine COCHRAN (Nashville, Tennessee);  Anita MAHADEVAN-JANSEN (Nashville, Tennessee);  Kristen Rose FINDLEY (Nashville, Tennessee);  William STOKES (Nashville, Tennessee);  Lowell HAYS (Nashville, Tennessee);  Mohsin TEJANI (Nashville, Tennessee);  Anne-Marie CROWE (Nashville, Tennessee)
ABSTRACT A method for identification of biochemical markers associated with cervical remodeling over the course of pregnancy of humans includes obtaining Raman signals from the cervix of each of a group of humans with pregnancy at each phase of pregnancy; finding Raman signatures corresponding to each type of cervical tissue from the obtained Raman signals; and identifying biochemical markers associated with cervical remodeling at each phase of pregnancy corresponding to the Raman signatures.
FILED Friday, May 18, 2018
APPL NO 16/613445
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/0075 (20130101) Original (OR) Class
A61B 5/435 (20130101)
A61B 5/6875 (20130101)

Measurement of Intensity, Velocity, Spectral Content, Polarisation, Phase or Pulse Characteristics of Infra-Red, Visible or Ultra-violet Light; Colorimetry; Radiation Pyrometry
G01J 3/0248 (20130101)
G01J 3/2823 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161395 BROPHY et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) VANDERBILT UNIVERSITY (Nashville, Tennessee)
ASSIGNEE(S)
INVENTOR(S) Colleen M. BROPHY (Nashville, Tennessee);  Kyle M. HOCKING (Nashville, Tennessee);  Susan S. EAGLE (Nashville, Tennessee);  Franz J. BAUDENBACHER (Nashville, Tennessee);  Bret D. ALVIS (Nashville, Tennessee)
ABSTRACT An example method includes detecting, via a sensor, vibrations originating from a vein of a subject and obtaining an intensity spectrum of the detected vibrations over a range of frequencies. The method further includes using the obtained intensity spectrum to determine a metric selected from a group that includes: a pulmonary capillary wedge pressure (PCWP), a mean pulmonary arterial pressure, a pulmonary artery diastolic pressure, a left ventricular end diastolic pressure, a left ventricular end diastolic volume, a cardiac output, total blood volume, and a volume responsiveness of the subject. An example computing device and an example non-transitory computer readable medium that are related to the method are disclosed as well.
FILED Friday, April 13, 2018
APPL NO 16/499703
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/029 (20130101)
A61B 5/0205 (20130101) Original (OR) Class
A61B 5/412 (20130101)
A61B 5/02133 (20130101)
A61B 5/4821 (20130101)
A61B 5/4845 (20130101)
A61B 5/7257 (20130101)
A61B 8/04 (20130101)
A61B 2503/40 (20130101)
A61B 2562/0247 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161405 Khine et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Education and Human Resources (EHR)
Division of Graduate Education (DGE)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) Michelle Khine (Irvine, California);  Nicole Eckmann (Folsom, California);  Kimberly Veliz (Paramount, California);  Jonathan Pegan (Irvine, California);  Joshua Kim (Irvine, California);  Sun-Jun Park (Irvine, California)
ABSTRACT A method of estimating a continuous blood pressure waveform or a continuous blood pressure in a subject including: measuring an arterial blood pressure waveform or an arterial blood pressure with a sensor supported by a supporting structure comprising a polymeric substrate and connected to a processor and a transmitter, wherein the supporting structure is configured to press the sensor against a skin surface of a subject, wherein the sensor is configured to detect a biological metric of the subject, and wherein the processor is configured to quantify one or more signal(s) corresponding to the biological metric and the transmitter is configured to transmit the one or more signals to an external user system, and transforming the arterial blood pressure waveform or the arterial blood pressure to the continuous blood pressure waveform or the continuous blood pressure using a transfer function.
FILED Friday, January 22, 2021
APPL NO 17/156235
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/021 (20130101)
A61B 5/024 (20130101)
A61B 5/0816 (20130101)
A61B 5/02055 (20130101) Original (OR) Class
A61B 5/6824 (20130101)
A61B 5/14542 (20130101)
A61B 2562/12 (20130101)
A61B 2562/0247 (20130101)
A61B 2562/0261 (20130101)
A61B 2562/0285 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162014 WEISS et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Materials Research (DMR)
APPLICANT(S) CASE WESTERN RESERVE UNIVERSITY (Cleveland, Ohio)
ASSIGNEE(S)
INVENTOR(S) Michael WEISS (Moreland Hills, Ohio);  Jon POKORSKI (Cleveland, Ohio)
ABSTRACT An insulin composition comprises an insulin analogue and polymer blend. The insulin analogue contains cysteine substitutions at positions B4 and A10 (to form cystine B4-A10), and one or more additional substitutions selected from the group consisting of: a connecting domain of 5-11 amino acids between insulin A- and B domains; a non-beta-branched amino-acid substitution at position A8; a non-beta-branched acidic or polar side chain at position A14; a halogenic modification of PheB24 at the ortho position; and substitution of lysine at position B29 by Glu, Ala, Val, Ile, Leu, amino-propionic acid, amino-butryic acid, or Norleucine. The insulin analogue is compatible with a process of manufacture that includes one or more steps within the temperature range 90-120 oC. The encapsulated insulin analogue may optionally contain free PEG or be PEGylated. The insulin analogue-encapsulated polymer blend may be cast as a microneedle patch for topical administration or as micropellets for subcutaneous injection.
FILED Friday, December 23, 2016
APPL NO 16/065596
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0021 (20130101)
A61K 38/28 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162373 Miller et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Engineering Education and Centers (EEC)
APPLICANT(S) PURDUE RESEARCH FOUNDATION (West Lafayette, Indiana)
ASSIGNEE(S) PURDUE RESEARCH FOUNDATION (West Lafayette, Indiana)
INVENTOR(S) Jeffrey Miller (Naperville, Illinois);  Nicole Libretto (Lakewood, Colorado);  Christopher K. Russell (West Lafayette, Indiana);  Matthew A. Conrad (West Lafayette, Indiana)
ABSTRACT Oligomerization catalyst and method for oligomerization using the catalyst. The catalyst comprises a single Zn(II) or Ga(III) metal ion center directly bonded to a support through a shared oxygen atom, the catalyst having at least one M-O bond which forms an active site for oligomerization. The method includes reacting one or more C2 to C12 olefins with the oligomerization catalyst at a temperature of about 200° C. or higher to provide an oligomer product comprising C4 to C26 olefins.
FILED Wednesday, December 02, 2020
APPL NO 17/109515
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 23/06 (20130101) Original (OR) Class
B01J 23/08 (20130101)
B01J 29/005 (20130101)
B01J 35/1014 (20130101)
B01J 35/1019 (20130101)
B01J 35/1023 (20130101)
B01J 35/1057 (20130101)

Acyclic or Carbocyclic Compounds
C07C 2/10 (20130101)
C07C 2523/06 (20130101)
C07C 2523/08 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162504 Pan et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) The Curators of the University of Missouri (Columbia, Missouri)
ASSIGNEE(S) The Curators of the University of Missouri (Columbia, Missouri)
INVENTOR(S) Heng Pan (Rolla, Missouri);  Chinmoy Podder (Rolla, Missouri);  Wan Shou (Allston, Massachusetts);  Xiaowei Yu (Rolla, Missouri)
ABSTRACT A method for manufacturing a component comprising bombarding nanoparticles in a dispersion with a laser to transform the ligand and cause the nanoparticles to drop out of the dispersion and deposit onto a substrate; and bombarding additional nanoparticles in the dispersion with the laser to transform the ligand and cause the nanoparticles to drop out of the dispersion and deposit onto the nanoparticles previously deposited out of the dispersion.
FILED Monday, February 08, 2021
APPL NO 17/170405
CURRENT CPC
Working Metallic Powder; Manufacture of Articles From Metallic Powder; Making Metallic Powder
B22F 1/0022 (20130101)
B22F 10/25 (20210101) Original (OR) Class
B22F 2304/054 (20130101)

Shaping Clay or Other Ceramic Compositions; Shaping Slag; Shaping Mixtures Containing Cementitious Material, e.g Plaster
B28B 1/001 (20130101)

Additive Manufacturing, i.e Manufacturing of Three-dimensional [3-D] Objects by Additive Deposition, Additive Agglomeration or Additive Layering, e.g by 3-d Printing, Stereolithography or Selective Laser Sintering
B33Y 10/00 (20141201)
B33Y 70/10 (20200101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163297 LI et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Civil, Mechanical and Manufacturing Innovation (CMMI)
APPLICANT(S) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas)
ASSIGNEE(S)
INVENTOR(S) Weigu LI (Austin, Texas);  Donglei FAN (Austin, Texas)
ABSTRACT Disclosed herein are dendritically porous three-dimensional structures, including hierarchical dendritically porous three-dimensional structures. The structures include metal foams and graphite structures, and are useful in energy storage devices as well as chemical catalysis.
FILED Thursday, March 08, 2018
APPL NO 16/491748
CURRENT CPC
Non-metallic Elements; Compounds Thereof;
C01B 32/205 (20170801) Original (OR) Class

Indexing Scheme Relating to Structural and Physical Aspects of Solid Inorganic Compounds
C01P 2002/72 (20130101)
C01P 2002/85 (20130101)
C01P 2004/03 (20130101)
C01P 2006/10 (20130101)
C01P 2006/12 (20130101)
C01P 2006/16 (20130101)
C01P 2006/40 (20130101)

Coating Metallic Material; Coating Material With Metallic Material; Surface Treatment of Metallic Material by Diffusion into the Surface, by Chemical Conversion or Substitution; Coating by Vacuum Evaporation, by Sputtering, by Ion Implantation or by Chemical Vapour Deposition, in General
C23C 16/26 (20130101)

Processes for the Electrolytic or Electrophoretic Production of Coatings; Electroforming; Apparatus Therefor
C25D 1/003 (20130101)
C25D 1/006 (20130101)

Capacitors; Capacitors, Rectifiers, Detectors, Switching Devices or Light-sensitive Devices, of the Electrolytic Type
H01G 11/24 (20130101)
H01G 11/36 (20130101)
H01G 11/86 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163384 Petitjean et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
National Science Foundation (NSF)
APPLICANT(S) YALE UNIVERSITY (New Haven, Connecticut)
ASSIGNEE(S)
INVENTOR(S) Laurene Petitjean (New Haven, Connecticut);  Paul Thomas Anastas (Guilford, Connecticut);  Tamara Marie DeWinter (San Francisco, California);  Philip Coish (North Haven, Connecticut);  Hanno Christian Erythropel (New Haven, Connecticut);  Predrag Petrovic (New Haven, Connecticut)
ABSTRACT The invention relates to novel, scalable synthetic routes that allow for direct reduction of enones to the corresponding saturated alcohols. The invention relates, in certain aspects, to synthetic routes that allow for the reduction of enones to the corresponding ketones. Such reactions take place under mild conditions, are compatible with a wide range of functional groups, and expand the repertoire of existing green chemistry methodology. In certain embodiments, the reactions are run in aqueous solvent.
FILED Wednesday, December 02, 2020
APPL NO 17/109719
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 21/04 (20130101)
B01J 21/10 (20130101)
B01J 23/72 (20130101)

Acyclic or Carbocyclic Compounds
C07C 29/145 (20130101) Original (OR) Class
C07C 45/62 (20130101)
C07C 49/04 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163386 Dinca et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Materials Research (DMR)
APPLICANT(S) Massachusetts Institute of Technology (Cambridge, Massachusetts)
ASSIGNEE(S) Massachusetts Institute of Technology (Cambridge, Massachusetts)
INVENTOR(S) Mircea Dinca (Belmont, Massachusetts);  Constanze Nicole Neumann (Somerville, Massachusetts)
ABSTRACT Compositions and methods of use related to metal organic frameworks (MOFs) and/or nanoparticles are generally described. In some embodiments, methods and compositions for the catalytic upgrading of alcohols using MOFs and/or nanoparticles associated with MOFs are generally described. In some embodiments, a catalytic MOF composition is provided, wherein the MOF composition comprises a MOF compound and a plurality of metal catalytic compounds. In some embodiments, an alcohol may be exposed to the MOF composition and/or a plurality of nanoparticles associated with the MOF composition such that the alcohol is converted to a higher order alcohol. Advantageously, in some embodiments, the alcohol conversion occurs at a relatively high turnover frequency and/or with a relatively high selectivity as compared to traditional methods for converting alcohols.
FILED Monday, November 30, 2020
APPL NO 17/106345
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 31/1691 (20130101)
B01J 2231/46 (20130101)
B01J 2531/0208 (20130101)
B01J 2531/821 (20130101)
B01J 2531/845 (20130101)
B01J 2531/847 (20130101)

Acyclic or Carbocyclic Compounds
C07C 29/16 (20130101)
C07C 29/44 (20130101) Original (OR) Class
C07C 31/12 (20130101)
C07C 31/125 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163424 Sivaguru et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
United States Army (USA)
National Science Foundation (NSF)
Office of Experimental Program To Stimulate Competitive Research (EPSCOR)
APPLICANT(S) NDSU RESEARCH FOUNDATION (Fargo, North Dakota)
ASSIGNEE(S)
INVENTOR(S) Jayaraman Sivaguru (Fargo, North Dakota);  Akila Iyer (Fargo, North Dakota);  Mukund Sibi (Fargo, North Dakota);  Dean Webster (Fargo, North Dakota);  Saravana Kumar Rajendran (Fargo, North Dakota);  Ramya Raghunathan (Fargo, North Dakota);  Ravichandanath Singathi (Fargo, North Dakota);  Retheesh Krishnan (Fargo, North Dakota);  Anthony Clay (Fargo, North Dakota)
ABSTRACT The invention relates to novel hydrazide-based templates, methods of making the same, and methods of using the hydrazide-based templates as molecular scaffolds for asymmetric light driven transformations, light driven material synthesis, and biological applications. Furthermore, the present invention relates to photoinitiators, monomers, and polymers derived from biomass, together with methods and methods of using the same.
FILED Friday, February 12, 2021
APPL NO 17/248924
CURRENT CPC
Acyclic or Carbocyclic Compounds
C07C 243/28 (20130101)
C07C 243/30 (20130101)
C07C 243/34 (20130101)
C07C 243/38 (20130101)

Heterocyclic Compounds
C07D 207/24 (20130101)
C07D 209/48 (20130101)
C07D 239/88 (20130101) Original (OR) Class

Macromolecular Compounds Obtained by Reactions Only Involving Carbon-to-carbon Unsaturated Bonds
C08F 2/48 (20130101)
C08F 120/14 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163521 Altenberg et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Chemistry (CHE)
APPLICANT(S) Texas Tech University System (Lubbock, Texas)
ASSIGNEE(S)
INVENTOR(S) Guillermo A. Altenberg (Lubbock, Texas);  Cheng-Wei Tom Chang (Logan, Utah)
ABSTRACT The present invention includes novel molecules and methods of using an amphiphilic kanamycin molecule having substitutions at the O-4″, O-6″, or O-4″ and O-6″ positions having reduced antimicrobial activity for targeting Connexin Hemichannels.
FILED Friday, December 11, 2020
APPL NO 17/119301
CURRENT CPC
Sugars; Derivatives Thereof; Nucleosides; Nucleotides; Nucleic Acids
C07H 15/234 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163558 Sourlis et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S)  (Cambridge, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Arjirios Sourlis (Zurich, Switzerland);  Anna Duraj-Thatte (Kensington, California);  Avinash Manjula Basavanna (Allston, Massachusetts);  Neel Satish Joshi (Somerville, Massachusetts)
ABSTRACT Disclosed herein are engineered bacteria that manufacture biofilms from bacterial amyloid structures. These biofilms and biofilm matrices are capable of generating fibrous proteinaceous networks and being used as 3D-printing inks.
FILED Friday, June 21, 2019
APPL NO 17/254019
CURRENT CPC
Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 15/32 (20130101)
A61L 15/42 (20130101)
A61L 24/0031 (20130101)
A61L 24/108 (20130101)
A61L 27/52 (20130101)
A61L 27/227 (20130101)

Additive Manufacturing, i.e Manufacturing of Three-dimensional [3-D] Objects by Additive Deposition, Additive Agglomeration or Additive Layering, e.g by 3-d Printing, Stereolithography or Selective Laser Sintering
B33Y 70/00 (20141201)

Peptides
C07K 14/75 (20130101)
C07K 14/78 (20130101)
C07K 14/4711 (20130101) Original (OR) Class
C07K 2319/00 (20130101)

Coating Compositions, e.g Paints, Varnishes or Lacquers; Filling Pastes; Chemical Paint or Ink Removers; Inks; Correcting Fluids; Woodstains; Pastes or Solids for Colouring or Printing; Use of Materials Therefor
C09D 11/04 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163676 BALASUBRAMANIAN et al.
FUNDED BY
National Science Foundation (NSF)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) POLYSPECTRA, INC. (Berkeley, California)
ASSIGNEE(S)
INVENTOR(S) Aditya BALASUBRAMANIAN (Berkeley, California);  Raymond A. WEITEKAMP (Berkeley, California)
ABSTRACT Described herein are compositions and methods for processing photopolymers based on olefin metathesis. The compositions and methods comprise latent ruthenium complexes and photoacids and/or photoacid generators.
FILED Wednesday, October 14, 2020
APPL NO 17/070557
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 31/2278 (20130101)
B01J 2231/543 (20130101)
B01J 2531/821 (20130101)

Macromolecular Compounds Obtained Otherwise Than by Reactions Only Involving Unsaturated Carbon-to-carbon Bonds
C08G 61/08 (20130101) Original (OR) Class
C08G 2261/374 (20130101)
C08G 2261/418 (20130101)
C08G 2261/3321 (20130101)

Use of Inorganic or Non-macromolecular Organic Substances as Compounding Ingredients
C08K 5/07 (20130101)
C08K 5/45 (20130101)
C08K 5/5313 (20130101)
C08K 5/5397 (20130101)

Photomechanical Production of Textured or Patterned Surfaces, e.g for Printing, for Processing of Semiconductor Devices; Materials Therefor; Originals Therefor; Apparatus Specially Adapted Therefor;
G03F 7/028 (20130101)
G03F 7/0037 (20130101)
G03F 7/2004 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163707 Mirkin et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Industrial Innovation and Partnerships (IIP)
APPLICANT(S) NORTHWESTERN UNIVERSITY (Evanston, Illinois)
ASSIGNEE(S)
INVENTOR(S) Chad A. Mirkin (Wilmette, Illinois);  PengCheng Chen (Evanston, Illinois)
ABSTRACT Disclosed herein are method and design rules for making polyelemental systems with specific heterostructures, including tetra-phase nanopartides with as many as six junctions. In accordance with an embodiment, a method of making a tetra-phase polyelemental nanoparticle using tri-phase nanoparticle architectures can include selecting two or more triphase nanoparticle architectures, wherein the two or more tri-phase nanoparticle architectures are one or more striped tri-phase architectures, one or more pie-shaped tri-phase architectures, or combinations thereof; identifying from the selected two or more tri-phase nanoparticle architectures groups of metals for generating each of the two or more tri-phase nanoparticle architectures; contacting a tip coated with an ink to a substrate to form a nanoreactor, the ink comprising block copolymer and the metals from the groups of metals identified for generating each of the two or more tri-phase nanoparticle architectures; and annealing the nanoreactors under conditions sufficient to synthesize a tetra-phase polyelemental nanoparticle.
FILED Friday, August 16, 2019
APPL NO 17/268027
CURRENT CPC
Use of Inorganic or Non-macromolecular Organic Substances as Compounding Ingredients
C08K 3/08 (20130101) Original (OR) Class
C08K 3/11 (20180101)
C08K 2003/085 (20130101)
C08K 2003/0806 (20130101)
C08K 2003/0831 (20130101)
C08K 2003/0843 (20130101)
C08K 2003/0862 (20130101)
C08K 2201/014 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163759 Zalich et al.
FUNDED BY
Department of Energy (DOE)
National Science Foundation (NSF)
APPLICANT(S) PPG Industries Ohio, Inc. (Cleveland, Ohio);  The Regents of the University of California (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) Michael A. Zalich (Wexford, Pennsylvania);  Paul H. Berdahl (Walnut Creek, California);  Stuart D. Hellring (Pittsburgh, Pennsylvania);  William H. Retsch, Jr. (Allison Park, Pennsylvania)
ABSTRACT A coating composition includes: (i) a film-forming resin; (ii) an infrared reflective pigment; and (iii) an infrared fluorescent pigment or dye different from the infrared reflective pigment. A multi-layer coating including the coating composition, and a substrate at least partially coated with the coating composition is also disclosed. A method of detecting an article at least partially coated with the coating composition is also disclosed.
FILED Friday, October 28, 2016
APPL NO 16/067537
CURRENT CPC
Processes for Applying Fluent Materials to Surfaces, in General
B05D 5/063 (20130101)
B05D 7/546 (20130101)

Use of Inorganic or Non-macromolecular Organic Substances as Compounding Ingredients
C08K 3/013 (20180101)

Coating Compositions, e.g Paints, Varnishes or Lacquers; Filling Pastes; Chemical Paint or Ink Removers; Inks; Correcting Fluids; Woodstains; Pastes or Solids for Colouring or Printing; Use of Materials Therefor
C09D 5/004 (20130101)
C09D 5/22 (20130101) Original (OR) Class
C09D 7/62 (20180101)
C09D 127/16 (20130101)

Materials for Miscellaneous Applications, Not Provided for Elsewhere
C09K 11/06 (20130101)
C09K 11/592 (20130101)
C09K 11/685 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 21/6428 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163776 Beckford et al.
FUNDED BY
National Science Foundation (NSF)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) SURFTEC, LLC (Fayetteville, Arkansas)
ASSIGNEE(S) SURFTEC, LLC (Fayetteville, Arkansas)
INVENTOR(S) Samuel George Beckford (Fayetteville, Arkansas);  Cameron Crane (Fayetteville, Arkansas);  Randy Espinal Cabrera (Fayetteville, Arkansas);  German Perez (Fayetteville, Arkansas);  Seyed Mohammad Reza Razavi (Fayetteville, Arkansas);  Giselle Toledo (Fayetteville, Arkansas)
ABSTRACT The present invention relates to a coating composition comprising a fluoropolymer and a dopamine derivative. Further, the present invention relates to a process for coating a substrate, comprising the steps of (a) providing a coating composition comprising a fluoropolymer, a dopamine derivative and a solvent; (b) locating the coating composition on a substrate; (c) heating the coated substrate to remove the solvent; and (d) optionally pressing the heated coated substrate against another material surface to bond these to each other. The present coating composition allows the bonding of fluoropolymers through a process that eliminates the need for mechanical keying and hazardous or costly etching processes.
FILED Wednesday, December 02, 2020
APPL NO 17/110225
CURRENT CPC
Layered Products, i.e Products Built-up of Strata of Flat or Non-flat, e.g Cellular or Honeycomb, Form
B32B 15/18 (20130101)
B32B 15/085 (20130101)
B32B 27/322 (20130101)
B32B 37/10 (20130101)
B32B 2255/10 (20130101)
B32B 2255/26 (20130101)
B32B 2311/30 (20130101)
B32B 2327/18 (20130101)

Coating Compositions, e.g Paints, Varnishes or Lacquers; Filling Pastes; Chemical Paint or Ink Removers; Inks; Correcting Fluids; Woodstains; Pastes or Solids for Colouring or Printing; Use of Materials Therefor
C09D 127/18 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163797 Zhao et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Army Research Office (ARO)
Department of the Navy (DON)
Office of Naval Research (ONR)
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Civil, Mechanical and Manufacturing Innovation (CMMI)
APPLICANT(S) Massachusetts Institute of Technology (Cambridge, Massachusetts);  Mayo Foundation for Medical Education and Research (Rochester, Minnesota)
ASSIGNEE(S)
INVENTOR(S) Xuanhe Zhao (Allston, Massachusetts);  Hyunwoo Yuk (Cambridge, Massachusetts);  Xinyu Mao (Cambridge, Massachusetts);  Christoph Nabzdyk (Rochester, Minnesota)
ABSTRACT A tissue adhesive material that provides fast and robust adhesion even on tissue surfaces covered in bodily fluids. The tissue adhesive material is formed of a hydrophobic matrix and a plurality of bioadhesive microparticles dispersed within the hydrophobic matrix configured such that disposing the adhesive material directly on a fluid covered surface and applying pressure causes the (a) hydrophobic matrix to repel the fluid, (b) the bioadhesive particles to compress forming an adhesive layer, and (c) the bioadhesive particles to form temporary crosslinks followed by covalent crosslinks with the surface.
FILED Thursday, December 03, 2020
APPL NO 17/110841
CURRENT CPC
Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 24/0042 (20130101)
A61L 24/0094 (20130101)
A61L 2400/04 (20130101)

Adhesives; Non-mechanical Aspects of Adhesive Processes in General; Adhesive Processes Not Provided for Elsewhere; Use of Materials as Adhesives
C09J 9/00 (20130101)
C09J 11/06 (20130101)
C09J 105/08 (20130101) Original (OR) Class
C09J 133/02 (20130101)
C09J 151/003 (20130101)
C09J 2483/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163867 Angelini et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Materials Research (DMR)
APPLICANT(S) University of Florida Research Foundation, Inc. (Gainesville, Florida)
ASSIGNEE(S)
INVENTOR(S) Thomas Ettor Angelini (Gainesville, Florida);  Tapomoy Bhattacharjee (Gainesville, Florida);  Wallace Gregory Sawyer (Gainesville, Florida);  Cameron Morley (Gainesville, Florida)
ABSTRACT Disclosed herein is a bioreactor system that allows perfusive flow through a porous support medium enabling 3D growth of biological samples. In some embodiments, the system comprises a sample well filled with a three-dimensional (3D) cell growth medium. The system can further comprises a liquid medium reservoir fluidly connected to the sample well by a first filter material. The system can further comprises a medium collection chamber fluidly connected to the sample well by a second filter material. The system can further comprise an absorbant material that creates an osmotic pressure gradient to produce perfusive flow. In some embodiments, osmotic pressure draws fluid from the liquid medium reservoir, through the first filter material, into the sample well where it permeates the three-dimensional cell growth medium, through the second filter material, and finally into the medium collection chamber.
FILED Thursday, August 01, 2019
APPL NO 17/263712
CURRENT CPC
Preservation of Bodies of Humans or Animals or Plants or Parts Thereof; Biocides, e.g as Disinfectants, as Pesticides or as Herbicides; Pest Repellants or Attractants; Plant Growth Regulators
A01N 1/0231 (20130101)

Apparatus for Enzymology or Microbiology;
C12M 25/04 (20130101) Original (OR) Class
C12M 33/00 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0062 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163940 FU et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
National Science Foundation (NSF)
APPLICANT(S) The Board of Trustees of the Leland Stanford Junior University (Stanford, California)
ASSIGNEE(S) The Board of Trustees of the Leland Stanford Junior University (Stanford, California)
INVENTOR(S) Xu Hua FU (Stanford, California);  Andrew FIRE (Stanford, California);  Justin D. SMITH (Stanford, California)
ABSTRACT The disclosure describes that both Cas9 and Cpf1 enzymes can exhibit potent nickase activities on an extensive class of mismatched dsDNA targets. These properties allow the production of efficient nickases for a chosen dsDNA target sequence, without modification of the nuclease protein, using guide RNAs with a variety of patterns of mismatch to the intended DNA target. In parallel to the nicking activities observed with purified Cas9 in vitro, sequence-dependent nicking for both perfectly matched and partially mismatched target sequences in a Saccharomyces cerevisae in vivo system was observed.
FILED Thursday, October 29, 2020
APPL NO 17/083918
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/22 (20130101)
C12N 15/113 (20130101) Original (OR) Class
C12N 2310/20 (20170501)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164005 FOX et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Chemistry (CHE)
APPLICANT(S) Joseph M. FOX (Landenberg, Pennsylvania);  Colin THORPE (Newark, Delaware);  Amanda M. TALLON (Claymont, Delaware);  Yixin XIE (Newark, Delaware);  William TROUT (Wilmington, Delaware);  Ashlyn S. CANTREL (Catasauqua, Pennsylvania);  Julia E. ROSENBERGER (Wilmington, Delaware)
ASSIGNEE(S) University of Delaware (Newark, Delaware)
INVENTOR(S) Joseph M. FOX (Landenberg, Pennsylvania);  Colin THORPE (Newark, Delaware);  Amanda M. TALLON (Claymont, Delaware);  Yixin XIE (Newark, Delaware);  William TROUT (Wilmington, Delaware);  Ashlyn S. CANTREL (Catasauqua, Pennsylvania);  Julia E. ROSENBERGER (Wilmington, Delaware)
ABSTRACT A method for catalytically converting a dihydrotetrazine 1 into a tetrazine 2, wherein the dihydrotetrazine 1 comprises a first R group and a second R group, wherein the first R group is a substituted or unsubstituted aryl, heteroaryl, alkyl, alkenyl, alkynyl, carbonyl, or heteroatom-containing group, and the second R group is selected from the group consisting of H and substituted or unsubstituted aryl, heteroaryl, alkyl, alkenyl, alkynyl, carbonyl, and heteroatom-containing groups; wherein the method comprises (a) providing the dihydrotetrazine 1 in a reaction medium, and (b) adding an enzyme as a catalyst and an oxidant to the reaction medium, whereby the dihydrotetrazine 1 is converted to the tetrazine 2.
FILED Wednesday, December 23, 2020
APPL NO 17/132532
CURRENT CPC
Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture
C12P 17/12 (20130101)
C12P 17/165 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164870 Fraden et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) BRANDEIS UNIVERSITY (Waltham, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Seth Fraden (Newton, Massachusetts);  Michael Heymann (Hamburg, Germany);  Markus Ludwig (Waltham, Massachusetts)
ABSTRACT Microfluidic devices and methods for investigating crystallization and/or for controlling a reaction or a phase transition are disclosed. In one embodiment, the microfluidic device includes a reservoir layer; a membrane disposed on the reservoir layer; a wetting control layer disposed on the membrane; and a storage layer disposed on the wetting control layer, wherein the wetting control layer and the storage layer define a microfluidic channel comprising an upstream portion, a downstream portion, a first fluid path in communication with the upstream and the downstream portions, and a storage well positioned within the first fluid path, wherein the wetting control layer includes a fluid passageway in communication with the storage well and the membrane, and wherein the wetting control layer wets a first fluid introduced into the microfluidic channel, the first fluid comprising a hydrophilic, lipophilic, fluorophilic or gas phase as the continuous phase in the microfluidic channel.
FILED Monday, February 08, 2021
APPL NO 17/170022
CURRENT CPC
Separation
B01D 9/0036 (20130101)
B01D 9/0072 (20130101)

Chemical or Physical Laboratory Apparatus for General Use
B01L 3/502707 (20130101)
B01L 3/502723 (20130101)
B01L 3/502761 (20130101)
B01L 3/502784 (20130101)
B01L 2200/025 (20130101)
B01L 2200/141 (20130101)
B01L 2300/088 (20130101)
B01L 2300/123 (20130101)
B01L 2300/161 (20130101)
B01L 2300/0829 (20130101)
B01L 2300/0887 (20130101)
B01L 2300/1894 (20130101)
B01L 2400/0487 (20130101)
B01L 2400/0688 (20130101)

Apparatus for Enzymology or Microbiology;
C12M 3/00 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 1/28 (20130101) Original (OR) Class
G01N 23/20025 (20130101)
G01N 2001/4016 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164953 Robertson et al.
FUNDED BY
National Science Foundation (NSF)
Department of Agriculture (USDA)
APPLICANT(S) University of Idaho (Moscow, Idaho)
ASSIGNEE(S) University of Idaho (, None)
INVENTOR(S) Daniel Robertson (Moscow, Idaho);  Douglas Cook (Fountain Green, Utah);  Will Seegmiller (Troy, Idaho);  Taylor Spence (Garden Valley, Idaho);  Kate Seegmiller (Moscow, Idaho);  Andrew Stucker (Moscow, Idaho)
ABSTRACT Certain disclosed method embodiments concern performing a stalk puncture test to determine force and displacement data. Plant features, such as rind thickness, stalk radius, stalk diameter, section modulus and/or integrative puncture score, primarily applicable to corn, sorghum, sunflower, wheat or rice, can be calculated using the force and displacement data. The calculated plant features are used to select plants for selective breeding to produce lodging-resistant crop hybrids. The present invention also provides embodiments of a hand-held puncture device that can be used to practice disclosed method embodiments.
FILED Wednesday, December 02, 2020
APPL NO 17/109989
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 3/30 (20130101)
G01N 33/0098 (20130101) Original (OR) Class
G01N 2021/8466 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164955 PETERMAN et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Industrial Innovation and Partnerships (IIP)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) OndaVia, Inc. (Hayward, California)
ASSIGNEE(S)
INVENTOR(S) Mark Charles PETERMAN (Fremont, California);  Merwan BENHABIB (San Francisco, California);  Carlos Atico ARIZA (Hayward, California);  Samuel Louis KLEINMAN (Oakland, California)
ABSTRACT A hand-held microfluidic testing device is provided that includes a housing having a cartridge receiving port and a cartridge for input to the cartridge receiving port. An optical detection system in the housing is capable of providing an illuminated electric field useful for Raman spectroscopy. The cartridge may have a sample well. The sample well is loaded with a mixture of water containing the analyte, Raman-scattering nanoparticles and a calibration solution. The calibration solution contains an analogue of the analyte differing in its Raman response, for example an isotope of the analyte. Optionally, a chemical compound capable of increasing interaction between the analyte and the nanoparticles may be added.
FILED Thursday, December 10, 2020
APPL NO 17/118482
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 21/658 (20130101)
G01N 33/18 (20130101) Original (OR) Class
G01N 33/182 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164971 Walt et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Materials Research (DMR)
APPLICANT(S) The Brigham and Women's Hospital, Inc. (Boston, Massachusetts);  President and Fellows of Harvard College (Cambridge, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) David R. Walt (Boston, Massachusetts);  Limor Cohen (Boston, Massachusetts);  David A. Weitz (Bolton, Massachusetts);  Nai Wen Cui (Cambridge, Massachusetts);  Yamei Cai (Cambridge, Massachusetts)
ABSTRACT The invention provides high-sensitivity methods for detection and quantification of target analytes in liquid samples (e.g., biological or environmental samples). The methods can be multiplexed to allow simultaneous detection and quantification of multiple target analytes that are contained in the same sample. The invention also provides related compositions and kits.
FILED Thursday, August 15, 2019
APPL NO 17/267827
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/581 (20130101)
G01N 33/54333 (20130101) Original (OR) Class
G01N 2333/55 (20130101)
G01N 2333/57 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210165069 Przybyla et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Industrial Innovation and Partnerships (IIP)
APPLICANT(S) Chirp Microsystems, Inc. (Berkeley, California)
ASSIGNEE(S)
INVENTOR(S) Richard J. Przybyla (Emeryville, California);  Ryan Young (El Cerrito, California);  Mitchell H. Kline (Alameda, California);  David A. Horsley (Berkeley, California)
ABSTRACT Time of flight between two or more ultrasonic transceivers is measured using known delays. First and second transceivers are duty cycled, each having a respective receive period that is less than a measurement period during which the transceivers are configured to receive transmissions. An ultrasonic trigger pulse is transmitted by the first transceiver. The second transceiver, upon receiving the trigger pulse, transmits an ultrasonic response pulse after a first predefined delay time that is known to the first transceiver and greater than the receive period of the second transceiver. Subsequently, the first transceiver receives the ultrasonic response pulse and determines a receive time. The first transceiver determines the distance between the first transceiver and the second transceiver from a speed of sound, an elapsed time between the time of transmission of the trigger pulse and the receive time, and the first predetermine delay time.
FILED Friday, January 22, 2021
APPL NO 17/156242
CURRENT CPC
Radio Direction-finding; Radio Navigation; Determining Distance or Velocity by Use of Radio Waves; Locating or Presence-detecting by Use of the Reflection or Reradiation of Radio Waves; Analogous Arrangements Using Other Waves
G01S 3/808 (20130101) Original (OR) Class
G01S 5/30 (20130101)
G01S 15/876 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210166078 Chellappan et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Chemical, Bioengineering, Environmental and Transport Systems (CBET)
APPLICANT(S) University of South Florida (Tampa, Florida)
ASSIGNEE(S)
INVENTOR(S) Sriram Chellappan (Tampa, Florida);  Pratool Bharti (Tampa, Florida);  Mona Minakshi (Tampa, Florida);  Willie McClinton (Tampa, Florida);  Jamshidbek Mirzakhalov (Tampa, Florida)
ABSTRACT Identifying insect species integrates image processing, feature selection, unsupervised clustering, and a support vector machine (SVM) learning algorithm for classification. Results with a total of 101 mosquito specimens spread across nine different vector carrying species demonstrate high accuracy in species identification. When implemented as a smart-phone application, the latency and energy consumption were minimal. The currently manual process of species identification and recording can be sped up, while also minimizing the ensuing cognitive workload of personnel. Citizens at large can use the system in their own homes for self-awareness and share insect identification data with public health agencies.
FILED Friday, February 05, 2021
APPL NO 17/168941
CURRENT CPC
Recognition of Data; Presentation of Data; Record Carriers; Handling Record Carriers
G06K 9/00677 (20130101)
G06K 9/2054 (20130101)
G06K 9/4604 (20130101)
G06K 9/4652 (20130101)
G06K 9/6218 (20130101)
G06K 9/6228 (20130101)
G06K 9/6259 (20130101) Original (OR) Class
G06K 9/6269 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210166138 Larson et al.
FUNDED BY
National Science Foundation (NSF)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) Clinc, Inc. (Ann Arbor, Michigan)
ASSIGNEE(S)
INVENTOR(S) Stefan Larson (Ann Arbor, Michigan);  Anish Mahendran (Ann Arbor, Michigan);  Parker Hill (Ann Arbor, Michigan);  Jonathan K. Kummerfeld (Ann Arbor, Michigan);  Michael A. Laurenzano (Ann Arbor, Michigan);  Lingjia Tang (Ann Arbor, Michigan);  Jason Mars (Ann Arbor, Michigan)
ABSTRACT Systems and methods for automatically detecting annotation discrepancies in annotated training data samples and repairing the annotated training data samples for a machine learning-based automated dialogue system include evaluating a corpus of a plurality of distinct training data samples; identifying one or more of a slot span defect and a slot label defect of a target annotated slot span of a target training data sample of the corpus based on the evaluation; and automatically correcting one or more annotations of the target annotated slot span based on the identified one or more of the slot span defect and the slot label defect.
FILED Friday, January 15, 2021
APPL NO 17/149998
CURRENT CPC
Computer Systems Based on Specific Computational Models
G06N 5/04 (20130101) Original (OR) Class
G06N 20/00 (20190101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210166393 Ramani et al.
FUNDED BY
National Science Foundation (NSF)
Office of Integrative Activities (OIA)
APPLICANT(S) Purdue Research Foundation (West Lafayette, Indiana)
ASSIGNEE(S)
INVENTOR(S) Karthik Ramani (West Lafayette, Indiana);  Sangpil Kim (Champaign, Illinois);  Hyung-gun Chi (West Lafayette, Indiana)
ABSTRACT A method for generating a multi-modal video dataset with pixel-wise hand segmentation is disclosed. To address the challenges of conventional dataset creation, the method advantageously utilizes multi-modal image data that includes thermal images of the hands, which enables efficient pixel-wise hand segmentation of the image data. By using the thermal images, the method is not affected by fingertip and joint occlusions and does not require hand pose ground truth. Accordingly, the method can produce more accurate pixel-wise hand segmentation in an automated manner, with less human effort. The method can thus be utilized to generate a large multi-modal hand activity video dataset having hand segmentation labels, which is useful for training machine learning models, such as deep neural networks.
FILED Wednesday, December 02, 2020
APPL NO 17/109193
CURRENT CPC
Recognition of Data; Presentation of Data; Record Carriers; Handling Record Carriers
G06K 9/00375 (20130101)
G06K 9/6256 (20130101)
G06K 9/6279 (20130101)

Image Data Processing or Generation, in General
G06T 7/11 (20170101) Original (OR) Class
G06T 7/30 (20170101)
G06T 7/70 (20170101)
G06T 7/136 (20170101)
G06T 7/174 (20170101)
G06T 2207/10016 (20130101)
G06T 2207/10028 (20130101)
G06T 2207/10048 (20130101)
G06T 2207/20081 (20130101)
G06T 2207/20084 (20130101)
G06T 2207/20092 (20130101)
G06T 2207/30196 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210167394 Archer et al.
FUNDED BY
Department of Energy (DOE)
Advanced Research Projects Agency Energy (ARPAE)
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Materials Research (DMR)
APPLICANT(S) Cornell University (Ithaca, New York)
ASSIGNEE(S)
INVENTOR(S) Lynden A. Archer (Ithaca, New York);  Zhengyuan Tu (Nanchang, China PRC);  Snehashis Choudhury (Ithaca, New York);  Shuya Wei (Sanmenxia, China PRC);  Qing Zhao (Ithaca, New York);  Dylan Vu (Ithaca, New York)
ABSTRACT Rechargeable batteries are disclosed having a protective membrane layer on surfaces of an electrode such as cathode active material. Such membranes include anionically charged groups and include an anionic membrane or a zwitterionic membrane. Such membranes can minimize contact of electrolyte to the surfaces of the active materials of the cathode where oxidation of electrolyte typically occurs thus promoting thermal stability of the electrolyte especially for high voltage batteries.
FILED Wednesday, June 20, 2018
APPL NO 16/644734
CURRENT CPC
Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy
H01M 4/366 (20130101)
H01M 4/382 (20130101)
H01M 4/628 (20130101) Original (OR) Class
H01M 10/052 (20130101)
H01M 10/0567 (20130101)
H01M 2300/0025 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210167743 ODAME et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Computer and Information Science and Engineering (CISE)
Division of Information and Intelligent Systems (IIS)
APPLICANT(S) THE TRUSTEES OF DARTMOUTH COLLEGE (Hanover, New Hampshire)
ASSIGNEE(S)
INVENTOR(S) Kofi ODAME (Hanover, New Hampshire);  Yueh-Ching TENG (Lebanon, New Hampshire)
ABSTRACT An amplitude detector has a phase shifter such as one using an analog differentiator and an adjustable gain stage, or one using a determinable delay, the phase shifter coupled to shift phase of an input signal to the amplitude detection apparatus. The detector also has a first analog multiplier coupled to square the input signal, a second analog multiplier coupled to square output of the phase shifter; and an analog adder coupled to sum outputs of the first and second analog multiplier. An automatic gain control circuit has the amplitude detector coupled to control gain of a controllable amplifier.
FILED Wednesday, January 04, 2017
APPL NO 16/067539
CURRENT CPC
Amplifiers
H03F 3/24 (20130101)

Control of Amplification
H03G 3/3036 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210168063 D'Antoni et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) Wisconsin Alumni Research Foundation (Madison, Wisconsin)
ASSIGNEE(S)
INVENTOR(S) Loris D'Antoni (Madison, Wisconsin);  Srinivasa Akella (Middleton, Wisconsin);  Kausik Subramanian (Madison, Wisconsin)
ABSTRACT A network switch holds a routing table and a network topology table so that when a link failure is detected at the network switch, the network switch may independently reroute a packet intended for that failed link using the network topology table. This processing can be performed in the data plane at a speed that can eliminate dropped packets. Intercommunication with a central controller is not required and intercommunication with other network switches may be accomplished through data plane communication by embedding the link failure information in the affected packet.
FILED Tuesday, December 03, 2019
APPL NO 16/701703
CURRENT CPC
Transmission of Digital Information, e.g Telegraphic Communication
H04L 45/02 (20130101)
H04L 45/04 (20130101)
H04L 45/22 (20130101) Original (OR) Class
H04L 45/28 (20130101)
H04L 45/70 (20130101)
H04L 49/3009 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210168238 Adolphe et al.
FUNDED BY
National Science Foundation (NSF)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) Forward Edge AI, Inc. (San Antonio, Texas)
ASSIGNEE(S)
INVENTOR(S) Eric Adolphe (San Antonio, Texas);  JESSE CAI (MCLEAN, Virginia);  KARTHIK PRASANNA MAIYA (CHANTILLY, Virginia);  HONGYI GUAN (HERNDON, Virginia);  BEN SISKO ADOLPHE (SAN ANTONIO, Texas)
ABSTRACT An innovative method is implemented to determine a robocall and blocks the incoming communication deemed to be a robocall. The method leverages blockchain's shared storage, memory, and ability to transact all information across a network and independently verified and stored on the immutable blockchain. The method takes advantage high-speed cellular network to process each communication with high-speed. Further, the method integrates blockchain encryption, swarm intelligence (SI), artificial intelligence (AI) and machine learning (ML) algorithms, a telecommunication expert knowledge graph (TEKG), and real-time parsing of records to block robocalls and reduce connection delays. All modules can evolve and update themselves with each use of the present invention through various SI, AI, and ML technologies. Additionally, the method includes a localized call-filtering feature based on state and federal laws to ensure the blocking of calls that are prohibited by either federal or state governments thereby facilitating recovery of damages.
FILED Thursday, December 03, 2020
APPL NO 17/110688
CURRENT CPC
Transmission of Digital Information, e.g Telegraphic Communication
H04L 9/06 (20130101)
H04L 2209/38 (20130101)

Telephonic Communication
H04M 3/436 (20130101) Original (OR) Class
H04M 2203/6027 (20130101)

Wireless Communication Networks
H04W 12/12 (20130101)
H04W 12/00514 (20190101)
VIEW PATENT @ USPTO:  Full Text   PDF 

Department of Defense (DOD) 

US 20210161126 Uygun et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
APPLICANT(S) The General Hospital Corporation (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Musfata Korkut Uygun (Boston, Massachusetts);  Bote G. Bruinsma (Boston, Massachusetts);  Maria-Louisa Izamis (Boston, Massachusetts)
ABSTRACT The present invention relates to organ perfusion systems that can be used at room temperature. The organ perfusion systems do not comprise a temperature controller. In some embodiments, the organ perfusion systems do not comprise a cleaning device for cleaning the perfusion fluid. The perfusion fluid can comprise Williams' medium E. The organ perfusion systems can be portable and can be used to preserving an organ, preventing ischemic damage in an organ, or recovering an ischemically damaged organ.
FILED Friday, February 12, 2021
APPL NO 17/175160
CURRENT CPC
Preservation of Bodies of Humans or Animals or Plants or Parts Thereof; Biocides, e.g as Disinfectants, as Pesticides or as Herbicides; Pest Repellants or Attractants; Plant Growth Regulators
A01N 1/0226 (20130101)
A01N 1/0247 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161850 D'Agostino et al.
FUNDED BY
Department of Defense (DOD)
Department of the Navy (DON)
Office of Naval Research (ONR)
APPLICANT(S) University of South Florida (Tampa, Florida)
ASSIGNEE(S)
INVENTOR(S) Dominic Paul D'Agostino (Tampa, Florida);  Jay B. Dean (Land O'Lakes, Florida);  Raffaele Pilla (Tampa, Florida);  Patrick Arnold (Champaign, Illinois)
ABSTRACT The present invention demonstrates the therapeutic use of ketone esters for seizure disorders, Alzheimer's disease and malignant brain cancer, which are associated with metabolic dysregulation. The administration of ketone esters resulted therapeutic ketosis and neuroprotection against seizures resulting from CNS oxygen toxicity. Supplemental ketones were also found to reduce superoxide production in cultured cortex neurons exposed to hyperbaric oxygen and Aβ-42, and to decrease proliferation and viability in U87 glioma cells. These observations support the therapeutic effect of ketones for seizure disorders, Alzheimer's disease and malignant brain cancer. The ketone esters may be derived from acetoacetate and can include R,S-1,3-butanediol acetoacetate monoester, R,S-1,3-butanediol acetoacetate diester, or a combination of the two.
FILED Monday, November 23, 2020
APPL NO 17/101931
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/22 (20130101)
A61K 31/225 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161890 Henry et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
United States Army (USA)
APPLICANT(S) BACH PHARMA, INC. (North Andover, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Mark O. Henry (North Andover, Massachusetts);  William S. Lynn (Hillsborough, North Carolina)
ABSTRACT The present invention relates to compositions that can be used, for example, in methods of treating medical conditions and symptoms associated with brain dysfunction, including but not limited to Gulf War illness (GWI), multiple chemical sensitivity (MCS), cognitive dysfunction (CD), multiple sclerosis (MS), and neurological disorders such as amyotrophic lateral sclerosis (ALS). in various embodiments, the compositions of the invention, which can be administered or prepared as a medicament for use in the treatment methods described herein, are phthalazinediones or pharmaceutically acceptable salts thereof. As described further below, the phthalazinedione can be 5-amino-2,3-dihydro-1;4-phthala2:inedione; an analog or variant thereof; or a salt of the specified compound, the analog, or the variant. The compounds described herein can be formulated as diagnostic or pharmaceutical compositions, and the invention features kits including one or more of these compounds.
FILED Saturday, December 31, 2016
APPL NO 16/067542
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0053 (20130101)
A61K 31/502 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/22 (20180101)
A61P 25/28 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210161900 Wang et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Duke University (Durham, North Carolina)
ASSIGNEE(S)
INVENTOR(S) Xiao-Fan Wang (Durham, North Carolina);  Christopher Pan (Durham, North Carolina);  Lifeng Yuan (Durham, North Carolina)
ABSTRACT The present disclosure comprises compositions and methods for the treatment of senescent tumor cells. In particular, compositions and methods for countering negative effects of cancer therapy-induced senescence in tumor cells are provided.
FILED Monday, April 29, 2019
APPL NO 17/047258
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/443 (20130101)
A61K 31/506 (20130101)
A61K 31/519 (20130101) Original (OR) Class
A61K 31/4439 (20130101)
A61K 31/5377 (20130101)
A61K 38/10 (20130101)
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/04 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162002 Chen
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
United States Army (USA)
APPLICANT(S) The Penn State Research Foundation (University Park, Pennsylvania)
ASSIGNEE(S)
INVENTOR(S) Gong Chen (State College, Pennsylvania)
ABSTRACT This document provides methods and materials involved in treating mammals having a spinal cord injury (SCI). For example, methods and materials for administering a composition containing exogenous nucleic acid encoding a NeuroD1polypeptide (or a biologically active fragment thereof) alone or in combination with a D1x2 polypeptide (or a biologically active fragment thereof) to a mammal having SCI are provided. This document also provides methods and materials involved in treating mammals having amyotrophic lateral sclerosis (ALS). For example, methods and materials for administering a composition containing exogenous nucleic acid encoding a NeuroD1 polypeptide (or a biologically active fragment thereof) alone or in combination with an Isl 1 polypeptide (or a biologically active fragment thereof) to a mammal having ALS are provided.
FILED Friday, October 16, 2020
APPL NO 17/072951
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/17 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/00 (20180101)

Peptides
C07K 14/4702 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0619 (20130101)
C12N 15/86 (20130101)
C12N 2750/14141 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162076 LIU
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
APPLICANT(S) Augusta University Research Institute, Inc. (Augusta, Georgia)
ASSIGNEE(S) Augusta University Research Institute, Inc. (Augusta, Georgia)
INVENTOR(S) Hong Yan LIU (Martinez, Georgia)
ABSTRACT An aptamer platform capable of efficiently delivering and silencing one, two or more genes in vivo or in vitro is provided. Methods of using the aptamer compositions for selectively targeting cells to down-regulate the expression of multiple genes are also provided.
FILED Tuesday, February 09, 2021
APPL NO 17/171050
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 48/0066 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/12 (20180101)
A61P 35/00 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/113 (20130101)
C12N 15/115 (20130101)
C12N 15/1138 (20130101)
C12N 2310/14 (20130101)
C12N 2310/16 (20130101)
C12N 2310/531 (20130101)
C12N 2310/3519 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210162709 Boyd et al.
FUNDED BY
Department of Defense (DOD)
Department of the Navy (DON)
Secretary of the Navy (SECNAV)
APPLICANT(S) The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, Virginia)
ASSIGNEE(S)
INVENTOR(S) Darryl A. Boyd (Alexandria, Virginia);  Jason D. Myers (Alexandria, Virginia);  Vinh Q. Nguyen (Fairfax, Virginia);  Danial J. Gibson (Cheverly, Maryland);  Colin C. Baker (Alexandria, Virginia);  Woohong Kim (Lorton, Virginia);  Jasbinder S. Sanghera (Ashburn, Virginia)
ABSTRACT A method for bonding infrared transparent materials by placing a polymer comprising at least one chalcogenide element and crosslinking moieties between infrared-transparent optical elements and applying heat, pressure, or both. The crosslinking moieties may be organic, inorganic, or both. Also disclosed is the related bonded assembly comprising infrared transparent optical elements.
FILED Thursday, December 03, 2020
APPL NO 17/110687
CURRENT CPC
Layered Products, i.e Products Built-up of Strata of Flat or Non-flat, e.g Cellular or Honeycomb, Form
B32B 7/12 (20130101) Original (OR) Class
B32B 7/023 (20190101)
B32B 33/00 (20130101)
B32B 37/1207 (20130101)
B32B 2305/72 (20130101)
B32B 2307/412 (20130101)
B32B 2307/704 (20130101)
B32B 2318/00 (20130101)
B32B 2551/00 (20130101)

Adhesives; Non-mechanical Aspects of Adhesive Processes in General; Adhesive Processes Not Provided for Elsewhere; Use of Materials as Adhesives
C09J 11/04 (20130101)
C09J 163/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163298 Pate et al.
FUNDED BY
Department of Defense (DOD)
Department of the Navy (DON)
Secretary of the Navy (SECNAV)
APPLICANT(S) The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, Virginia)
ASSIGNEE(S) The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, Virginia)
INVENTOR(S) Bradford B. Pate (Arlington, Virginia);  William Maza (Camp Spring, Maryland);  Vanessa Breslin (Alexandria, Virginia);  Paul A. DeSario (Alexandria, Virginia);  Tatyana I. Feygelson (Springfield, Virginia);  Albert Epshteyn (Potomac, Maryland);  Jeffrey C. Owrutsky (Silver Spring, Maryland);  Carlos Hangarter (Alexandria, Virginia)
ABSTRACT Disclosed is a method of irradiating a composition having water and hydrogen-terminated nanodiamonds with light that generates water-solvated electrons from the nanodiamonds. The method can be used to degrade fluoroalkyl compounds such as perfluorooctane sulfonate.
FILED Wednesday, November 25, 2020
APPL NO 17/104676
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 19/123 (20130101)

Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures
B82Y 30/00 (20130101)

Non-metallic Elements; Compounds Thereof;
C01B 32/28 (20170801) Original (OR) Class

Indexing Scheme Relating to Structural and Physical Aspects of Solid Inorganic Compounds
C01P 2004/64 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163370 Cook et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Secretary of the Air Force (SECAF)
APPLICANT(S) Govemment of the United States, as represented by the Secretary of the Air Force (wright-Patterson AFB, Ohio)
ASSIGNEE(S)
INVENTOR(S) Gary Cook (Beavercreek, Ohio);  Ronald W. Stites (Beavercreek, Ohio)
ABSTRACT A method of forming a doped substrate comprises heating a substrate comprising a layer of a dopant on at least one surface to a predetermined temperature; applying a predetermined degree of isostatic external pressure on the surface of said substrate at said predetermined temperature for a time sufficient to induce thermal migration of the dopant into the substrate to provide a doped substrate; and removing the isostatic pressure and cooling the doped substrate to about room temperature. The substrate is a glass material, a single crystal material, a poly-crystalline material, a ceramic material, or a semiconductor material, and the substrate may be optically transparent. The dopant comprises one or more transition metals, one or more rare earth elements, or a combination of both. The layer of a dopant comprises one or more segregated layers of distinct chemical species. The isostatic pressure and elevated temperature may be applied simultaneously or sequentially.
FILED Monday, April 03, 2017
APPL NO 16/067209
CURRENT CPC
Lime, Magnesia; Slag; Cements; Compositions Thereof, e.g Mortars, Concrete or Like Building Materials; Artificial Stone; Ceramics; Refractories; Treatment of Natural Stone
C04B 35/547 (20130101)
C04B 41/009 (20130101)
C04B 41/0072 (20130101)
C04B 41/4517 (20130101)
C04B 41/4521 (20130101)
C04B 41/5133 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163403 FREEMAN et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
APPLICANT(S) Cedars-Sinai Medical Center (Los Angeles, California)
ASSIGNEE(S) Cedars-Sinai Medical Center (Los Angeles, California)
INVENTOR(S) Michael FREEMAN (West Hollywood, California);  Mirja ROTINEN (Beverly Hills, California);  Ramachandran MURALI (Beverly Hills, California);  Sungyong YOU (Los Angeles, California)
ABSTRACT Provided herein are compositions and methods for treating, inhibiting and/or reducing the severity of cancer in subjects in need thereof. The methods include providing an agent that inhibits expression or activity of ONECUT2 and administering a therapeutically effective amount of the agent so as to treat, inhibit and/or reduce the severity of cancer in the subject.
FILED Friday, January 08, 2021
APPL NO 17/145152
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/40 (20130101)
A61K 31/45 (20130101)
A61K 31/165 (20130101)
A61K 31/397 (20130101)
A61K 31/416 (20130101)
A61K 31/417 (20130101)
A61K 31/445 (20130101)
A61K 31/4164 (20130101)
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

General Methods of Organic Chemistry; Apparatus Therefor
C07B 2200/07 (20130101)

Acyclic or Carbocyclic Compounds
C07C 233/31 (20130101)
C07C 237/08 (20130101) Original (OR) Class
C07C 237/22 (20130101)
C07C 259/06 (20130101)

Heterocyclic Compounds
C07D 205/04 (20130101)
C07D 207/09 (20130101)
C07D 207/16 (20130101)
C07D 211/60 (20130101)
C07D 211/76 (20130101)
C07D 211/78 (20130101)
C07D 231/56 (20130101)
C07D 233/64 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/68 (20130101)
C12Q 1/6886 (20130101)
C12Q 2600/106 (20130101)
C12Q 2600/158 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163424 Sivaguru et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
United States Army (USA)
National Science Foundation (NSF)
Office of Experimental Program To Stimulate Competitive Research (EPSCOR)
APPLICANT(S) NDSU RESEARCH FOUNDATION (Fargo, North Dakota)
ASSIGNEE(S)
INVENTOR(S) Jayaraman Sivaguru (Fargo, North Dakota);  Akila Iyer (Fargo, North Dakota);  Mukund Sibi (Fargo, North Dakota);  Dean Webster (Fargo, North Dakota);  Saravana Kumar Rajendran (Fargo, North Dakota);  Ramya Raghunathan (Fargo, North Dakota);  Ravichandanath Singathi (Fargo, North Dakota);  Retheesh Krishnan (Fargo, North Dakota);  Anthony Clay (Fargo, North Dakota)
ABSTRACT The invention relates to novel hydrazide-based templates, methods of making the same, and methods of using the hydrazide-based templates as molecular scaffolds for asymmetric light driven transformations, light driven material synthesis, and biological applications. Furthermore, the present invention relates to photoinitiators, monomers, and polymers derived from biomass, together with methods and methods of using the same.
FILED Friday, February 12, 2021
APPL NO 17/248924
CURRENT CPC
Acyclic or Carbocyclic Compounds
C07C 243/28 (20130101)
C07C 243/30 (20130101)
C07C 243/34 (20130101)
C07C 243/38 (20130101)

Heterocyclic Compounds
C07D 207/24 (20130101)
C07D 209/48 (20130101)
C07D 239/88 (20130101) Original (OR) Class

Macromolecular Compounds Obtained by Reactions Only Involving Carbon-to-carbon Unsaturated Bonds
C08F 2/48 (20130101)
C08F 120/14 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163532 Aldrich et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
APPLICANT(S) University of Florida Research Foundation, Incorporated (Gainesville, Florida)
ASSIGNEE(S) University of Florida Research Foundation, Incorporated (Gainesville, Florida)
INVENTOR(S) Jane V. Aldrich (Gainesville, Florida);  Michael J. Ferracane (Irvine, California)
ABSTRACT The invention relates to macrocyclic peptides and pharmaceutical compositions thereof. The invention further provides macrocyclic tetrapeptides comprising sarcosine. The invention further relates to pharmaceutical compositions for modulating opioid receptor activity. The macrocyclic tetrapeptides provided herein are useful in treating diseases or disorders relating to the activity of one or more opioid receptors, such as neurological disorders.
FILED Wednesday, April 17, 2019
APPL NO 17/047977
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/00 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/04 (20180101)

Peptides
C07K 5/126 (20130101) Original (OR) Class
C07K 7/64 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163539 So et al.
FUNDED BY
Department of Defense (DOD)
Department of the Navy (DON)
Secretary of the Navy (SECNAV)
APPLICANT(S) The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, Virginia)
ASSIGNEE(S) The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, Virginia)
INVENTOR(S) Christopher R. So (Alexandria, Virginia);  Kathryn J. Wahl (Alexandria, Virginia)
ABSTRACT Peptides that form adhesive bonds, even in aqueous and/or saline environments, are disclosed. When aggregated, the peptides may be used in methods for producing hydrogels and/or adhesive materials. Synthetic peptide analogs are provided that are designed based on protein sequences found in barnacle adhesive, and may optionally be augmented with chemistry from other organisms that secrete proteins that adhere to substrates. The peptides may be used, for example, in biomedical and aqueous applications. Methods of using the aggregated peptides as adhesives are also provided.
FILED Monday, February 01, 2021
APPL NO 17/163733
CURRENT CPC
Layered Products, i.e Products Built-up of Strata of Flat or Non-flat, e.g Cellular or Honeycomb, Form
B32B 37/12 (20130101)

Peptides
C07K 14/001 (20130101) Original (OR) Class

Adhesives; Non-mechanical Aspects of Adhesive Processes in General; Adhesive Processes Not Provided for Elsewhere; Use of Materials as Adhesives
C09J 5/04 (20130101)
C09J 189/00 (20130101)
C09J 2489/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163542 Cui et al.
FUNDED BY
Department of Defense (DOD)
Uniformed Services University of the Health Sciences (USU)
Henry M Jackson Foundation for the Advancement of Military Medicine, Inc (HJF)
APPLICANT(S) THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (BETHESDA, Maryland)
ASSIGNEE(S)
INVENTOR(S) Xinle Cui (Gaithersburg, Maryland);  Clifford M. Snapper (Potomac, Maryland)
ABSTRACT Provided are antigenic compositions and uses thereof that include at least two human herpesvirus (HHV) polypeptides involved in mediating HHV binding, fusion, and entry into host cells, such as gp350, gH, gL, and gB, or nucleic acids encoding the polypeptides. The two HHV polypeptides comprise any combination of: a gB polypeptide; a gp350 polypeptide; a gL polypeptide; and a gH polypeptide, and optionally any one or more of the following polypeptides: gp42, gM, gN, gl, gC, gE, gD, ORF68, BMRF-2, BDLF2, UL128, UL130, UL131A, and gpK8.1. Also disclosed are methods of inducing an immune response or treating or preventing an HHV infection in a subject by administering to the subject at least two of the HHV polypeptides or nucleic acid(s) encoding the same. Methods of passively transferring immunity using high-titer anti-HHV antibodies or immune cells are also disclosed.
FILED Tuesday, February 02, 2021
APPL NO 17/165310
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 39/25 (20130101)
A61K 39/245 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/22 (20180101)

Peptides
C07K 14/005 (20130101) Original (OR) Class

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 7/00 (20130101)
C12N 2710/16034 (20130101)
C12N 2710/16071 (20130101)
C12N 2710/16134 (20130101)
C12N 2710/16171 (20130101)
C12N 2710/16234 (20130101)
C12N 2710/16271 (20130101)
C12N 2710/16334 (20130101)
C12N 2710/16371 (20130101)
C12N 2710/16634 (20130101)
C12N 2710/16671 (20130101)
C12N 2710/16734 (20130101)
C12N 2710/16771 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163731 Kohl et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
APPLICANT(S) Georgia Tech Research Corporation (Atlanta, Georgia)
ASSIGNEE(S)
INVENTOR(S) Paul A. Kohl (Atlanta, Georgia);  Anthony Engler (Pearland, Texas);  Jisu Jiang (Atlanta, Georgia);  Chi Kin Lo (Atlanta, Georgia);  Matthew Warner (Atlanta, Georgia);  Oluwadamilola Phillips (Tampa, Florida)
ABSTRACT Transient polymers and compositions comprising such polymers are described. The polymers are copolymers of phthalaldehyde and one or more additional aldehydes and can degrade/decompose upon exposure to a desired stimulus, like light, heat, sound, or chemical trigger. Films comprising the copolymers and devices comprising surfaces coated with the film are also described.
FILED Tuesday, March 26, 2019
APPL NO 17/042004
CURRENT CPC
Macromolecular Compounds Obtained Otherwise Than by Reactions Only Involving Unsaturated Carbon-to-carbon Bonds
C08G 2/20 (20130101)

Working-up; General Processes of Compounding; After-treatment Not Covered by Subclasses C08B, C08C, C08F, C08G or C08H
C08J 5/043 (20130101)
C08J 5/046 (20130101)

Use of Inorganic or Non-macromolecular Organic Substances as Compounding Ingredients
C08K 5/12 (20130101)
C08K 5/0016 (20130101)
C08K 5/3415 (20130101)

Compositions of Macromolecular Compounds
C08L 27/06 (20130101)
C08L 61/02 (20130101) Original (OR) Class
C08L 2203/16 (20130101)
C08L 2312/00 (20130101)

Coating Compositions, e.g Paints, Varnishes or Lacquers; Filling Pastes; Chemical Paint or Ink Removers; Inks; Correcting Fluids; Woodstains; Pastes or Solids for Colouring or Printing; Use of Materials Therefor
C09D 161/02 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163797 Zhao et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Army Research Office (ARO)
Department of the Navy (DON)
Office of Naval Research (ONR)
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Civil, Mechanical and Manufacturing Innovation (CMMI)
APPLICANT(S) Massachusetts Institute of Technology (Cambridge, Massachusetts);  Mayo Foundation for Medical Education and Research (Rochester, Minnesota)
ASSIGNEE(S)
INVENTOR(S) Xuanhe Zhao (Allston, Massachusetts);  Hyunwoo Yuk (Cambridge, Massachusetts);  Xinyu Mao (Cambridge, Massachusetts);  Christoph Nabzdyk (Rochester, Minnesota)
ABSTRACT A tissue adhesive material that provides fast and robust adhesion even on tissue surfaces covered in bodily fluids. The tissue adhesive material is formed of a hydrophobic matrix and a plurality of bioadhesive microparticles dispersed within the hydrophobic matrix configured such that disposing the adhesive material directly on a fluid covered surface and applying pressure causes the (a) hydrophobic matrix to repel the fluid, (b) the bioadhesive particles to compress forming an adhesive layer, and (c) the bioadhesive particles to form temporary crosslinks followed by covalent crosslinks with the surface.
FILED Thursday, December 03, 2020
APPL NO 17/110841
CURRENT CPC
Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 24/0042 (20130101)
A61L 24/0094 (20130101)
A61L 2400/04 (20130101)

Adhesives; Non-mechanical Aspects of Adhesive Processes in General; Adhesive Processes Not Provided for Elsewhere; Use of Materials as Adhesives
C09J 9/00 (20130101)
C09J 11/06 (20130101)
C09J 105/08 (20130101) Original (OR) Class
C09J 133/02 (20130101)
C09J 151/003 (20130101)
C09J 2483/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163938 BAWAGE et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Department of the Army (DOA)
APPLICANT(S) Georgia Tech Research Corporation (Atlanta, Georgia)
ASSIGNEE(S)
INVENTOR(S) Swapnil BAWAGE (Atlanta, Georgia);  Pooja M. TIWARI (Atlanta, Georgia);  Philip J. SANTANGELO (Atlanta, Georgia)
ABSTRACT Compositions and methods for treating or inactivating viruses in a subject in need thereof are provided herein. Exemplary compositions include nucleic acids encoding an RNA-guided endonuclease and a guide RNA that is complementary to a target sequence in a virus. The RNA-guided endonuclease specifically targets viral nucleic acid sequences for destruction and suppression of that virus in a host cell in vitro or in vivo.
FILED Monday, April 15, 2019
APPL NO 17/047978
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/22 (20130101)
C12N 15/113 (20130101) Original (OR) Class
C12N 2310/321 (20130101)
C12N 2310/322 (20130101)
C12N 2310/335 (20130101)

Enzymes
C12Y 301/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163947 Silverman et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Materiel Command (AFMC)
Air Force Research Laboratory (AFRL)
APPLICANT(S) Northwestern University (Evanston, Illinois)
ASSIGNEE(S)
INVENTOR(S) Adam D. Silverman (Chicago, Illinois);  Michael C. Jewett (Evanston, Illinois);  Julius B. Lucks (Evanston, Illinois)
ABSTRACT Disclosed are methods, devices, kits, components, and compositions for detecting a target molecule in a test sample using a cell-free protein synthesis (CFPS) reaction. The methods, devices, kits, components, and compositions may be utilized for detecting target molecules which may include small molecules and/or metabolites of small molecules. The methods, devices, kits, components, and compositions employ one or more transcription templates that encode and conditionally express one or more exogenous RNA polymerases in the presence of the target molecule. The expressed RNA polymerases in turn induce expression of one or more reporter molecules from transcription templates comprising promoters for the RNA polymerases, thereby amplifying an output signal that is generated in the presence of a detected target molecule.
FILED Tuesday, December 22, 2020
APPL NO 17/131538
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/1247 (20130101)
C12N 15/115 (20130101) Original (OR) Class
C12N 15/1068 (20130101)

Enzymes
C12Y 207/07006 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163954 Goel et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) University of Massachusetts (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Hira Lal Goel (Shrewsbury, Massachusetts);  Arthur M. Mercurio (Boston, Massachusetts)
ABSTRACT Methods and compositions for treating cancer, e.g., prostate cancer, using a combination of P-Rex1 or Rac1 inhibitors and VEGF/VEGFR-targeted therapy.
FILED Thursday, February 04, 2021
APPL NO 17/167317
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/404 (20130101)
A61K 31/506 (20130101)
A61K 31/7088 (20130101)
A61K 39/3955 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Peptides
C07K 14/00 (20130101)
C07K 14/4702 (20130101)
C07K 16/22 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/1137 (20130101) Original (OR) Class
C12N 2310/11 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163969 Jewett et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
APPLICANT(S) Northwestern University (Evanston, Illinois);  Massachusetts Institute of Technology (Cambridge, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Michael Christopher Jewett (Evanston, Illinois);  Lauren Clark (Chicago, Illinois);  Christopher A. Voigt (Cambridge, Massachusetts);  Eszter Majer (Boston, Massachusetts)
ABSTRACT Disclosed are compositions, methods, and kits for performing cell-free protein synthesis (CFPS). The disclosed compositions, methods, and kits include or utilize components prepared from plant plastids or extracts thereof. The compositions, methods, and kits may be used for in vitro protein synthesis and prototyping of genetic expression in plants and are suitable for automation.
FILED Monday, February 08, 2021
APPL NO 17/170702
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/1086 (20130101)
C12N 15/8214 (20130101) Original (OR) Class
C12N 15/8251 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164059 Jewett et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Materiel Command (AFMC)
Air Force Research Laboratory (AFRL)
Defense Advanced Research Projects Agency (DARPA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) NORTHWESTERN UNIVERSITY (Evanston, Illinois)
ASSIGNEE(S)
INVENTOR(S) Michael Christopher Jewett (Evanston, Illinois);  Julius B. Lucks (Evanston, Illinois);  Adam D. Silverman (Chicago, Illinois);  Khalid K. Alam (Evanston, Illinois)
ABSTRACT Disclosed are methods, devices, kits, components, and compositions for detecting a target molecule in a test sample using a cell-free protein synthesis (CFPS) reaction. The methods, devices, kits, components, and compositions may be utilized for detecting target molecules which may include small molecules and/or metabolites of small molecules. The components and compositions used in the disclosed methods, devices, and kits may be dried or lyophilized and may be present or immobilized on a paper substrate, for example, as a paper test article.
FILED Monday, August 05, 2019
APPL NO 17/265785
CURRENT CPC
Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/485 (20130101)
C12Q 1/6897 (20130101) Original (OR) Class

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/521 (20130101)
G01N 33/1826 (20130101)
G01N 2033/184 (20130101)
G01N 2430/20 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164592 Di Carlo et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
APPLICANT(S) The Boeing Company (Chicago, Illinois)
ASSIGNEE(S)
INVENTOR(S) Tony Di Carlo (Long Beach, California);  Brian T. Vaniman (Fountain Valley, California);  John P. Leuer (Newport Beach, California)
ABSTRACT A method of fabricating a conduit comprises steps of attaching a first first-tubular-outboard-ply-end of a first tubular outboard ply to a first inner collar portion of a first collar with a second weld and attaching a second first-tubular-outboard-ply end of the first tubular outboard ply to a second inner collar portion of a second collar with a fourth weld. The method also comprises steps of inserting a second tubular outboard ply into the first tubular outboard ply and inserting a tubular inboard ply into the second tubular outboard ply, so that the second tubular outboard ply is interposed between the tubular inboard ply and the first tubular outboard ply. The method further comprises steps of threadably interconnecting the first inner collar portion and a first outer collar portion of the first collar and threadably interconnecting the second inner collar portion and a second outer collar portion of the second collar.
FILED Thursday, January 14, 2021
APPL NO 17/149543
CURRENT CPC
Pipes; Joints or Fittings for Pipes; Supports for Pipes, Cables or Protective Tubing; Means for Thermal Insulation in General
F16L 11/22 (20130101)
F16L 11/121 (20130101) Original (OR) Class

Testing Static or Dynamic Balance of Machines or Structures; Testing of Structures or Apparatus, Not Otherwise Provided for
G01M 3/18 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164841 Gord et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Secretary of the Air Force (SECAF)
APPLICANT(S) Government of the United States, as represented by the Secretary of the Air Force (Wright-Patterson AFB, Ohio)
ASSIGNEE(S)
INVENTOR(S) James R. Gord (Beavercreek, Ohio);  Sukesh Roy (Dayton, Ohio);  Paul S. Hsu (Dayton, Ohio);  Naibo Jiang (Dayton, Ohio);  Mikhail N. Slipchenko (West Lafayette, Indiana)
ABSTRACT Systems and methods for measuring temperature in an environment by creating a first beam having an energy of about 50 mJ/pulse, and a pulse duration of about 100 ps. A second beam is also created, having an energy of about 2.3 mJ/pulse, and a pulse duration of about 58 ps. The first beam and the second beam are directed into a probe region, thereby expressing an optical output. Properties of the optical output are measured at a sampling rate of at least about 100 kHz, and temperature measurements are derived from the measured properties of the optical output. Such systems and methods can be used to measure temperature in environments exhibiting highly turbulent and transient flow dynamics.
FILED Wednesday, November 18, 2020
APPL NO 16/950949
CURRENT CPC
Measurement of Intensity, Velocity, Spectral Content, Polarisation, Phase or Pulse Characteristics of Infra-Red, Visible or Ultra-violet Light; Colorimetry; Radiation Pyrometry
G01J 3/4412 (20130101)
G01J 5/0014 (20130101)
G01J 5/601 (20130101) Original (OR) Class

Devices Using the Process of Light Amplification by Stimulated Emission of Radiation [LASER] to Amplify or Generate Light; Devices Using Stimulated Emission of Electromagnetic Radiation in Wave Ranges Other Than Optical
H01S 3/1024 (20130101)
H01S 3/1666 (20130101)
H01S 3/10007 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164930 Mirica et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
APPLICANT(S) Trustees of Dartmouth College (Hanover, New Hampshire)
ASSIGNEE(S) Trustees of Dartmouth College (Hanover, New Hampshire)
INVENTOR(S) Katherine A. Mirica (Hanover, New Hampshire);  Lukasz K. Mendecki (White River Junction, Vermont)
ABSTRACT Embodiments of the present disclosure pertain to ion-selective electrodes that include a metal-organic framework and an electrode surface. The metal-organic framework is associated with the electrode surface in a manner that forms an interface between the metal-organic framework and the electrode surface. Additional embodiments pertain to methods of detecting an ion in a sample by associating the sample with the ion-selective electrodes of the present disclosure. The metal-organic frameworks of the ion-selective electrodes mediate ion-to-electron transduction through the interface between the metal-organic and the electrode surface. Thereafter, the presence or absence of the ion in the sample is detected by detecting a change in potential of the ion-selective electrode and correlating the change in the potential to the presence or absence of the ion. The metal organic frameworks may simultaneously mediate ion sensing and ion-to-electron transduction through the interface between the metal-organic frameworks and the electrode surface.
FILED Monday, August 13, 2018
APPL NO 16/636081
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 27/308 (20130101)
G01N 27/3335 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164991 JOHNSTON et al.
FUNDED BY
Department of Homeland Security (DHS)
Department of Defense (DOD)
Defense Threat Reduction Agency (DTRA)
APPLICANT(S) ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (Scottsdale, Arizona)
ASSIGNEE(S) ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (Scottsdale, Arizona)
INVENTOR(S) Stephen JOHNSTON (Tempe, Arizona);  Lu WANG (Tempe, Arizona)
ABSTRACT A method of inducing a generalized immune response, includes administering to a subject an immunologically effective amount of one or more isolated immunogenic peptides comprising an amino acid sequence of SEQ. ID NOs: 1-46, thereby inducing a generalized immune response to infection by a pathogen in a subject. A prophylactic or therapeutic composition for inducing a generalized immune response, includes an immunologically effective amount of one or more isolated immunogenic peptides comprising an amino acid sequence of SEQ. ID NOs: 1-46. A method of distinguishing a subject infected with a pathogen from an uninfected subject, includes detecting an antibody in the subject that selectively binds one or more isolated immunogenic peptides comprising an amino acid sequence of SEQ. ID NOs: 1-46, wherein the presence of the antibody indicates that the subject is infected with the pathogen. A general method to discover broadly protective components for a vaccine is also disclosed.
FILED Wednesday, January 16, 2019
APPL NO 16/954187
CURRENT CPC
Peptides
C07K 14/4702 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 1/10 (20130101)
C12N 1/20 (20130101)
C12N 7/00 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/6854 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210165092 Hester et al.
FUNDED BY
Department of Defense (DOD)
Defense Threat Reduction Agency (DTRA)
APPLICANT(S) GEORGIA TECH RESEARCH CORPORATION (Atlanta, Georgia)
ASSIGNEE(S) GEORGIA TECH RESEARCH CORPORATION (Atlanta, Georgia)
INVENTOR(S) Jimmy Georges Donald Hester (Atlanta, Georgia);  Emmanouil M Tentzeris (Atlanta, Georgia)
ABSTRACT A system for using thin and energy-autonomous backscatter tags and corresponding sensing nodes may operate with 24 GHz backscatter reflectarray tags having low power consumption. A digital beam steering, frequency-modulated continuous wave (FMCW) radar may be used for detection, localization, identification and communications. The tags may include environmental sensors that are used to modulate backscatter waves for data communications directed to a reader or may digitally modulate the backscatter transmissions without sensor data for independent localization of each tag in a network.
FILED Friday, December 21, 2018
APPL NO 16/956587
CURRENT CPC
Radio Direction-finding; Radio Navigation; Determining Distance or Velocity by Use of Radio Waves; Locating or Presence-detecting by Use of the Reflection or Reradiation of Radio Waves; Analogous Arrangements Using Other Waves
G01S 7/025 (20130101)
G01S 13/758 (20130101) Original (OR) Class
G01S 13/825 (20130101)

Recognition of Data; Presentation of Data; Record Carriers; Handling Record Carriers
G06K 7/10168 (20130101)

Antennas, i.e Radio Aerials
H01Q 3/2647 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210165852 GRANGER et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Department of the Navy (DON)
Office of Naval Research (ONR)
APPLICANT(S) Richard GRANGER (Hanover, New Hampshire);  Eli BOWEN (Hanover, New Hampshire);  Antonio RODRIGUEZ (Hanover, New Hampshire);  Andrew FELCH (Hanover, New Hampshire);  THE TRUSTEES OF DARTMOUTH COLLEGE (Hanover, New Hampshire)
ASSIGNEE(S)
INVENTOR(S) Richard GRANGER (Hanover, New Hampshire);  Eli BOWEN (Hanover, New Hampshire);  Antonio RODRIGUEZ (Hanover, New Hampshire);  Andrew FELCH (Hanover, New Hampshire)
ABSTRACT Systems and methods provide a mathematical framework and corresponding hardware for defining, manipulating, and using perception according to a non-Euclidean space. Embodiments may be used to approximate existing mappings or to create new mappings for arbitrary stimuli and numerous tasks. An efficient electronic perceptual apparatus projects multivariate input data onto a perceptual manifold using Jacobian matrices, and methods presented herein generate Jacobians so as to replicate non-Euclidean perceptual spaces. Examples of perceptual stimuli that may benefit from the embodiments include digital images, audio, and video. In one example, lossy compression of digital images according to a non-Euclidean space advantageously produces compressed images with lower entropy for a given image quality, or better image quality for a given entropy, as compared to JPEG compression.
FILED Thursday, July 26, 2018
APPL NO 16/632702
CURRENT CPC
Electric Digital Data Processing
G06F 7/50 (20130101)
G06F 7/523 (20130101)
G06F 17/16 (20130101) Original (OR) Class
G06F 17/141 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210166107 Alvarez-Icaza Rivera et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
APPLICANT(S) International Business Machines Corporation (Armonk, New York)
ASSIGNEE(S)
INVENTOR(S) Rodrigo Alvarez-Icaza Rivera (San Jose, California);  John V. Arthur (Mountain View, California);  Andrew S. Cassidy (Austin, Texas);  Bryan L. Jackson (Fremont, California);  Paul A. Merolla (Palo Alto, California);  Dharmendra S. Modha (San Jose, California);  Jun Sawada (Austin, Texas)
ABSTRACT The present invention provides a system comprising multiple core circuits. Each core circuit comprises multiple electronic axons for receiving event packets, multiple electronic neurons for generating event packets, and a fanout crossbar including multiple electronic synapse devices for interconnecting the neurons with the axons. The system further comprises a routing system for routing event packets between the core circuits. The routing system virtually connects each neuron with one or more programmable target axons for the neuron by routing each event packet generated by the neuron to the target axons. Each target axon for each neuron of each core circuit is an axon located on the same core circuit as, or a different core circuit than, the neuron.
FILED Monday, July 30, 2018
APPL NO 16/049539
CURRENT CPC
Computer Systems Based on Specific Computational Models
G06N 3/049 (20130101)
G06N 3/063 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210166159 RUBENSTEIN et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
APPLICANT(S) BROWN UNIVERSITY (Providence, Rhode Island)
ASSIGNEE(S)
INVENTOR(S) Brenda RUBENSTEIN (Providence, Rhode Island);  Jacob Karl ROSENSTEIN (Providence, Rhode Island);  Christopher ARCADIA (Providence, Rhode Island);  Shui Ling CHEN (Harrisburg, Pennsylvania);  Amanda Doris DOMBROSKI (Cranston, Rhode Island);  Joseph D. GEISER (Barrington, Rhode Island);  Eamonn KENNEDY (West Warwick, Rhode Island);  Eunsuk KIM (Providence, Rhode Island);  Kady M. OAKLEY (North Attleboro, Massachusetts);  Sherief REDA (Barrington, Rhode Island);  Christopher ROSE (Providence, Rhode Island);  Jason Kelby SELLO (Tiverton, Rhode Island);  Hokchhay TANN (Providence, Rhode Island);  Peter WEBER (Barrington, Rhode Island)
ABSTRACT The invention provides methods for computing with chemicals by encoding digital data into a plurality of chemicals to obtain a dataset; translating the dataset into a chemical form; reading the data set; querying the dataset by performing an operation to obtain a perceptron; and analyzing the perceptron for identifying chemical structure and/or concentration of at least one of the chemicals, thereby developing a chemical computational language. The invention demonstrates a workflow for representing abstract data in synthetic metabolomes. Also presented are several demonstrations of kilobyte-scale image data sets stored in synthetic metabolomes, recovered at >99% accuracy.
FILED Thursday, June 20, 2019
APPL NO 17/253013
CURRENT CPC
Computer Systems Based on Specific Computational Models
G06N 99/007 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210166583 BURAS et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
National Aeronautics and Space Administration (NASA)
APPLICANT(S) Tienovix, LLC (Houston, Texas)
ASSIGNEE(S) Tienovix, LLC (Houston, Texas)
INVENTOR(S) William R. BURAS (Friendswood, Texas);  Craig S. RUSSELL (League City, Texas);  Kyle Q. NGUYEN (League City, Texas)
ABSTRACT Methods for providing real-time, three-dimensional (3D) augmented reality (AR) feedback guidance to a user of an equipment system to achieve improved diagnostic or treatment outcomes, including comparing sensed, real-time user positioning data and data received from the equipment system during use to reference positioning and procedure outcome data, and generating and providing to a user real-time position-based and outcome-based 3D AR feedback based on comparing the sensed and reference data.
FILED Monday, October 05, 2020
APPL NO 17/063651
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 8/06 (20130101)
A61B 8/52 (20130101)
A61B 8/085 (20130101)
A61B 8/466 (20130101)
A61B 8/467 (20130101)
A61B 8/4245 (20130101)
A61B 8/4254 (20130101)
A61B 8/4263 (20130101)
A61B 34/20 (20160201)
A61B 90/361 (20160201)
A61B 2034/2048 (20160201)
A61B 2034/2055 (20160201)
A61B 2090/365 (20160201)
A61B 2090/378 (20160201)
A61B 2090/3945 (20160201)
A61B 2562/0219 (20130101)

Optical Elements, Systems, or Apparatus
G02B 27/017 (20130101)

Electric Digital Data Processing
G06F 3/011 (20130101)
G06F 3/016 (20130101)

Computer Systems Based on Specific Computational Models
G06N 20/00 (20190101)

Educational or Demonstration Appliances; Appliances for Teaching, or Communicating With, the Blind, Deaf or Mute; Models; Planetaria; Globes; Maps; Diagrams
G09B 5/065 (20130101)
G09B 23/286 (20130101) Original (OR) Class

Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data
G16H 30/20 (20180101)
G16H 40/63 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210167244 Razeghi
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Department of the Army (DOA)
APPLICANT(S) Northwestern University (Evanston, Illinois)
ASSIGNEE(S)
INVENTOR(S) Manijeh Razeghi (Wilmette, Illinois)
ABSTRACT Diffusion-based and ion implantation-based methods are provided for fabricating planar photodetectors. The methods may be used to fabricate planar photodetectors comprising type II superlattice absorber layers but without mesa structures. The fabricated planar photodetectors exhibit high quantum efficiencies, low dark current densities, and high specific detectivities as compared to photodetectors having mesa structures.
FILED Monday, November 30, 2020
APPL NO 17/106937
CURRENT CPC
Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 31/1844 (20130101) Original (OR) Class
H01L 31/03046 (20130101)
H01L 31/035236 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210167390 Treger
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
APPLICANT(S) CAMX Power, LLC (Lexington, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Jack Treger (Quincy, Massachusetts)
ABSTRACT Provided are processes of preventing or eliminating caking of particulate materials during milling operations. Processes include the addition of an anti-caking additive such as a rosin, abietic acid, fatty acid, or derivative of any of the foregoing to a mill prior to or along with a particulate chemical, and milling the combination. The addition of the anti-caking additive prevents or reduces the amount of caking observed thereby increasing yields and maintaining or enhancing the resulting properties of the milled product.
FILED Tuesday, July 24, 2018
APPL NO 17/261940
CURRENT CPC
Crushing, Pulverising, or Disintegrating in General; Milling Grain
B02C 17/20 (20130101)

Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy
H01M 4/485 (20130101)
H01M 4/505 (20130101)
H01M 4/525 (20130101)
H01M 4/622 (20130101) Original (OR) Class
H01M 4/5825 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210167494 Marr
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
APPLICANT(S) Raytheon Company (Waltham, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Harry B. Marr (Manhattan Beach, California)
ABSTRACT A beamforming system includes a plurality of channelizers and a channel switching module in signal communication with the channelizers. Each channelizer is configured to receive a respective input radio frequency signal and to generate a plurality of respective channels in response to downsampling the respective input radio frequency signal. The channel switching module includes a channel combining circuit configured to selectively combine a common channel generated by each channelizer to form at least one steered analog beam.
FILED Thursday, January 21, 2021
APPL NO 17/154008
CURRENT CPC
Antennas, i.e Radio Aerials
H01Q 3/00 (20130101) Original (OR) Class
H01Q 3/26 (20130101)

Transmission
H04B 7/0617 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 

Department of Energy (DOE) 

US 20210162371 MA et al.
FUNDED BY
Department of Energy (DOE)
APPLICANT(S) University of South Florida (Tampa, Florida)
ASSIGNEE(S)
INVENTOR(S) Shengqian MA (Tampa, Florida);  Qi SUN (Tampa, Florida);  Briana AGUILA (Tampa, Florida)
ABSTRACT Compositions are provided for efficient uranium extraction, for example from wastewater, seawater, or other water sources. The compositions can include a functionalized porous organic polymer functionalized with one or more uranium binding moieties, e.g. having a plurality of amidoxime or amidrazone groups covalently attached thereto. The compositions can include covalent organic frameworks, porous aromatic frameworks, and various porous organic polymers, especially those having a hierarchical pore size distribution over a range of pore sizes. The compositions can have functional groups such as amidoxime or an amidrazone covalently attached thereto. The hierarchical pore size distribution can be determined based upon at least 60% of the pore sizes in the range of pore sizes having a pore volume of at least 0.01 cm3 g−1 in the pore size distribution at 77 K. Methods of making the compositions and methods of using the compositions are also provided.
FILED Saturday, January 12, 2019
APPL NO 16/961158
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 20/267 (20130101) Original (OR) Class
B01J 20/2808 (20130101)
B01J 20/3085 (20130101)
B01J 20/28066 (20130101)
B01J 20/28071 (20130101)
B01J 20/28083 (20130101)

Macromolecular Compounds Obtained by Reactions Only Involving Carbon-to-carbon Unsaturated Bonds
C08F 112/34 (20130101)
C08F 2810/00 (20130101)

Protection Against X-radiation, Gamma Radiation, Corpuscular Radiation or Particle Bombardment; Treating Radioactively Contaminated Material; Decontamination Arrangements Therefor
G21F 9/12 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163377 SCHINSKI et al.
FUNDED BY
Department of Energy (DOE)
Office of Science (DOEOS)
APPLICANT(S) University of Virginia Patent Foundation (Charlottesville, Virginia)
ASSIGNEE(S)
INVENTOR(S) William SCHINSKI (San Rafael, California);  Alan GOLDMAN (Highland Park, New Jersey);  Thomas B. GUNNOE (Palmyra, Virginia);  Michael S. WEBSTER-GARDINER (Mims, Florida);  Nichole SCHWARTZ (Charlottesville, Virginia)
ABSTRACT Catalytic methods for synthesis of super linear alkenyl arenes and alkyl arenes are provided. The methods are capable of synthesizing super linear alkyl and alkenyl arenes from simple arene and olefin starting materials and with high selectivity for linear coupling. Methods are also provided for making a 2,6-dimethylnapthalene (DMN) or 2,6-methylethylnapthalene (MEN).
FILED Friday, March 30, 2018
APPL NO 16/499756
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 21/04 (20130101)
B01J 21/08 (20130101)
B01J 23/42 (20130101)
B01J 23/464 (20130101)
B01J 29/44 (20130101)
B01J 31/183 (20130101)
B01J 31/2226 (20130101)
B01J 31/2291 (20130101)
B01J 2231/32 (20130101)
B01J 2531/0244 (20130101)
B01J 2531/822 (20130101)
B01J 2531/827 (20130101)

Acyclic or Carbocyclic Compounds
C07C 2/66 (20130101) Original (OR) Class
C07C 5/41 (20130101)
C07C 5/333 (20130101)
C07C 2521/04 (20130101)
C07C 2521/08 (20130101)
C07C 2523/46 (20130101)
C07C 2529/44 (20130101)
C07C 2531/22 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163759 Zalich et al.
FUNDED BY
Department of Energy (DOE)
National Science Foundation (NSF)
APPLICANT(S) PPG Industries Ohio, Inc. (Cleveland, Ohio);  The Regents of the University of California (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) Michael A. Zalich (Wexford, Pennsylvania);  Paul H. Berdahl (Walnut Creek, California);  Stuart D. Hellring (Pittsburgh, Pennsylvania);  William H. Retsch, Jr. (Allison Park, Pennsylvania)
ABSTRACT A coating composition includes: (i) a film-forming resin; (ii) an infrared reflective pigment; and (iii) an infrared fluorescent pigment or dye different from the infrared reflective pigment. A multi-layer coating including the coating composition, and a substrate at least partially coated with the coating composition is also disclosed. A method of detecting an article at least partially coated with the coating composition is also disclosed.
FILED Friday, October 28, 2016
APPL NO 16/067537
CURRENT CPC
Processes for Applying Fluent Materials to Surfaces, in General
B05D 5/063 (20130101)
B05D 7/546 (20130101)

Use of Inorganic or Non-macromolecular Organic Substances as Compounding Ingredients
C08K 3/013 (20180101)

Coating Compositions, e.g Paints, Varnishes or Lacquers; Filling Pastes; Chemical Paint or Ink Removers; Inks; Correcting Fluids; Woodstains; Pastes or Solids for Colouring or Printing; Use of Materials Therefor
C09D 5/004 (20130101)
C09D 5/22 (20130101) Original (OR) Class
C09D 7/62 (20180101)
C09D 127/16 (20130101)

Materials for Miscellaneous Applications, Not Provided for Elsewhere
C09K 11/06 (20130101)
C09K 11/592 (20130101)
C09K 11/685 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 21/6428 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163770 Mitkova et al.
FUNDED BY
Department of Energy (DOE)
APPLICANT(S) BOISE STATE UNIVERSITY (Boise, Idaho)
ASSIGNEE(S)
INVENTOR(S) Maria Mitkova (Boise, Idaho);  Al-Amin Ahmed Simon (Boise, Idaho);  Shah Mohammad Rahmot Ullah (Milpitas, California);  Bahareh Badamchi (Boise, Idaho);  Harish Subbaraman (Boise, Idaho)
ABSTRACT A device formation method may include printing a chalcogenide glass ink onto a surface to form a chalcogenide glass layer, where the chalcogenide glass ink comprises chalcogenide glass and a fluid medium. The method may further include sintering the chalcogenide glass layer at a first temperature for a first duration. The method may also include annealing the chalcogenide glass layer at a second temperature for a second duration. A device may include a substrate and a printed chalcogenide glass layer on the substrate, where the printed chalcogenide glass layer includes annealed chalcogenide glass, and where the printed chalcogenide glass layer is free from cracks.
FILED Thursday, December 03, 2020
APPL NO 17/111353
CURRENT CPC
Additive Manufacturing, i.e Manufacturing of Three-dimensional [3-D] Objects by Additive Deposition, Additive Agglomeration or Additive Layering, e.g by 3-d Printing, Stereolithography or Selective Laser Sintering
B33Y 10/00 (20141201)
B33Y 30/00 (20141201)
B33Y 70/10 (20200101)

Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures
B82Y 30/00 (20130101)

Chemical Composition of Glasses, Glazes or Vitreous Enamels; Surface Treatment of Glass; Surface Treatment of Fibres or Filaments Made From Glass, Minerals or Slags; Joining Glass to Glass or Other Materials
C03C 3/321 (20130101)
C03C 21/005 (20130101)

Coating Compositions, e.g Paints, Varnishes or Lacquers; Filling Pastes; Chemical Paint or Ink Removers; Inks; Correcting Fluids; Woodstains; Pastes or Solids for Colouring or Printing; Use of Materials Therefor
C09D 11/38 (20130101) Original (OR) Class

Static Stores
G11C 13/0011 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163917 Kucharzyk et al.
FUNDED BY
Department of Energy (DOE)
Battelle Memorial Institute (BATTELLE)
APPLICANT(S) Battelle Memorial Institute (Columbus, Ohio)
ASSIGNEE(S)
INVENTOR(S) Katarzyna Hanna Kucharzyk (Columbus, Ohio);  Ramanathan Lalgudi (Columbus, Ohio)
ABSTRACT An enzyme formulation includes an encapsulated fungal enzyme which is effective for degrading at least one material selected from the group consisting of hydrocarbons, vulcanized rubber, synthetic rubber, natural rubber, vulcanized polymers and perfluorinated compounds. A degradation method includes treating one of the above-mentioned materials with an encapsulated fungal enzyme to degrade the material.
FILED Wednesday, December 09, 2020
APPL NO 17/116978
CURRENT CPC
Reclamation of Contaminated Soil
B09C 1/10 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 11/04 (20130101) Original (OR) Class
C12N 11/10 (20130101)

Enzymes
C12Y 110/03002 (20130101)
C12Y 111/01013 (20130101)
C12Y 111/01014 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163966 Deng et al.
FUNDED BY
Department of Energy (DOE)
Battelle Memorial Institute (BATTELLE)
Pacific Northwest National Laboratory (PNNL)
APPLICANT(S) Battelle Memorial Institute (Richland, Washington)
ASSIGNEE(S) Battelle Memorial Institute (Richland, Washington)
INVENTOR(S) Shuang Deng (Richland, Washington);  Ziyu Dai (Richland, Washington);  Jon K. Magnuson (Richland, Washington)
ABSTRACT This application provides recombinant Aspergillus fungi having an endogenous cis-aconitic acid decarboxylase (cadA) gene genetically inactivated, which allows aconitic acid production by the recombinant fungi. Such recombinant fungi can further include an exogenous nucleic acid molecule encoding aspartate decarboxylase (panD), an exogenous nucleic acid molecule encoding β-alanine-pyruvate aminotransferase (BAPAT), and an exogenous nucleic acid molecule encoding 3-hydroxypropironate dehydrogenase (HPDH). Kits including these fungi, and methods of using these fungi to produce aconitic acid and 3-hydroxypropionic acid (3-HP) are also provided.
FILED Wednesday, February 10, 2021
APPL NO 17/172660
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/0006 (20130101)
C12N 9/88 (20130101)
C12N 9/1096 (20130101)
C12N 15/80 (20130101) Original (OR) Class

Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture
C12P 7/42 (20130101)
C12P 7/48 (20130101)

Enzymes
C12Y 101/01059 (20130101)
C12Y 206/01018 (20130101)
C12Y 401/01011 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164116 Kuhl et al.
FUNDED BY
Department of Energy (DOE)
APPLICANT(S) Opus 12 Inc. (Berkeley, California)
ASSIGNEE(S)
INVENTOR(S) Kendra P. Kuhl (Oakland, California);  Etosha R. Cave (Berkeley, California);  George Leonard (Oakland, California)
ABSTRACT A platform technology that uses a novel membrane electrode assembly, including a cathode layer, an anode layer, a membrane layer arranged between the cathode layer and the anode layer, the membrane conductively connecting the cathode layer and the anode layer, in a COx reduction reactor has been developed. The reactor can be used to synthesize a broad range of carbon-based compounds from carbon dioxide and other gases containing carbon.
FILED Monday, November 02, 2020
APPL NO 16/949538
CURRENT CPC
Electrolytic or Electrophoretic Processes for the Production of Compounds or Non-metals; Apparatus Therefor
C25B 3/25 (20210101)
C25B 9/23 (20210101) Original (OR) Class
C25B 11/051 (20210101)
C25B 11/057 (20210101)
C25B 13/08 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164118 Strongin et al.
FUNDED BY
Department of Energy (DOE)
Office of Science (DOEOS)
APPLICANT(S) Temple University-Of The Commonwealth System of Higher Education (Philadelphia, Pennsylvania)
ASSIGNEE(S)
INVENTOR(S) Daniel R. Strongin (Wynnewood, Pennsylvania);  Akila C. Thenuwara (Philadelphia, Pennsylvania)
ABSTRACT Novel multi-metal catalysts comprising abundant Earth metals are described herein. Devices comprising the catalysts of the invention are also described. Methods of producing the catalysts are also described herein. Methods of producing hydrogen using the catalysts of the invention are also described herein.
FILED Friday, July 20, 2018
APPL NO 16/632602
CURRENT CPC
Electrolytic or Electrophoretic Processes for the Production of Compounds or Non-metals; Apparatus Therefor
C25B 1/04 (20130101)
C25B 1/50 (20210101)
C25B 11/052 (20210101)
C25B 11/061 (20210101)
C25B 11/075 (20210101) Original (OR) Class

Processes for the Electrolytic or Electrophoretic Production of Coatings; Electroforming; Apparatus Therefor
C25D 9/08 (20130101)

Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 31/022425 (20130101)

Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy
H01M 4/90 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164695 Ho et al.
FUNDED BY
Department of Energy (DOE)
National Nuclear Security Administration (NNSA)
National Technology and Engineering Solutions of Sandia, LLC (NTESS)
Sandia National Laboratories (SNL)
APPLICANT(S) National Technology and Engineering Solutions of Sandia, LLC (Albuquerque, New Mexico)
ASSIGNEE(S)
INVENTOR(S) Clifford K. Ho (Albuquerque, New Mexico);  Kevin Albrecht (Albuquerque, New Mexico)
ABSTRACT The present disclosure is directed to systems and methods to control particle mass flow rate in solar receivers and associated heat exchangers based on feedback from one or more temperatures of particles in the system.
FILED Thursday, May 02, 2019
APPL NO 17/047335
CURRENT CPC
Solar Heat Collectors; Solar Heat Systems
F24S 20/20 (20180501) Original (OR) Class
F24S 50/40 (20180501)
F24S 80/20 (20180501)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164697 Ho et al.
FUNDED BY
Department of Energy (DOE)
National Nuclear Security Administration (NNSA)
National Technology and Engineering Solutions of Sandia, LLC (NTESS)
Sandia National Laboratories (SNL)
APPLICANT(S) National Technology and Engineering Solutions of Sandia, LLC (Albuquerque, New Mexico);  CSIRO (Canberra, Australia)
ASSIGNEE(S)
INVENTOR(S) Clifford K. Ho (Albuquerque, New Mexico);  Jin-Soo Kim (Corlette, Australia);  Apurv Kumar (Palmerston, Australia)
ABSTRACT The present disclosure is directed to multi-stage falling particle receivers and methods of falling particle heating. As the particles fall through the receiver, the particles are periodically collected and released by flow retarding devices. The periodic catch-and-release of the particles falling through the receiver reduces particle flow dispersion, increases particle opacity and solar absorption, and reduces erosion and damage to surfaces caused by direct particle impingement.
FILED Tuesday, January 26, 2021
APPL NO 17/158745
CURRENT CPC
Solar Heat Collectors; Solar Heat Systems
F24S 25/40 (20180501)
F24S 30/00 (20180501)
F24S 60/00 (20180501)
F24S 70/16 (20180501) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164923 AVERY et al.
FUNDED BY
Department of Energy (DOE)
Office of Energy Efficiency and Renewable Energy (EERE)
Alliance for Sustainable Energy, LLC (ASE)
National Renewable Energy Laboratory (NREL)
APPLICANT(S) Alliance for Sustainable Energy, LLC (Golden, Colorado)
ASSIGNEE(S)
INVENTOR(S) Azure Dee AVERY (Denver, Colorado);  Jeffrey Lee BLACKBURN (Golden, Colorado);  Andrew John FERGUSON (Louisville, Colorado);  Taylor Christie Julia AUBRY-KOMIN (Louisville, Colorado)
ABSTRACT Methods for determining desired doping conditions for a semiconducting single-walled carbon nanotube (s-SWCNT) are provided. One exemplary method includes doping each of a plurality of s-SWCNT networks under a respective set of doping conditions; determining a thermoelectric (TE) power factor as a function of a fractional bleach of an absorption spectrum for the plurality of s-SWCNT networks doped under the respective sets of doping conditions; and using the function to identify one of the TE power factors within a range of the fractional bleach of the absorption spectrum. The identified TE power factor corresponds to the desired doping conditions.
FILED Friday, January 15, 2021
APPL NO 17/150134
CURRENT CPC
Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures
B82Y 30/00 (20130101)

Non-metallic Elements; Compounds Thereof;
C01B 32/168 (20170801)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 21/62 (20130101)
G01N 23/20 (20130101) Original (OR) Class

Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 27/16 (20130101)
H01L 35/22 (20130101)
H01L 51/002 (20130101)
H01L 51/0048 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210165381 Abdel-Khalik
FUNDED BY
Department of Energy (DOE)
National Nuclear Security Administration (NNSA)
APPLICANT(S) Purdue Research Foundation (West Lafayette, Indiana)
ASSIGNEE(S) Purdue Research Foundation (West Lafayette, Indiana)
INVENTOR(S) Hany S. Abdel-Khalik (Lafayette, Indiana)
ABSTRACT A system architecture encoded on a non-transitory computer readable medium, the system architecture includes a first protocol. The first protocol is configured to receive a plurality of outputs from an ICS used in controlling an industrial system. The first protocol is configured to receive a plurality of inputs from a physical module. The physical module includes at least one of a component, a sensor, or the ICS. Additionally, the system architecture includes a second protocol, wherein the second protocol is configured to validate the plurality of inputs from the first protocol. Moreover, the system architectures includes a third protocol, wherein the third protocol is configured to validate the plurality of outputs from the first protocol. Further, the system architecture includes a fourth protocol, wherein the fourth protocol is configured to manage the ICS based on the second protocol and the third protocol.
FILED Monday, February 08, 2021
APPL NO 17/169550
CURRENT CPC
Control or Regulating Systems in General; Functional Elements of Such Systems; Monitoring or Testing Arrangements for Such Systems or Elements
G05B 17/02 (20130101)
G05B 19/0425 (20130101) Original (OR) Class
G05B 19/4185 (20130101)

Electric Digital Data Processing
G06F 17/18 (20130101)
G06F 21/85 (20130101)
G06F 21/552 (20130101)

Recognition of Data; Presentation of Data; Record Carriers; Handling Record Carriers
G06K 9/66 (20130101)

Transmission of Digital Information, e.g Telegraphic Communication
H04L 63/1416 (20130101)
H04L 63/1425 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210165606 Blagodurov
FUNDED BY
Department of Energy (DOE)
Exascale Computing Project (ECP)
PathForward Project (PATHFORWARD)
Lawrence Livermore National Laboratory (LLNL)
APPLICANT(S) Advanced Micro Devices, Inc. (Santa Clara, California)
ASSIGNEE(S)
INVENTOR(S) Sergey Blagodurov (Seattle, Washington)
ABSTRACT An apparatus and method for managing packet transfer between a memory fabric having a physical layer interface higher data rate than a data rate of a physical layer interface of another device, receives incoming packets from the memory fabric physical layer interface wherein at least some of the packets include different instruction types. The apparatus and method determine a packet type of the incoming packet received from the memory fabric physical layer interface and when the determined incoming packet type is of a type containing an atomic request, the method and apparatus prioritizes transfer of the incoming packet with the atomic request over other packet types of incoming packets, to memory access logic that accesses local memory within an apparatus.
FILED Tuesday, December 03, 2019
APPL NO 16/701794
CURRENT CPC
Electric Digital Data Processing
G06F 3/061 (20130101)
G06F 3/0659 (20130101) Original (OR) Class
G06F 3/0673 (20130101)
G06F 13/4221 (20130101)
G06F 2213/0026 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210165984 Kaehr et al.
FUNDED BY
Department of Energy (DOE)
National Nuclear Security Administration (NNSA)
National Technology and Engineering Solutions of Sandia, LLC (NTESS)
APPLICANT(S) Joseph J. Reczek (, None);  Madeline Van Winkle (, None);  Harper O.W. Wallace (, None);  National Technology and Engineering Solutions of Sandia, LLC (Albuquerque, New Mexico)
ASSIGNEE(S)
INVENTOR(S) Bryan James Kaehr (Albuquerque, New Mexico);  Joseph J. Reczek (New Albany, Ohio);  Madeline Van Winkle (Berkeley, California);  Harper O.W. Wallace (Dallas, Texas)
ABSTRACT A charge-transfer material enables patterning approach where the polarization angle in stand-alone films can be precisely defined at the single pixel level and reconfigured following initial alignment. This capability enables new routes for non-binary information storage, retrieval, and intrinsic encryption, and it suggests future technologies such as photonic chips that can be reconfigured using non-contact patterning.
FILED Thursday, January 21, 2021
APPL NO 17/154220
CURRENT CPC
Materials for Miscellaneous Applications, Not Provided for Elsewhere
C09K 19/3483 (20130101)

Recognition of Data; Presentation of Data; Record Carriers; Handling Record Carriers
G06K 7/1417 (20130101) Original (OR) Class
G06K 19/06037 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210167394 Archer et al.
FUNDED BY
Department of Energy (DOE)
Advanced Research Projects Agency Energy (ARPAE)
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Materials Research (DMR)
APPLICANT(S) Cornell University (Ithaca, New York)
ASSIGNEE(S)
INVENTOR(S) Lynden A. Archer (Ithaca, New York);  Zhengyuan Tu (Nanchang, China PRC);  Snehashis Choudhury (Ithaca, New York);  Shuya Wei (Sanmenxia, China PRC);  Qing Zhao (Ithaca, New York);  Dylan Vu (Ithaca, New York)
ABSTRACT Rechargeable batteries are disclosed having a protective membrane layer on surfaces of an electrode such as cathode active material. Such membranes include anionically charged groups and include an anionic membrane or a zwitterionic membrane. Such membranes can minimize contact of electrolyte to the surfaces of the active materials of the cathode where oxidation of electrolyte typically occurs thus promoting thermal stability of the electrolyte especially for high voltage batteries.
FILED Wednesday, June 20, 2018
APPL NO 16/644734
CURRENT CPC
Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy
H01M 4/366 (20130101)
H01M 4/382 (20130101)
H01M 4/628 (20130101) Original (OR) Class
H01M 10/052 (20130101)
H01M 10/0567 (20130101)
H01M 2300/0025 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210167395 WANG et al.
FUNDED BY
Department of Energy (DOE)
APPLICANT(S) THE PENN STATE RESEARCH FOUNDATION (University Park, Pennsylvania)
ASSIGNEE(S) The Penn State Research Foundation (University Park, Pennsylvania)
INVENTOR(S) Donghai WANG (University Park, Pennsylvania);  Guoxing LI (University Park, Pennsylvania)
ABSTRACT A battery includes an electrolyte, a metal anode and a cathode. The metal anode includes a porous material disposed thereon to protect the metal anode. The porous material has a zeta potential with a magnitude of at least above 15 mV in the electrolyte. The porous material can include a cross-linked polymer having segments with polar functional groups. Examples of polar functional groups include, but are not limited to, those comprising one or more among O, N, P, S, and B.
FILED Friday, April 12, 2019
APPL NO 17/044683
CURRENT CPC
Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy
H01M 4/366 (20130101)
H01M 4/382 (20130101)
H01M 4/628 (20130101) Original (OR) Class
H01M 10/052 (20130101)
H01M 10/0568 (20130101)
H01M 10/0569 (20130101)
H01M 2004/021 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210167427 Ganguli et al.
FUNDED BY
Department of Energy (DOE)
Advanced Research Projects Agency Energy (ARPAE)
APPLICANT(S) Palo Alto Research Center Incorporated (Palo Alto, California)
ASSIGNEE(S)
INVENTOR(S) Anurag Ganguli (Milpitas, California);  Julian Schwartz (Palo Alto, California);  Ajay Raghavan (Mountain View, California);  Peter Kiesel (Palo Alto, California);  Bhaskar Saha (Redwood City, California);  Saroj Sahu (Fremont, California);  Lars Wilko Sommer (Bretten, Germany)
ABSTRACT A system includes a first optical sensor sensitive to both a parameter of interest, Parameter1, and at least one confounding parameter, Parameter2 and a second optical sensor sensitive only to the confounding parameter. Measurement circuitry measures M1 in response to light scattered by the first optical sensor, where M1=value of Parameter1+K*value of Parameter2. The measurement circuitry also measures M2 in response to light scattered by the second optical sensor, where M2=value of Parameter2. Compensation circuitry determines a compensation factor, K, for the confounding parameter based on measurements of M1 and M2 taken over multiple load/unload cycles or over one or more thermal cycles. The compensation factor is used to determine the parameter of interest.
FILED Monday, November 30, 2020
APPL NO 17/106726
CURRENT CPC
Measuring Not Specially Adapted for a Specific Variable; Arrangements for Measuring Two or More Variables Not Covered in a Single Other Subclass; Tariff Metering Apparatus; Measuring or Testing Not Otherwise Provided for
G01D 3/036 (20130101)
G01D 5/353 (20130101)

Measuring Force, Stress, Torque, Work, Mechanical Power, Mechanical Efficiency, or Fluid Pressure
G01L 1/246 (20130101)

Measuring Electric Variables; Measuring Magnetic Variables
G01R 31/392 (20190101)

Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy
H01M 10/48 (20130101)
H01M 10/425 (20130101)
H01M 10/486 (20130101)
H01M 10/4285 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210167429 Johnson et al.
FUNDED BY
Department of Energy (DOE)
Argonne National Laboratory (ANL)
UChicago Argonne, LLC (UCHICAGO)
APPLICANT(S) UChicago Argonne, LLC (Chicago, Illinois)
ASSIGNEE(S) UChicago Argonne, LLC (Chicago, Illinois)
INVENTOR(S) Christopher S. Johnson (Naperville, Illinois);  Anna Lee (Darien, Illinois)
ABSTRACT A process for charging a discharged electrochemical cell includes applying a voltage bias to the discharged electrochemical cell; and illuminating the cathode with a light source.
FILED Thursday, January 14, 2021
APPL NO 17/148875
CURRENT CPC
Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy
H01M 4/505 (20130101)
H01M 4/525 (20130101)
H01M 10/44 (20130101) Original (OR) Class
H01M 10/0525 (20130101)
H01M 2004/028 (20130101)

Circuit Arrangements or Systems for Supplying or Distributing Electric Power; Systems for Storing Electric Energy
H02J 7/00 (20130101)
H02J 7/35 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210167462 Spoerke et al.
FUNDED BY
Department of Energy (DOE)
National Nuclear Security Administration (NNSA)
National Technology and Engineering Solutions of Sandia, LLC (NTESS)
APPLICANT(S) National Technology and Engineering Solutions of Sandia, LLC (Albuquerque, New Mexico)
ASSIGNEE(S)
INVENTOR(S) Erik David Spoerke (Albuquerque, New Mexico);  Martha Gross (Albuquerque, New Mexico);  Stephen Percival (Albuquerque, New Mexico);  Mark A. Rodriguez (Albuquerque, New Mexico);  Leo J. Small (Albuquerque, New Mexico)
ABSTRACT The present invention is directed to the modification of sodium electrochemical interfaces to improve performance of NaSICON-type ceramics in a variety of electrochemical applications. Enhanced mating of the separator-sodium interface by means of engineered coatings or other surface modifications results in lower interfacial resistance and higher performance at increased current densities, enabling the effective operation of molten sodium batteries and other electrochemical technologies at low and high temperatures.
FILED Wednesday, November 25, 2020
APPL NO 17/104306
CURRENT CPC
Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy
H01M 10/054 (20130101)
H01M 50/434 (20210101)
H01M 50/449 (20210101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 

Small Business Administration (SBA) 

US 20210161084 ZHANG et al.
FUNDED BY
National Science Foundation (NSF)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) ZYNNOVATION LLC (Ashland, Virginia)
ASSIGNEE(S) ZYNNOVATION LLC (Ashland, Virginia)
INVENTOR(S) Wei ZHANG (Midlothian, Virginia);  Hailing YANG (Midlothian, Virginia)
ABSTRACT One embodiment provides a modular green roof tray, house plant growth media and horticulture growth media, and a tree protection mat for weed and moisture control made from recycled disposable diapers. The growth medium and tree protection mat contain superabsorbent materials from diaper that can absorb waters and greatly reduce irrigation so to provide a drought resistant feature. One embodiment also provides a manufacturing process to perform 100% recycling of disposed diapers.
FILED Monday, March 16, 2020
APPL NO 16/819726
CURRENT CPC
Horticulture; Cultivation of Vegetables, Flowers, Rice, Fruit, Vines, Hops or Seaweed; Forestry; Watering
A01G 9/033 (20180201)
A01G 13/0268 (20130101)
A01G 13/0281 (20130101) Original (OR) Class
A01G 24/00 (20180201)

Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 11/00 (20130101)

Preparation or Pretreatment of the Material to be Shaped; Making Granules or Preforms; Recovery of Plastics or Other Constituents of Waste Material Containing Plastics
B29B 17/02 (20130101)
B29B 2017/0203 (20130101)
B29B 2017/0244 (20130101)

Indexing Scheme Associated With Subclass B29C, Relating to Particular Articles
B29L 2031/4878 (20130101)

Inorganic Fertilisers Not Covered by Subclasses C05B, C05C; Fertilisers Producing Carbon Dioxide
C05D 1/005 (20130101)

Organic Fertilisers Not Covered by Subclasses C05B, C05C, e.g Fertilisers From Waste or Refuse
C05F 3/04 (20130101)

Mixtures of Fertilisers Covered Individually by Different Subclasses of Class C05; Mixtures of One or More Fertilisers With Materials Not Having a Specific Fertilising Activity, e.g Pesticides, Soil-conditioners, Wetting Agents; Fertilisers Characterised by Their Form
C05G 3/00 (20130101)
C05G 5/45 (20200201)

Working-up; General Processes of Compounding; After-treatment Not Covered by Subclasses C08B, C08C, C08F, C08G or C08H
C08J 11/04 (20130101)
C08J 2300/14 (20130101)

Roof Coverings; Sky-lights; Gutters; Roof-working Tools
E04D 11/002 (20130101)

Technologies for Adaptation to Climate Change
Y02A 30/254 (20180101)
Y02A 40/20 (20180101)

Climate Change Mitigation Technologies Related to Buildings, e.g Housing, House Appliances or Related End-user Applications
Y02B 80/32 (20130101)

Climate Change Mitigation Technologies in the Production or Processing of Goods
Y02P 20/143 (20151101)
Y02P 20/145 (20151101)

Climate Change Mitigation Technologies Related to Wastewater Treatment or Waste Management
Y02W 30/52 (20150501)
Y02W 30/62 (20150501)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163676 BALASUBRAMANIAN et al.
FUNDED BY
National Science Foundation (NSF)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) POLYSPECTRA, INC. (Berkeley, California)
ASSIGNEE(S)
INVENTOR(S) Aditya BALASUBRAMANIAN (Berkeley, California);  Raymond A. WEITEKAMP (Berkeley, California)
ABSTRACT Described herein are compositions and methods for processing photopolymers based on olefin metathesis. The compositions and methods comprise latent ruthenium complexes and photoacids and/or photoacid generators.
FILED Wednesday, October 14, 2020
APPL NO 17/070557
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 31/2278 (20130101)
B01J 2231/543 (20130101)
B01J 2531/821 (20130101)

Macromolecular Compounds Obtained Otherwise Than by Reactions Only Involving Unsaturated Carbon-to-carbon Bonds
C08G 61/08 (20130101) Original (OR) Class
C08G 2261/374 (20130101)
C08G 2261/418 (20130101)
C08G 2261/3321 (20130101)

Use of Inorganic or Non-macromolecular Organic Substances as Compounding Ingredients
C08K 5/07 (20130101)
C08K 5/45 (20130101)
C08K 5/5313 (20130101)
C08K 5/5397 (20130101)

Photomechanical Production of Textured or Patterned Surfaces, e.g for Printing, for Processing of Semiconductor Devices; Materials Therefor; Originals Therefor; Apparatus Specially Adapted Therefor;
G03F 7/028 (20130101)
G03F 7/0037 (20130101)
G03F 7/2004 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163776 Beckford et al.
FUNDED BY
National Science Foundation (NSF)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) SURFTEC, LLC (Fayetteville, Arkansas)
ASSIGNEE(S) SURFTEC, LLC (Fayetteville, Arkansas)
INVENTOR(S) Samuel George Beckford (Fayetteville, Arkansas);  Cameron Crane (Fayetteville, Arkansas);  Randy Espinal Cabrera (Fayetteville, Arkansas);  German Perez (Fayetteville, Arkansas);  Seyed Mohammad Reza Razavi (Fayetteville, Arkansas);  Giselle Toledo (Fayetteville, Arkansas)
ABSTRACT The present invention relates to a coating composition comprising a fluoropolymer and a dopamine derivative. Further, the present invention relates to a process for coating a substrate, comprising the steps of (a) providing a coating composition comprising a fluoropolymer, a dopamine derivative and a solvent; (b) locating the coating composition on a substrate; (c) heating the coated substrate to remove the solvent; and (d) optionally pressing the heated coated substrate against another material surface to bond these to each other. The present coating composition allows the bonding of fluoropolymers through a process that eliminates the need for mechanical keying and hazardous or costly etching processes.
FILED Wednesday, December 02, 2020
APPL NO 17/110225
CURRENT CPC
Layered Products, i.e Products Built-up of Strata of Flat or Non-flat, e.g Cellular or Honeycomb, Form
B32B 15/18 (20130101)
B32B 15/085 (20130101)
B32B 27/322 (20130101)
B32B 37/10 (20130101)
B32B 2255/10 (20130101)
B32B 2255/26 (20130101)
B32B 2311/30 (20130101)
B32B 2327/18 (20130101)

Coating Compositions, e.g Paints, Varnishes or Lacquers; Filling Pastes; Chemical Paint or Ink Removers; Inks; Correcting Fluids; Woodstains; Pastes or Solids for Colouring or Printing; Use of Materials Therefor
C09D 127/18 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164011 Schellenberger et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) Amunix Pharmaceuticals, Inc. (South San Francisco, California)
ASSIGNEE(S)
INVENTOR(S) Volker Schellenberger (Palo Alto, California);  Joshua Silverman (Los Altos Hills, California);  Chia-wei Wang (Santa Clara, California);  Benjamin Spink (San Carlos, California);  Willem P.C. Stemmer (Los Gatos, California);  Nathan C. Geething (Santa Clara, California)
ABSTRACT The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.
FILED Tuesday, September 29, 2020
APPL NO 17/036396
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/00 (20130101)

Peptides
C07K 14/00 (20130101)
C07K 14/7155 (20130101)
C07K 14/8125 (20130101)
C07K 14/70521 (20130101)
C07K 16/18 (20130101)
C07K 16/32 (20130101)
C07K 16/40 (20130101)
C07K 16/241 (20130101)
C07K 16/244 (20130101)
C07K 16/2809 (20130101)
C07K 16/2863 (20130101)
C07K 16/2878 (20130101)
C07K 2317/31 (20130101)
C07K 2317/92 (20130101)
C07K 2317/94 (20130101)
C07K 2317/569 (20130101)
C07K 2317/622 (20130101)
C07K 2319/31 (20130101)
C07K 2319/70 (20130101)
C07K 2319/74 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/625 (20130101)

Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture
C12P 21/02 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164955 PETERMAN et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Industrial Innovation and Partnerships (IIP)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) OndaVia, Inc. (Hayward, California)
ASSIGNEE(S)
INVENTOR(S) Mark Charles PETERMAN (Fremont, California);  Merwan BENHABIB (San Francisco, California);  Carlos Atico ARIZA (Hayward, California);  Samuel Louis KLEINMAN (Oakland, California)
ABSTRACT A hand-held microfluidic testing device is provided that includes a housing having a cartridge receiving port and a cartridge for input to the cartridge receiving port. An optical detection system in the housing is capable of providing an illuminated electric field useful for Raman spectroscopy. The cartridge may have a sample well. The sample well is loaded with a mixture of water containing the analyte, Raman-scattering nanoparticles and a calibration solution. The calibration solution contains an analogue of the analyte differing in its Raman response, for example an isotope of the analyte. Optionally, a chemical compound capable of increasing interaction between the analyte and the nanoparticles may be added.
FILED Thursday, December 10, 2020
APPL NO 17/118482
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 21/658 (20130101)
G01N 33/18 (20130101) Original (OR) Class
G01N 33/182 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210166138 Larson et al.
FUNDED BY
National Science Foundation (NSF)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) Clinc, Inc. (Ann Arbor, Michigan)
ASSIGNEE(S)
INVENTOR(S) Stefan Larson (Ann Arbor, Michigan);  Anish Mahendran (Ann Arbor, Michigan);  Parker Hill (Ann Arbor, Michigan);  Jonathan K. Kummerfeld (Ann Arbor, Michigan);  Michael A. Laurenzano (Ann Arbor, Michigan);  Lingjia Tang (Ann Arbor, Michigan);  Jason Mars (Ann Arbor, Michigan)
ABSTRACT Systems and methods for automatically detecting annotation discrepancies in annotated training data samples and repairing the annotated training data samples for a machine learning-based automated dialogue system include evaluating a corpus of a plurality of distinct training data samples; identifying one or more of a slot span defect and a slot label defect of a target annotated slot span of a target training data sample of the corpus based on the evaluation; and automatically correcting one or more annotations of the target annotated slot span based on the identified one or more of the slot span defect and the slot label defect.
FILED Friday, January 15, 2021
APPL NO 17/149998
CURRENT CPC
Computer Systems Based on Specific Computational Models
G06N 5/04 (20130101) Original (OR) Class
G06N 20/00 (20190101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210168238 Adolphe et al.
FUNDED BY
National Science Foundation (NSF)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) Forward Edge AI, Inc. (San Antonio, Texas)
ASSIGNEE(S)
INVENTOR(S) Eric Adolphe (San Antonio, Texas);  JESSE CAI (MCLEAN, Virginia);  KARTHIK PRASANNA MAIYA (CHANTILLY, Virginia);  HONGYI GUAN (HERNDON, Virginia);  BEN SISKO ADOLPHE (SAN ANTONIO, Texas)
ABSTRACT An innovative method is implemented to determine a robocall and blocks the incoming communication deemed to be a robocall. The method leverages blockchain's shared storage, memory, and ability to transact all information across a network and independently verified and stored on the immutable blockchain. The method takes advantage high-speed cellular network to process each communication with high-speed. Further, the method integrates blockchain encryption, swarm intelligence (SI), artificial intelligence (AI) and machine learning (ML) algorithms, a telecommunication expert knowledge graph (TEKG), and real-time parsing of records to block robocalls and reduce connection delays. All modules can evolve and update themselves with each use of the present invention through various SI, AI, and ML technologies. Additionally, the method includes a localized call-filtering feature based on state and federal laws to ensure the blocking of calls that are prohibited by either federal or state governments thereby facilitating recovery of damages.
FILED Thursday, December 03, 2020
APPL NO 17/110688
CURRENT CPC
Transmission of Digital Information, e.g Telegraphic Communication
H04L 9/06 (20130101)
H04L 2209/38 (20130101)

Telephonic Communication
H04M 3/436 (20130101) Original (OR) Class
H04M 2203/6027 (20130101)

Wireless Communication Networks
H04W 12/12 (20130101)
H04W 12/00514 (20190101)
VIEW PATENT @ USPTO:  Full Text   PDF 

Department of Agriculture (USDA) 

US 20210162039 Zhang et al.
FUNDED BY
Department of Agriculture (USDA)
APPLICANT(S) Kansas State University Research Foundation (Manhattan, Kansas)
ASSIGNEE(S)
INVENTOR(S) Weiping Zhang (Manhattan, Kansas);  Ying Fang (Manhattan, Kansas)
ABSTRACT The present disclosure provides vaccines or immunogenic compositions against clinical signs, symptoms, and losses attributable to or caused by infection with PEDV and/or ETEC. Antigenic epitopes from PEDV and ETEC are used to construct an immunogenic composition, preferably in the form of a multi-epitope fusion antigen or as a live strain through E. coli.
FILED Monday, May 13, 2019
APPL NO 17/250020
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 39/225 (20130101) Original (OR) Class
A61K 39/0258 (20130101)
A61K 2039/523 (20130101)

Peptides
C07K 14/165 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164953 Robertson et al.
FUNDED BY
National Science Foundation (NSF)
Department of Agriculture (USDA)
APPLICANT(S) University of Idaho (Moscow, Idaho)
ASSIGNEE(S) University of Idaho (, None)
INVENTOR(S) Daniel Robertson (Moscow, Idaho);  Douglas Cook (Fountain Green, Utah);  Will Seegmiller (Troy, Idaho);  Taylor Spence (Garden Valley, Idaho);  Kate Seegmiller (Moscow, Idaho);  Andrew Stucker (Moscow, Idaho)
ABSTRACT Certain disclosed method embodiments concern performing a stalk puncture test to determine force and displacement data. Plant features, such as rind thickness, stalk radius, stalk diameter, section modulus and/or integrative puncture score, primarily applicable to corn, sorghum, sunflower, wheat or rice, can be calculated using the force and displacement data. The calculated plant features are used to select plants for selective breeding to produce lodging-resistant crop hybrids. The present invention also provides embodiments of a hand-held puncture device that can be used to practice disclosed method embodiments.
FILED Wednesday, December 02, 2020
APPL NO 17/109989
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 3/30 (20130101)
G01N 33/0098 (20130101) Original (OR) Class
G01N 2021/8466 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 

Department of Veterans Affairs (DVA) 

US 20210161837 Chen et al.
FUNDED BY
Department of Veterans Affairs (DVA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S) The Regents of the University of California (Oakland, California);  Guangzhou Institutes of Biomedicine and Health (Guangzhou, China PRC);  U.S. Government represented by the Department of Veterans Affairs (Washington, District of Columbia)
INVENTOR(S) Hongwu Chen (Davis, California);  June X. Zou (Davis, California);  Junjian Wang (Davis, California);  Demin Cai (Davis, California);  Yong Xu (Guangzhou, China PRC);  Xiaoqian Xue (Guangzhou, China PRC);  Yan Zhang (Guangzhou, China PRC)
ABSTRACT The present invention provides compositions, methods, and kits comprising one or more compounds of Formula I, such as XY018, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, gastric cancer, lymphoma, and glioma.
FILED Tuesday, June 30, 2020
APPL NO 16/917818
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/58 (20130101)
A61K 31/138 (20130101)
A61K 31/167 (20130101) Original (OR) Class
A61K 31/222 (20130101)
A61K 31/277 (20130101)
A61K 31/337 (20130101)
A61K 31/4166 (20130101)
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Acyclic or Carbocyclic Compounds
C07C 205/11 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163406 Erker et al.
FUNDED BY
Department of Veterans Affairs (DVA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
APPLICANT(S) University of Pittsburgh - Of the Commonwealth System of Higher Education (Pittsburgh, Pennsylvania);  The United States Government as represented by the Department of Veterans Affairs (Washington, District of Columbia);  Universität Wien (Wien, Austria)
ASSIGNEE(S)
INVENTOR(S) Thomas Erker (Vienna, Austria);  Philipp Schreppel (Vienna, Austria);  Dandan Sun (Pittsburgh, Pennsylvania)
ABSTRACT The present invention relates to bumetanide derivatives of formula (I) as well as pharmaceutical compositions comprising these compounds for use in the treatment or prevention of neurological diseases/disorders involving Na+-K+-20Γ-cotransporters (NKCCs), such as stroke, traumatic brain injury (TBI), spinal cord injury (SCI), peripheral nerve injury (PNI), brain edema, or glioma, and particularly for use in the treatment or prevention of stroke. The invention likewise relates to a method of treating or preventing a neurological disease or disorder involving an NKCC, such as stroke, TBI, SCI, PNI, brain edema, or glioma, the method comprising administering a compound of formula (I) to a subject in need thereof.
FILED Friday, April 05, 2019
APPL NO 17/045395
CURRENT CPC
Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 9/10 (20180101)
A61P 35/00 (20180101)

Acyclic or Carbocyclic Compounds
C07C 311/39 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 

National Aeronautics and Space Administration (NASA) 

US 20210163766 Mitkova et al.
FUNDED BY
National Aeronautics and Space Administration (NASA)
APPLICANT(S) BOISE STATE UNIVERSITY (Boise, Idaho)
ASSIGNEE(S)
INVENTOR(S) Maria Mitkova (Boise, Idaho);  Al Amin Ahmed Simon (Boise, Idaho);  Shah Mohammad Rahmot Ullah (Milpitas, California);  David Estrada (Boise, Idaho)
ABSTRACT An additive manufacturing ink composition may include a fluid medium. The ink may further include a chalcogenide glass suspended within the fluid medium to form a chalcogenide glass mixture. The ink may also include a surfactant. A method for forming an additive manufacturing ink may include wet milling a chalcogenide glass in a fluid medium and a surfactant to produce a chalcogenide glass mixture. The method may also include, after wet milling the chalcogenide glass, processing the chalcogenide glass mixture to reduce an average particle size of the chalcogenide glass.
FILED Thursday, December 03, 2020
APPL NO 17/111316
CURRENT CPC
Additive Manufacturing, i.e Manufacturing of Three-dimensional [3-D] Objects by Additive Deposition, Additive Agglomeration or Additive Layering, e.g by 3-d Printing, Stereolithography or Selective Laser Sintering
B33Y 30/00 (20141201)
B33Y 40/10 (20200101)
B33Y 70/10 (20200101)

Manufacture, Shaping, or Supplementary Processes
C03B 5/2252 (20130101)
C03B 19/12 (20130101)

Chemical Composition of Glasses, Glazes or Vitreous Enamels; Surface Treatment of Glass; Surface Treatment of Fibres or Filaments Made From Glass, Minerals or Slags; Joining Glass to Glass or Other Materials
C03C 1/006 (20130101)
C03C 3/321 (20130101)

Coating Compositions, e.g Paints, Varnishes or Lacquers; Filling Pastes; Chemical Paint or Ink Removers; Inks; Correcting Fluids; Woodstains; Pastes or Solids for Colouring or Printing; Use of Materials Therefor
C09D 11/03 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210166583 BURAS et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
National Aeronautics and Space Administration (NASA)
APPLICANT(S) Tienovix, LLC (Houston, Texas)
ASSIGNEE(S) Tienovix, LLC (Houston, Texas)
INVENTOR(S) William R. BURAS (Friendswood, Texas);  Craig S. RUSSELL (League City, Texas);  Kyle Q. NGUYEN (League City, Texas)
ABSTRACT Methods for providing real-time, three-dimensional (3D) augmented reality (AR) feedback guidance to a user of an equipment system to achieve improved diagnostic or treatment outcomes, including comparing sensed, real-time user positioning data and data received from the equipment system during use to reference positioning and procedure outcome data, and generating and providing to a user real-time position-based and outcome-based 3D AR feedback based on comparing the sensed and reference data.
FILED Monday, October 05, 2020
APPL NO 17/063651
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 8/06 (20130101)
A61B 8/52 (20130101)
A61B 8/085 (20130101)
A61B 8/466 (20130101)
A61B 8/467 (20130101)
A61B 8/4245 (20130101)
A61B 8/4254 (20130101)
A61B 8/4263 (20130101)
A61B 34/20 (20160201)
A61B 90/361 (20160201)
A61B 2034/2048 (20160201)
A61B 2034/2055 (20160201)
A61B 2090/365 (20160201)
A61B 2090/378 (20160201)
A61B 2090/3945 (20160201)
A61B 2562/0219 (20130101)

Optical Elements, Systems, or Apparatus
G02B 27/017 (20130101)

Electric Digital Data Processing
G06F 3/011 (20130101)
G06F 3/016 (20130101)

Computer Systems Based on Specific Computational Models
G06N 20/00 (20190101)

Educational or Demonstration Appliances; Appliances for Teaching, or Communicating With, the Blind, Deaf or Mute; Models; Planetaria; Globes; Maps; Diagrams
G09B 5/065 (20130101)
G09B 23/286 (20130101) Original (OR) Class

Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data
G16H 30/20 (20180101)
G16H 40/63 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 

Central Intelligence Agency (CIA) 

US 20210163155 Beck et al.
FUNDED BY
Central Intelligence Agency (CIA)
APPLICANT(S) Rocket Lab USA, Inc. (Huntington Beach, California)
ASSIGNEE(S)
INVENTOR(S) Peter Beck (Auckland, New Zealand);  Peter Barlow (Huntington Beach, California);  David Yoon (La Crescenta, California);  Ben Malcolm (Auckland, New Zealand)
ABSTRACT A satellite dispenser door release mechanism is disclosed. In various embodiments, a satellite door dispenser as disclosed herein includes a wire or cable having a first end configured to be secured in a structure comprising or coupled to a dispenser body of a satellite dispenser and a second end configured to be secured in a structure comprising or coupled to a dispenser door of the satellite dispenser; and a pyrotechnic cutter configured to receive the wire or cable in a position to cut the wire or cable upon firing of the pyrotechnic cutter.
FILED Thursday, January 21, 2021
APPL NO 17/154731
CURRENT CPC
Cutting; Details Common to Machines for Perforating, Punching, Cutting-out, Stamping-out or Severing
B26D 5/12 (20130101)

Vehicles Adapted for Load Transportation or to Transport, to Carry, or to Comprise Special Loads or Objects
B60P 7/16 (20130101)
B60P 7/135 (20130101)

Cosmonautics; Vehicles or Equipment Therefor
B64G 1/22 (20130101) Original (OR) Class
B64G 1/645 (20130101)

Hinges or Suspension Devices for Doors, Windows or Wings
E05D 3/08 (20130101)
E05D 7/00 (20130101)

Devices for Moving Wings into Open or Closed Position; Checks for Wings; Wing Fittings Not Otherwise Provided For, Concerned With the Functioning of the Wing
E05F 1/105 (20130101)
E05F 3/20 (20130101)

Shafts; Flexible Shafts; Elements or Crankshaft Mechanisms; Rotary Bodies Other Than Gearing Elements; Bearings
F16C 29/005 (20130101)
F16C 33/24 (20130101)
F16C 2326/47 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 

Department of Commerce (DOC) 

US 20210163543 KRISHNA et al.
FUNDED BY
Department of Commerce (DOC)
APPLICANT(S) REALTA HOLDINGS, LLC (Norfolk, Virginia)
ASSIGNEE(S) REALTA HOLDINGS, LLC (Norfolk, Virginia)
INVENTOR(S) Neel K. KRISHNA (Norfolk, Virginia);  Kenji CUNNION (Norfolk, Virginia)
ABSTRACT The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.
FILED Monday, February 08, 2021
APPL NO 17/169758
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/00 (20130101)
A61K 38/162 (20130101)
A61K 47/60 (20170801)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 7/00 (20180101)
A61P 25/00 (20180101)
A61P 37/06 (20180101)

Peptides
C07K 14/005 (20130101) Original (OR) Class

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 2770/12071 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 

Department of Homeland Security (DHS) 

US 20210164991 JOHNSTON et al.
FUNDED BY
Department of Homeland Security (DHS)
Department of Defense (DOD)
Defense Threat Reduction Agency (DTRA)
APPLICANT(S) ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (Scottsdale, Arizona)
ASSIGNEE(S) ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (Scottsdale, Arizona)
INVENTOR(S) Stephen JOHNSTON (Tempe, Arizona);  Lu WANG (Tempe, Arizona)
ABSTRACT A method of inducing a generalized immune response, includes administering to a subject an immunologically effective amount of one or more isolated immunogenic peptides comprising an amino acid sequence of SEQ. ID NOs: 1-46, thereby inducing a generalized immune response to infection by a pathogen in a subject. A prophylactic or therapeutic composition for inducing a generalized immune response, includes an immunologically effective amount of one or more isolated immunogenic peptides comprising an amino acid sequence of SEQ. ID NOs: 1-46. A method of distinguishing a subject infected with a pathogen from an uninfected subject, includes detecting an antibody in the subject that selectively binds one or more isolated immunogenic peptides comprising an amino acid sequence of SEQ. ID NOs: 1-46, wherein the presence of the antibody indicates that the subject is infected with the pathogen. A general method to discover broadly protective components for a vaccine is also disclosed.
FILED Wednesday, January 16, 2019
APPL NO 16/954187
CURRENT CPC
Peptides
C07K 14/4702 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 1/10 (20130101)
C12N 1/20 (20130101)
C12N 7/00 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/6854 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 

Department of Transportation (USDOT) 

US 20210165417 Bell et al.
FUNDED BY
Department of Transportation (USDOT)
Federal Highway Administration (FHWA)
APPLICANT(S) INTELLIGENT MATERIAL SOLUTIONS, INC. (Princeton, New Jersey)
ASSIGNEE(S) INTELLIGENT MATERIAL SOLUTIONS, INC. (Princeton, New Jersey)
INVENTOR(S) Howard Y. Bell (Princeton, New Jersey);  Joshua E. Collins (Philadelphia, Pennsylvania);  Robert A. Ferlis (McLean, Virginia);  Kunik Lee (McLean, Virginia)
ABSTRACT A cooperative vehicle-highway communication system allows vehicles and pedestrians to determine their location by sensing selected coatings on roadways, sidewalks, and other paved surfaces in both indoor and outdoor environments. The systems recognize intelligent materials under sensors to determine geo-location. The intelligent materials are incorporated into paints on the roadway surface to mark key locations. Additionally, vehicles recognize highway paint/markings and signs with intelligent paint that provide specialized message content to support driver information and control applications. The intelligent paint materials include a coating that absorbs light while converting the absorbed light to electromagnetic energy. This electromagnetic energy is read by sensors to recognize the materials. The sensors transform the electromagnetic energy into processing signals to determine operating characteristics of the vehicle, including position and motion characteristics, and to provide operation actions of the vehicle. For mobility impaired pedestrians, the precisely defined geo-locations
FILED Wednesday, January 13, 2021
APPL NO 17/147818
CURRENT CPC
Coating Compositions, e.g Paints, Varnishes or Lacquers; Filling Pastes; Chemical Paint or Ink Removers; Inks; Correcting Fluids; Woodstains; Pastes or Solids for Colouring or Printing; Use of Materials Therefor
C09D 5/22 (20130101)

Systems for Controlling or Regulating Non-electric Variables
G05D 1/0088 (20130101)
G05D 1/0236 (20130101) Original (OR) Class

Recognition of Data; Presentation of Data; Record Carriers; Handling Record Carriers
G06K 9/2063 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 

U.S. Agency for International Development (USAID) 

US 20210163978 Mengiste et al.
FUNDED BY
U.S. Agency for International Development (USAID)
APPLICANT(S) Purdue Research Foundation (West Lafayette, Indiana)
ASSIGNEE(S)
INVENTOR(S) Tesfaye D Mengiste (West Lafayette, Indiana);  Fuyou Fu (Saskatoon, Canada);  Sanghun Lee (West Lafayette, Indiana);  Gebisa Ejeta (West Lafayette, Indiana)
ABSTRACT Disclosed herein is a unique molecular marker in sorghum genome for conferring broad range fungal resistance trait, and the use of the molecular marker to manipulate resistance in sorghum. A disease resistance gene called ANTHRACNOSE RESISTANCE GENE 1 (ARG1) and a negative regulator, i.e. antisense transcripts of ARG1, called CARRIER OF ARG (CARG) for the fungi resistance gene are knocked out within a quantitative trait locus (QTL).
FILED Wednesday, November 21, 2018
APPL NO 16/766218
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/8282 (20130101) Original (OR) Class

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6895 (20130101)
C12Q 2600/13 (20130101)
C12Q 2600/156 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 

Government Rights Acknowledged 

US 20210161913 Ren et al.
FUNDED BY
APPLICANT(S) Virginia Commonwealth University (Richmond, Virginia)
ASSIGNEE(S)
INVENTOR(S) Shunlin Ren (Richmond, Virginia);  Jin Koung Kim (Richmond, Virginia)
ABSTRACT Methods and compositions are provided for the prevention and/or treatment of symptoms associated with lipid accumulation disorders caused by attenuated leptin activity and by lipid storage disorders. The methods involve administering at least one oxygenated cholesterol sulfate (OCS) to a subject with the disorder. The disorder may be acquired or congenital (hereditary).
FILED Monday, November 02, 2020
APPL NO 17/087364
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/56 (20130101) Original (OR) Class
A61K 31/58 (20130101)
A61K 31/575 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 2800/044 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210163914 JO
FUNDED BY
APPLICANT(S) INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY (Gyeongsangnam-do, South Korea)
ASSIGNEE(S) INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY (Gyeongsangnam-do, South Korea)
INVENTOR(S) Byung-hoon JO (Gyeongsangnam-do, South Korea)
ABSTRACT A fusion tag according to an embodiment of the present invention may increase the water solubility and expression level of a target protein. As the water solubility and expression level of a target protein in host cell can be increased by a recombinant vector including the fusion tag, the fusion tag can be advantageously used in industry.
FILED Friday, December 28, 2018
APPL NO 16/772890
CURRENT CPC
Peptides
C07K 2319/00 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/88 (20130101) Original (OR) Class

Enzymes
C12Y 402/01001 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210164503 Corke et al.
FUNDED BY
APPLICANT(S) University of Notre Dame du Lac (South Bend, Indiana)
ASSIGNEE(S) University of Notre Dame du Lac (, None)
INVENTOR(S) Thomas C. Corke (Granger, Indiana);  Flint O. Thomas (Granger, Indiana)
ABSTRACT A plasma plate is used to minimize drag of a fluid flow over an exposed surface. The plasma plate includes a series of plasma actuators positioned on the surface. Each plasma actuator is made of a dielectric separating a first electrode exposed to a fluid flow and a second electrode separated from the fluid flow under the dielectric. A pulsed direct current power supply provides a first voltage to the first electrode and a second voltage to the second electrode. The series of plasma actuators is operably connected to a bus which distribute powers and is positioned to minimize flow disturbances. The plasma actuators are arranged into a series of linear rows such that a velocity component is imparted to the fluid flow.
FILED Friday, December 27, 2019
APPL NO 16/728924
CURRENT CPC
Aeroplanes; Helicopters
B64C 23/005 (20130101)
B64C 2230/12 (20130101)

Non-positive Displacement Machines or Engines, e.g Steam Turbines
F01D 17/00 (20130101)

Indexing Scheme for Aspects Relating to Non-positive-displacement Machines or Engines, Gas-turbines or Jet-propulsion Plants
F05D 2270/172 (20130101)

Fluid Dynamics, i.e Methods or Means for Influencing the Flow of Gases or Liquids
F15D 1/12 (20130101) Original (OR) Class
F15D 1/0075 (20130101)

Plasma Technique; Production of Accelerated Electrically-charged Particles or of Neutrons; Production or Acceleration of Neutral Molecular or Atomic Beams
H05H 1/2406 (20130101)
H05H 2001/2412 (20130101)
H05H 2001/2437 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210165772 ACKERMANN et al.
FUNDED BY
APPLICANT(S) INTERNATIONAL BUSINESS MACHINES CORPORATION (ARMONK, New York)
ASSIGNEE(S)
INVENTOR(S) CHRISTOPHER F. ACKERMANN (FAIRFAX, Virginia);  CHARLES E. BELLER (Baltimore, Maryland);  EDWARD G. KATZ (Washington, District of Columbia);  MICHAEL DRZEWUCKI (Woodbridge, Virginia)
ABSTRACT A service receives, from a query entity store, a query store result in response to an initial query referencing at least one of a name element and a first identifier component related to an entity, the query store result comprising a query store record comprising information related to the entity. The service receives, from a target entity store, a target store result to a target store query referencing the query store record, the target store result comprising one or more target store records related to the information found in the query store record. The service compares the one or more target store records to the information in the query store record. The service, responsive to determining a relevancy assessment indicates a match between the information in the query store record and two or more particular target store records from among the one or more target store records, triggers the target entity store to merge the two or more particular target store records.
FILED Tuesday, December 03, 2019
APPL NO 16/702513
CURRENT CPC
Electric Digital Data Processing
G06F 16/215 (20190101) Original (OR) Class
G06F 16/288 (20190101)
G06F 16/24565 (20190101)
G06F 16/24578 (20190101)
G06F 40/295 (20200101)
VIEW PATENT @ USPTO:  Full Text   PDF 

How To Use This Page 

THE FEDINVENT PATENT APPLICATION DETAILS PAGE

Each week, FedInvent analyzes newly granted patents and published patent applications whose origins lead back to funding by the US Federal Government. The FedInvent Patent Details page is a companion to the weekly FedInvents Patents Report.

This week's information is published in the FedInvent Patents report for Thursday, June 03, 2021.

The FedInvent Weekly Patent Details Page contains a subset of patent information to provide a deeper dive into the week's taxpayer-funded patents to help the reader better understand where a patent fits in the federal innovation ecosphere.

HOW IS THE INFORMATION ORGANIZED?

Patents are organized by the funding agency. Within each group, the patents are organized in numeric order. A patent funded by more than one agency will appear in the section of each of the agencies that funded the research and development that resulted in the invention. This approach gives the reader a complete view of the department or agency activity for the week.

WHAT INFORMATION WILL I FIND?

THE PANEL
There is a panel for each patent that contains the patent number and the title of the patent. When you click the panel, it opens to reveal the following information:

FUNDED BY
The agencies that funded the grants, contracts, or other research agreements that resulted in the patent. FedInvent includes as much information on the source of the funding as possible. The information is presented in a hierarchy going from the Federal Department down to the agencies, subagencies, and offices that funded the work. Here are two examples:

Department of Health and Human Services (HHS)
     National Institutes of Health (NIH)
         National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Department of Defense (DOD)
     Defense Advanced Research Projects Agency (DARPA)
         Army Research Office (ARO)

We do our best to provide detailed information about the funding. In some cases, the patent only reports limited information on the origins of the funding. FedInvents presents what it can confirm. We add the patents without the information required by the Bayh-Dole Act to our list of patents worthy of further investigation.

APPLICANT(S) and ASSIGNEES
FedInvent includes both the Applicants and the Assignees because having both provides more information about where the inventive work was done and by what organizations. Many organizations — universities, corporations, and federal agencies — standardize the Assignee/Owner information by the time a patent is granted. In the case of federal patents, many of the patents use the agency headquarters information for patent assignment.

Showing just the headquarters address would make Washington, DC the epicenter of all taxpayer-funded research and development. Providing both the applicant information and the assignee information provides a more accurate picture of where important taxpayer-funded innovation is happening in America. Here are two examples from two different patents:

APPLICANT: U.S. Army Research Laboratory, Adelphi, MD
ASSIGNEE: The United States of America as represented by the Secretary of the Army Washington, DC

APPLICANT: Optech Ventures, LLC (Torrance, California)
ASSIGNEE(S): The Regents of the University of California (Oakland, California); Optech Ventures, LLC (Torrance, California)

INVENTOR(S)
The inventors appear in the same order as they appear on the patent. FedInvents presents the names in first name/last name order because they are easier to read than the last name/first name order of the names on the USPTO patent documents.

ABSTRACT
The abstract is presented as it appears on the patent.

FILED
The date the patent application including the day of the week.

APPL NO
This is the patent application serial number. If you’d like to learn more about how application serial numbers work you can go to the Lists Page.

ART UNIT
Patent data includes the Art Unit where a patent was examined. (The Art Unit isn’t available for published patent applications.) The Art Unit provides insight into what group of patent examiners prosecuted the patent application and the subject matter that the examiners work on. For example:

3793 — Medical Instruments, Diagnostic Equipment, and Treatment Devices

You can learn more about ART UNITS on the FedInvent Patents Weekly panel called About Tech Center or you can find information on the FedInvent Lists Page.

CURRENT CPC
Current CPC provides a list of the Cooperative Patent Classification symbols assigned to the patent. These are the CPC symbols assigned at the time the patent was granted.

The FedInvent Project is a patent classification maximalist endeavor or put another way, we believe that the more you understand about patent classification the more you'll learn about the nature of the invention and the types of work that the federal government is funding.

The symbol presented in BOLD is the symbol identified as the "first" classification which is the most relevant classification on the patent. The date that follows the symbol is the date of the most recent revision to the art classed there.

  • A61B 1/149 (20130101)
  • A61B 1/71 (20130101)
  • A61B 1/105 (20130101)

The CPC symbols match the classifications found on the PDF version of the patent. Over time, the classifications on the full text version of the patent change to reflect how USPTO organizes patent art to support its examiners. The two sets of CPCs don’t always match.

VIEW PATENT
As of June 2021, we include two ways to view a patent at USPTO. FedInvent provides a link to the Full-Text Version of the patent and a link to the PDF version of the patent.

HOW DO I FIND A SPECIFIC PATENT ON A PAGE?

You can use the Command F or Control F to find a specific patent you are interested in.

HOW DO I GET HERE?

You navigate to the details of a patent by clicking the information icon that follows a patent on the FedInvent Patents Weekly Report.

You can also reach this page using the weekly page link that looks like this:

https://wayfinder.digital/fedinvent/patents-2021/details-patents-20210427.html

Just update the date portion of the URL. Tuesdays for patents. Thursdays for pre-grant publication of patent applications.

Download a copy of the How To Use This Page

HAVE MORE QUESTIONS?

info@wayfinder.digital